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EXPLORING INDUCED SECONDARY STRUCTURE AND UNMETHYLATED DNA 
BINDING DOMAINS OF METHYL CpG BINDING PROTEIN 2 (MeCP2) 
Our understanding of Methyl CpG binding protein 2 (MeCP2) structure and 
function has changed and expanded considerably over the last two decades.  Mutations 
along the entirety of the human MeCP2 gene product lead to a disease state - Rett 
syndrome.  The clinical connection of this protein has continued to drive intense 
research into the nature of MeCP2 structure and function. There is now considerable 
and corroborated evidence that proves MeCP2 is an archetypical intrinsically disordered 
protein acting as a global ATP independent chromatin architectural protein. The ubiquity 
of MeCP2 in vertebrate neuronal nuclei has only recently been realized and has focused 
my investigations.  Results from my work demonstrate a clear relationship between 
predicted α-molecular recognition features and inducible α- helical structure.  From these 
data I suggest that inducible α-helices and maintained intrinsic disorder participate in 
binding the pool the twenty reported MeCP2 binding partners. In addition to structural 
studies I have identified two non-specific unmethylated DNA binding domains unreported 
in the literature at the onset of my work. I have also shown that MeCP2 acquires some 
secondary structural stability when bound to DNA and relatively little additional stability 
when bound to methylated DNA. The results presented here improve the fine resolution 
functional understanding of MeCP2 by observing isolated fragments of MeCP2 using 
both structural and functional methods. This approach is significant in and of itself as, 
iii 
like the large disordered subset of all eukaryotic proteins, the full-length MeCP2 
molecule has proven impossible to crystallize thus far. Therefore narrowing the amino 
acid residues responsible for DNA binding activity or any other measureable functionality 
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Literature Review  
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1.1. Introduction:  An Historical Perspective of MeCP2 Structure and Fu nction  
MeCP2 (methyl CpG-Binding Protein 2) is a 53 kDa nuclear protein named for its 
ability to bind methylated DNA (1,2). In addition to preferentially binding methylated DNA, 
it was found that MeCP2 facilitated transcriptional repression in an in vitro transcription 
assay using native MeCP2 from rat brain nuclear extracts (3). These initial studies set a 
precedent for MeCP2 function to be predicated on methylated-DNA interactions. In this 
chapter I will discuss the heuristic evolution of the view of MeCP2 from a single-function 
protein to a multifunctional nuclear protein that directly affects chromatin architecture 
and is involved with actively transcribed and silenced regions of chromatin (4,5).  
A nuclear protein that preferentially bound methylated DNA in vitro without 
apparent regard for a consensus binding sequence was first described in 1989 and 
named methyl CpG-binding protein (MeCP) (6,7). This was accomplished using 
synthetic double stranded DNA oligomers methylated by bacterial methyl transferases. 
Competition of the protein from synthetic DNA probes was observed only when the 
competitor DNA was methylated (6).  These assays selectively pulled down a protein in 
complexes from mouse brain, spleen, kidney, rat liver, and rabbit liver extracts. In each 
extract, MeCP preferentially bound the methylated DNA templates without sequence 
specificity. Further experiments revealed that MeCP was two distinguishable proteins: 
MeCP1 and MeCP2 (1), with MeCP1 requiring at least 12 symmetrically methylated 
CpGs and MeCP2 able to bind a single methylated CpG pair.  MeCP2 was reported to 
be 100 times more abundant in adult somatic nuclei than MeCP1 (1).  When forming the 
initial hypothesis of MeCP2 function, it was proposed that MeCP2 normally binds 
methylated DNA in the context of chromatin, leading to long-term transcriptional 
repression. This hypothesis was corroborated by results showing that native MeCP2 
purified from rat brain extracts was released upon micrococcol nuclease digestion of a 
3 
methylated DNA probe but not present on a non-methylated DNA probe (1). The cDNA 
sequence for MeCP2 was also determined in this study by first deriving amino acid 
sequences of digested native MeCP2 protein from rat brain extract, and subsequently 
designing oligonucleotide primers to amplify the mRNA by the polymerase chain reaction.  
More evidence was provided when transiently transfected recombinant genes coding 
MeCP2 fused to the LacZ gene were expressed in mouse cell cultures, and similar 
localization to centromeric heterochomatin was observed when compared to 
endogenous MeCP2 stained with anti-MeCP2 antibody.  The inability of the MeCP2-
LacZ fusion protein to localize to centromeric hereochomatin in methyltransfererase-
deficient mouse cells was provided as evidence that MeCP2 required a methylated 
chromatin substrate for binding (2). 
The early driving hypothesis in MeCP2 research was methylated DNA binding 
preference. This hypothesis gave MeCP2 a name and also led to the isolation of the first 
functional domain: the methyl CpG-binding domain (MBD) (8).  By truncating either end 
of full length MeCP2 and probing for methylated DNA binding preference, Nan et al. (8) 
demonstrated that the MBD encompassed residues 78-163. This study was conducted 
using murine MeCP2 in mouse cell cultures. MeCP2 homologs in other mammals have 
not been fully characterized. Specifically, preferences for DNA methylation by MeCP2 
homologs have not been thoroughly addressed in the current literature.  The preference 
for methylated over unmethylated DNA for the Xenopus MeCP2 homolog is 20 fold, 
whereas the preference of mouse (9) and human (10) MeCP2 for methylated compared 
to unmethylated DNA is 2 to 3 fold.  
A solution structure of the isolated MBD was solved by NMR spectroscopy (11). 
The structured core appears as a wedge made up of a three-stranded anti-parallel β-
sheet on one side with an α-helix on the C-terminal side. β-strands 1 and 2 are 
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connected by a disordered loop of 5 residues with one positively charged and two polar 
residues.  The central wedge-shaped fold encompasses residues 103-145 of the MBD 
and is flanked by 26 residues on the N-terminal side and 19 residues on the C-terminal 
side having no detectable secondary structure. A high-resolution X-ray crystal structure 
of the MBD bound to DNA was published showing that the hydration state of the methyl 
group on the 5 carbon of cytosine stabilizes the MBD-DNA interface (12). The 
hydrophilic interaction between the MBD and stabilizing water molecules countered the 
previously proposed hypothesis that hydrophobic interactions stabilize the interaction. Of 
note, while the atomic structures have provided much detail about the MBD wedge motif, 
they do not explain the need for the flanking unstructured regions in recognizing 
methylated DNA. 
I recently participated in a collaborative investigation in which I expressed and 
purified recombinant human MeCP2 protein isoform e2, and methylated and 
unmethylated 198 base pair 5S DNA, and reconstituted MeCP2-DNA complexes. I sent 
these reagents to collaborators who used hydrogen-deuterium exchange (HD/X) to 
precisely monitor which amino acids in the MBD were stabilized when bound to 
unmethylated and methylated DNA (13). Results indicate that residues in the amino 
terminal of MBD, but not part of the ordered “wedge” structure, gain increased solvent 
protection when bound to methylated versus unmethylated DNA (see appendix II). This 
result suggests that residues outside the reported NMR and crystal structures are 
essential for the observed preference of the MBD for methylated DNA.   
The second MeCP2 domain to be characterized was the transcription repression 
domain (TRD). Using an in vitro ß-actin transcription assay, different regions of MeCP2 
were fused to the Gal 4 DNA-binding domain. Results showed that residues 205-310 
were required for transcriptional silencing, defining the TRD (3). Several mechanisms for 
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the transcriptional repression by the TRD have been proposed. These mechanisms were 
reviewed by Zlatanova (14). Perhaps the most compelling hypothesis for transcriptional 
repression is based on the observation that the TRD binds the corepressor mSin3A, 
which is thought to recruit histone deacetylases (15-17). In this model, MeCP2 indirectly 
causes changes in chromatin architecture through mediating post-translational 
modifications of the histone tails. This model is not universally applicable to MeCP2 
function as histone deacetylase-independent transcriptional repression has been 
observed (18). A lack of global histone tail modifications in MeCP2 null mice also argues 
against this molecular model (19). Since last reviewed, transcriptional repression by 
MeCP2 has been connected to cancer-causing gene expression patterns.  Repression 
of tumor-associated genes by the TRD of MeCP2 has been observed in a chromatin 
immunoprecipitation assay (20).  
 The identification and characterization of the MBD and TRD led to a more 
refined model in which MeCP2 functions as a methyl DNA specific proximal gene 
silencer that recruits co-repressors and HDACs (1,3,21).  In this regard, MeCP2 also 
binds to other transcriptional silencing factors besides mSin3a, including N-CoR, and c-
Ski (22).  
When the link between mutations in MeCP2 and RTT was established in 1999, 
research on MeCP2 increased dramatically and new studies were undertaken relating to 
how the protein functions on a global genomic scale (23). The first implication that 
MeCP2 has an HDAC-independent role in coordinating global chromatin architecture 
came from in vitro studies in 2003, which demonstrated that MeCP2 could directly 
compact chromatin without DNA methylation, ATP, or other proteins such as mSin3A 
(24). This study opened the door for understanding MeCP2 as a complex multifunctional 
nuclear protein with a prominent role in regulating global chromatin architecture. Since 
6 
this observation, several other functions have been suggested for the protein. Some of 

































Figure  1.1.  Chronological representation of MeCP2 functiona l understanding.   
Progression of traditional understanding of MeCP2 as a methyl DNA-dependent 
proximal gene silencer is shown in the time line. Studies implicating MeCP2 as 





Methyl-dependent gene-silencer model 
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In addition to the proposed roles in transcriptional repression and modulation of 
chromatin structure, there is a link between MeCP2 function and mRNA splicing.  Using 
coimmunoprecipitation from HeLa cell extracts, MeCP2 was shown to interact with YB-
1 (25).  The YB-1 protein is a highly conserved component of messenger 
ribonucleoprotein particles (mRNPs) and functions as the main mRNA-packaging protein. 
The interaction between MeCP2 and YB-1 requires the presence of RNA, as 
coimmunoprecipitation in HeLa cell extracts treated with RNase failed to pull down YB-1 
with MeCP2.  It is unclear whether the RNA bridges MeCP2 and YB-1 or stabilizes a 
protein-protein interaction between the two.  In the same study, it was also observed that 
MeCP2 affects the splicing of reporter mini-genes, and a functional MBD was not 
required for the YB-1 interaction or splice regulation. These findings, in conjunction with 
the observation that there are aberrant alternative splicing patterns in a mouse model of 
RTT (25), implies that MeCP2 has a previously uncharacterized function as a splice-site 
regulator. Previously reported evidence that MeCP2 directly binds RNA with high affinity 
(0-10 nM) (26) is of renewed interest in light of these more recent observations. 
Considering Rett syndrome as a neuronal-specific phenotype caused by mutations in 
MeCP2, it is worth testing predictions made by the model of MeCP2 having a crucial role 
in splice-site regulation and RNA-binding. Predictions include neuronal-specific aberrant 
splice variants of those genes already observed to have dysregulated expression in 
MeCP2 null mouse models (27). 
New data about the MeCP2 gene itself has also been reported.  The 
identification of a MeCP2 splice variant added an extra dimension to understanding how 
and where MeCP2 functions. This new splice variant was labeled e1 isoform and differs 
from the previously characterized e2 isoform only in the segments at their extreme 
amino termini. The e1 isoform has a 21-residue segment with an acidic pI of 4.25, while 
9 
the e2 isoform N-terminal segment is 9 residues and has an basic pI of 9.5  (28) (see Fig. 
1.2).  These distinct structural differences, together with the differential distribution of the 
e1 and e2 isoforms between the dorsal thalamus and hypothalamus in developing post-
natal mouse brains (29), suggest that there are important undiscovered differences 
between the functions of the two isoforms.  
Based on the observation that neurological defects in a mouse model of RTT can 
be reversed by re-expression of the wild-type protein, understanding the molecular 
mechanisms of native MeCP2 and how these mechanisms are malfunctioning in RTT 
has potential clinical application (30).  This observation is significant in establishing RTT 
as a neurodevelopmental rather than neurodegenerative disorder, and is consistent with 
a model for MeCP2 as a positive and negative regulator of transcription, a gene-specific 
splicing factor, and a chromatin architectural protein.   
Since the time of this initial “rescue” study a clinical research group has had 
success in rescuing dysfunctional synaptic activity in MeCP2 knock-out mice. They 
achieved this rescue by injecting exogenous brain-derived neurotrophic factor (BDNF) 
into the brainstem nucleus tractus solitarius site in MeCP2-null mice.  They hypothesize 















1.2 The Structural and Intrinsically Disordered Dom ains of MeCP2  
Protein function is inexorably linked to structure; therefore I will first consider recent 
advances in understanding the fundamental biochemistry of MeCP2. In particular, recent 
solution biophysical and protease digestion experiments have established that native 
MeCP2 is an intrinsically disordered protein composed of at least six distinct domains 
(32) (Fig 2). Trypsin digestion of MeCP2 has the potential to occur throughout the length 
of the polypeptide chain as there are approximately ninety potential digestion sites 
dispersed evenly throughout the human MeCP2 sequence. The rate of fragment 
appearance is related to trypsin accessibility to the tertiary structure.  N-terminal 
sequence analysis of kinetically stable tryptic bands identified six distinct MeCP2 
domains (32). Listed from amino to carboxy termini, these are the NTD, MBD, ID, TRD, 
CTD-α, and CTD-β (Fig. 1.2).  Of note, the observed trypsin cleavage sites mapped to 
the boundaries of the two well characterized functional domains (the MBD and TRD). 
There were also additional trypsin cleavage sites within both the MBD and TRD (32). 
The N-terminal domain (NTD) shares amino acid composition similarity with the HMGA2 
protein and was rapidly digested to completion once released from the neighboring MBD 
domain. Likewise, the second HMG-like domain now called the intervening domain (ID) 
was not detected as a kinetically stable band. The TRD sequence was recovered from 
the trypsin-digestion experiment indicating that the availability of trypsin cleavage sites is 
more restricted in this domain. The experimental approach allowed the CTD to be 
divided into a CTD-α (residues 310-354) and a CTD-β (residues 355-486) (32). The 
CTD-β contains two identifiable sequence motifs: seven consecutive histidines between 
residues 366-72 and a group 2 WW binding protein motif within a larger proline-rich 
region at residues 381-393. The His-rich motif in MeCP2 is highly conserved between 
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species.  The WW binding protein motif (residues 384-387) has been demonstrated to 
interact with splicing and transcription factors (33,34).  Interestingly, the proline-rich 
region in the CTD-β (residues 355-486) has been shown to bind HMGB1 (35). At the 
level of chromatin structure, the CTD is required for MeCP2-mediated chromatin 
compaction.  Nikitina et. al. showed that the R294X MeCP2 mutant was able to bind 
naked DNA as well as wild-type but could not condense chromatin into higher order 
structures (36).  This result is consistent with the early studies of Chandler, who showed 
that a region of the MeCP2 CTD contributed to the footprint of MeCP2 on nucleosomes 
(37). 
While delineating the structural domains of MeCP2 was an important advance, 
understanding how these domains are organized into a functional tertiary structure is 
essential for understanding the normal cellular functions of the protein, and why certain 
mutations lead to a RTT phenotype.  The next section discusses recent studies 
indicating that MeCP2 has an atypical tertiary structure permeated with an unusual 
amount of disorder.  
 
1.3 MeCP2 Tertiary Structure  
Due to the lack of NMR or X-ray crystal structure data, characterization of the tertiary 
structure of full-length MeCP2 has been accomplished by solution biochemical and 
biophysical methods.  Circular dichroism (CD) of recombinant human MeCP2 showed 
that full-length protein was approximately ~35% β-strand/turn, 5% α-helix and almost 
60% unstructured. CD further indicated that the isolated MBD fragment (residues 78-168) 
was ~10% α-helix, 51% β -strand/turn, and 38% unstructured (32), levels that 
approximated the amount of secondary structure seen by NMR (11). A recombinant 
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fragment of MeCP2 comprising the TRD (residues 198-305) was 85% unstructured 
according to CD. When studied by analytical ultracentrifugation, MeCP2 behaved as a 
monomer over a wide range of ionic conditions and molar concentrations, had an 
unusually low sedimentation coefficient (2.2 S), and a correspondingly high frictional 
coefficient ratio (f/fo = 2.4). These results were in agreement with sucrose gradient 
results obtained at a single set of experimental conditions (38).   Importantly, the CD 
data and the high f/fo value indicate that MeCP2 has a coil-like tertiary structure similar to 
that of a partially denatured protein (32). Based on these observations it is not surprising 
that MeCP2 has been reported to have certain anomalous physicochemical properties. 
For example, the 53 kDa MeCP2 monomer yields an apparent molecular mass of 500 
kDa according to gel filtration, and migrates at an apparent mass of 75-80 kDa on SDS 
gels (38).    
The CD and sedimentation results, together with the anomalous behavior in gel 
matrices, indicate that the MeCP2 tertiary structure possesses the features of an 
intrinsically disordered protein (32). The concept of intrinsic or native disorder in proteins 
has recently gained much attention (39-44). Prediction algorithms indicate that there is 
preponderance of intrinsic disorder (ID) in proteins such as transcription factors (45,46). 
It has been hypothesized that the presence of ID permits transient, low-affinity protein-
protein and protein-nucleic acid interactions (41,45). In the case of MeCP2, the location 
of order and disorder can be reproducibly predicted by several programs, e.g., PONDR 
(47) and FoldIndex (48). The FoldIndex prediction plot for MeCP2 is shown in Figure 1.2 
aligned with the domains of MeCP2. Unlike the core and linker histones, which are 
predicted to have disorder at their terminal domains, MeCP2 is predicted to have short 
stretches of order interspersed between long stretches of internal disorder over the 
length of the entire peptide chain.  Of note, many of the predicted order/disorder 
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boundaries coincide with the boundaries of the structural domains identified by 
proteolysis. Also, the known functional domains (i.e., the MBD and TRD) are predicted to 
be significantly disordered, consistent with the experimental data. Taken together, all 
available evidence suggests that ID is a key determinant of MeCP2 tertiary structure, 
and is likely to be an important feature of all six MeCP2 structural domains (Figs. 2, 3). 
Several conceptual models of MeCP2 tertiary structure can be imagined to fit the 
data.  In one model, several β-sheet/turn structural motifs are interspersed along the 
length of the MeCP2 amino acid chain, connected by disordered regions, and with no 
inter-motif interactions.  This could be viewed as an “inchworm” model. However, 
electron micrographs of MeCP2 do not support this model (36). Another model is based 
on the CD finding that beta strands/turns are the predominant type of classical 
secondary structure in MeCP2.  In this model, MeCP2 strand-forming regions that are 
separated by tens or possibly hundreds of amino acids apart on the linear polypeptide 
chain are connected by beta sheets or other forms of beta structures.  For example, one 
can picture a small half beta barrel with large regions of intrinsic disorder making up 
loops on either side of the beta sheet stacks. In Chapter 4 of this dissertation I propose 
an alternative model to explaining how MeCP2 may orchestrate chromatin architecture. 
This model is consistent with the data I will present in Chapters 2 and 3.  I discuss this 
model in depth in section  4.2.1 “Alternative hypothesis and future directions.” 
Although the new studies represent significant progress, a better understanding of 
the unusual tertiary structure of MeCP2 will be necessary to decipher the molecular links 
between MeCP2 domain organization, the multifunctionality of the protein, and the 




1.4 Evidence for Global Genomic Functions of MeCP2  
A recent genomics paper has raised questions about the current paradigms of 
how MeCP2 acts at the cellular level.  In the first study a ChIP-to-chip approach was 
used. Yasui et. al. have performed an overall epigenomic binding analysis of MeCP2 (5). 
Two important aspects of MeCP2 function were revealed by this work. First, MeCP2 is 
not always associated with transcriptionally repressed genes and instead is often 
associated with actively transcribed genes. Second, the majority (59%) of double-
stranded DNA binding sites for MeCP2 within the genome are thousands of base pairs 
away from intragenic regions, let alone methylated promoters. These new results 
suggest that the fundamental question of what MeCP2 is doing in the nucleus remains to 
be answered.  Clearly, the finding that a majority of MeCP2 molecules bind actively 
transcribed promoters indicates that this protein has additional functions that are not 
explained by the traditional proximal gene silencer model.  
This ChIP-to-chip analysis consisted of scanning 26.3 Mb of imprinted and non-
imprinted chromosomal loci of known or suspected genes targeted by MeCP2.  A 
custom high-density gene chip or oligonucleotide (oligo) micro-array was constructed 
with 50-mer oligos attached with a step of 32 base pairs per 50-mer such that each 
successive oligo contained 18 bp in the 5' end of the oligo matching the last 18 bp of the 
3' end of the previous oligo.  Repetitive sequences were removed prior to gene chip 
construction so only unique sequences were assayed for binding in the selected 
chromosomal regions. Human neurons from the SH-SY5Y cell line were used as the 
source of chromatin for immunoprecipitation of MeCP2.  The SH-SY5Y cell line was 
selected based on its ability to doubly express MeCP2 during differentiation (49).  The 
high affinity IgY specific antibody used in this study recognized the C-terminus of MeCP2. 
The c-terminus is identical in both e1 and e2 MeCP2 splice variants, so the antibody did 
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not distinguish between isoforms.  This yielded an averaged binding along the assayed 
chromosomal cross-section.  Further understanding of the difference between the two 
isoforms would come with a similar epigenomic analysis using isoform-specific 
antibodies.    
In the CHiP to chip experiments, MeCP2 was observed to occupy many active 
promoters and bind mostly to non-methylated sites along intergenic spaces (5).  Of 
those intergenic binding sites 58.4% were 10 kb or more away from transcription start 
sites or transcription end sites.  Interestingly, the majority of the MeCP2 intragenic 
binding sites were intronic, which is consistent with a potential functional role for MeCP2 
in pre-mRNA splicing (25). The other main conclusion gathered by the epigenomic ChIP-
to-chip analysis was that the majority (62.6%) of MeCP2-bound promoters are actively 
expressed genes including, for example, the immediate early response gene, JUNB (5).  
Perhaps the crux of this ChIP-to-Chip analysis, and the most contradictory to the 
initial paradigm of MeCP2 function, was the finding that MeCP2 is not concentrated at 
densely methylated promoters.  To determine which of the assayed promoters had the 
highest methylation levels, genome-wide promoter methylation analysis by methylated 
DNA immunoprecipitation (MeDIP) was performed on a microarray containing 24,275 
presumed human promoters (5).  This methylation-seeking immunoprecipitation 
technique was applied to identically differentiated SH-SY5Y cells.  Comparing the results 
from the promoter methylation-dependent immunoprecipitation assay to those from the 
MeCP2-binding assay revealed that only 2.2% of the top 4,062 promoters with highest 
measurable levels of methylation were bound by MeCP2.  The finding that MeCP2 is not 
concentrated at densely methylated promoters contradicts the original paradigm of 
MeCP2 function.  The hypothesis that MeCP2 promoter binding is coupled to 
transcriptional repression is further compromised by the finding that with certain 
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promoter occupancy, expression levels of the target protein actually increase. The 
observation that the RNASEH2A gene expression decreases with MeCP2 deficiency is 
another specific example implicating MeCP2 as a regulator rather than strictly a 
repressor of targeted genes associated with neuronal development (5).     
There are caveats to the applicability of results generated by in vitro ChIP to chip 
techniques to an in vivo model of RTT.  Using neuroblastoma cells as a source of 
chromatin may not reflect tissue-specific chromatin binding profiles for MeCP2 in normal 
neuronal tissue, and low-affinity DNA binding events may be over-exaggerated on the 
gene chip results.  However, the model of MeCP2 as being associated with actively 
transcribed genes and a majority of non-methylated CpG sequences is reinforced by 
more recent literature.  Gene expression patterns studied using the hypothalamus of 
mice reveal that nearly 85% of genes bound by MeCP2 are actively transcribed (4).  This 
study also adds to the list of MeCP2 interaction partners by demonstrating that CREB1 
protein is pulled down in chromatin immunoprecipitation with MeCP2.  The specificity of 
the interaction is further established by MeCP2 interacting with CREB1 at activated 
promoters but not at repressed targets. 
Recent in vivo work also corroborates the conclusions of the CHiP-to-chip 
epigenomic MeCP2 binding analysis. MeCP2-knockout mice and RTT patients do not 
aberrantly express genes regulated by promoter methylation (50,51). These results, 
together with the evidence that MeCP2 binds a majority of actively transcribing 
promoters, argue for MeCP2 having a role as both a positive and negative regulator of 
transcription (4,5). This evidence further supports the view that MeCP2 recognizes 
something in addition to, or other than, methylation for certain cellular functions, and 
suggests a model in which MeCP2 functions as an architectural chromatin protein, and 
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both a positive and negative regulator of transcription rather than a gene-specific, 
methylation-directed silencer. 
As mentioned previously, in vitro studies are also consistent with a role for 
MeCP2 in regulating global chromatin architecture independent of methylation status. 
Genomic double-stranded DNA is packed in chromatin by wrapping around octamers of 
basic histone proteins which form nucleosomes (52).  Nucleosomes are interspersed at 
semi-regular intervals along the DNA strand, creating arrays of nucleosomes termed 
chromatin. MeCP2 has been shown to bind to chromatin fibers and directly compact 
them into folded and oligomeric structures when bound to model nucleosomal arrays 
(10,24,36).  The arrays used in these studies were unmethylated, implicating a role for 
MeCP2 in modulating chromatin architecture independent of methylation status.  Though 
it is unequivocal that MeCP2 preferentially binds methylated DNA, and even more 
specifically the methylated linker DNA of mononucleosomes and nucleosomal arrays 
(53), the fact remains that MeCP2 is able to significantly alter higher order chromatin 
structure  independent of methylation remains a clearly documented property of the 
protein, and is likely due in part to the presence of multiple MeCP2 DNA/chromatin 
binding domains besides the MBD (see above). 
These observations have since been further corroborated by work from the lab of 
Dr. Adrian Bird. They recently reported that MeCP2 is expressed at nearly one molecule 
of MeCP2 per every two histone octamers in neuronal tissue (54). Though their own 
data demonstrate genome-wide distribution of MeCP2 in neuronal tissue, this group of 
researchers still maintains that MeCP2 “tracks” methylation.  I would argue that though 
MeCP2 may concentrate slightly at sites of genome methylation, the vast majority of 
MeCP2 binding sites in neuronal nuclei are methylation-independent.  They do concede 
that their data suggest a genome-wide role for MeCP2. 
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“Our data argue that MeCP2 may not act as a gene-specific transcriptional 
repressor in neurons, but might instead dampen transcriptional noise genome-
wide in a DNA methylation-dependent manner” (54). 
The abundance of MeCP2 in adult somatic nuclei (1-5 x105 molecules per nucleus) 
implies that there is a global genomic role for MeCP2. The in vitro studies of chromatin 
compaction are currently the best explanation for the genomic occupancy of MeCP2. 
Even though MeCP2 may function as a global chromatin architectural protein,  no 
change in histone modification profiles were observed compared to wild-type in MeCP2-
null mice (19). This finding can be reconciled by considering that MeCP2 can modify 
genomic chromatin architecture directly and independently of histone modifier proteins 
(24,36). Considering that specific genes such as BDNF and TRKB are either down-or-up 
regulated respectively in the MeCP2-knockout mouse model, this leaves open the 
prospect of unidentified factors directing MeCP2 localization (55).  
 
1.5 Potential Clinical Correlation between MeCP2 Do mains and Rett Syndrome:  
Missense and nonsense mutations that cause RTT are found in all six structural 
domains of MeCP2 (56). This argues that all domains are required for proper function of 
the protein. Toward this end, recent studies have attempted to correlate the location of 
the mutation with specific facets of RTT pathogenesis. Though the majority of RTT 
cases are caused by either single point mutations or truncation mutations in MeCP2, the 
diagnosis of RTT is defined via clinical observation, not genetically (57).  
Perhaps the most influential factor in disease severity is the type of X-
chromosome inactivation (XCI). Females with favorably skewed XCI may have very mild 
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learning disabilities while a spectrum of severity correlates with increasingly unfavorable 
XCI to autism and on to later onset RTT (57). Some attempts have been made to 
correlate MeCP2 mutations to disease severity by comparing data in the international 
RTT database to clinically reported severity. Two common RTT mutations in MeCP2, the 
R168X and T158M mutations, were chosen for a study in which the degree of XCI 
skewing and direction were observed and correlated with RTT severity (58). The study 
reports that there is a statistically significant correlation between unfavorable XCI and 
measured clinical severity.   Though the correlation appears to be statistically significant, 
it does not appear very robust. One MeCP2 mutation that has been directly implicated to 
have elevated severity regardless of XCI skew is the R270X mutant. This truncation 
mutant decreases life expectancy in RTT patients compared to all other recorded 
mutations (59).  Recently Neul et. al have established that individuals with the R168X 
mutation are more severely affected than those with R294X and other late carboxy-
terminal truncating mutations (60) highlighting the importance of domains that are C-
terminal to the MBD.  These researchers established that different point mutations affect 
the severity of the three main pathological problems associated with RTT: loss of 
language, walking, and hand use.  The correlation between domain mutation and 
disease phenotype is depicted in Figure 1.3. The most severe mutation observed was 
the R168X. Individuals with this truncation mutation lose the ability to walk, use their 
hands properly, and more frequently lose their entire vocabulary. The truncation 
mutations in the carboxyl-terminal are less severe. These patients have a higher 
probability of walking and retaining vocabulary, although they exhibit other significant 
problems. The R306C point mutation only affects language skills.  Taken together, the 
clinical studies and the distribution of mutations in the RTT database suggest that all six 
MeCP2 structural domains shown in Figure 1.2 must function together to mediate the 
normal cellular actions of MeCP2.  
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        The fundamental question of how MeCP2 functions in the nucleus of nearly all 
vertebrate tissues should be approached in the future from the new structural and 
functional perspectives discussed above. Specifically, at the molecular level, what is the 
relationship between intrinsic disorder, MeCP2 domain organization and protein function? 
How do different mutations in the highly disordered MeCP2 tertiary structure cause 
different neurodevelopmental RTT symptoms? How does MeCP2 affect chromatin 
architecture in vivo? Does MeCP2 have to bind to currently unknown proteins that 
modulate its capacity to regulate transcription?  What, exactly, is the role of MeCP2 in 
pre-mRNA splicing? Does MeCP2 directly bind to RNA molecules? Are there cellular 
functions of MeCP2 that have yet to be discovered? The new data requires that I step 
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The ability of full-length Methyl CpG binding protein 2 (MeCP2) and its isolated 
domains to gain α-helical structure in 2, 2, 2—trifluoroethanol (TFE) has been 
determined by deconvolution of circular dichroism (CD) data. The isolated MeCP2 
domains studied include the N-terminal domain (NTD), the methyl DNA binding domain 
(MBD), the intervening domain (ID), the transcription repression domain (TRD), and the 
C-terminal domain (CTD). Full-length MeCP2, which is 68% unstructured and 7% α-
helical in 0% TFE, becomes 55% α-helical in 70% TFE while remaining 24% 
unstructured. The NTD, MBD, TRD, and CTD acquired α-helical structure in 70% TFE, 
but not the ID. Thus, only those domains that contained predicted α-molecular 
recognition features (α -MoRFs) were induced to become more α -helical. In quantitative 
terms, the NTD, MBD, and CTD gained ~25-30% α-helix in 70% TFE while remaining 
~35% unstructured. This is in contrast to the TRD, which became almost completely α-
helical in 70% TFE. Based on these results we discuss the potential relationships 
between coil to helix transitions, intrinsic disorder, and MeCP2 structure and function. 
 
MeCP2 is a nuclear protein that has the ability to selectively recognize methylated 
DNA (2). It is particularly abundant in the nuclei of neuronal cells, where its stoichiometry 
approaches one MeCP2 per nucleosome (54).  MeCP2 is mainly distributed in both 
promoter and intergenic regions in vivo (5). While originally described as a DNA 
methylation-dependent gene repressor (16), more recently it has been shown that 
MeCP2 both activates and represses specific gene transcription (4). In the process, 
MeCP2 interacts with unmethylated and methylated DNA, nucleosomes (61,62) and 
chromatin (63), RNA and RNA splicing machinery (34,64-66), and thus far nearly 20 
different protein partners (16,22,67-81). In addition to defining the structure/function 
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relationships that apply to MeCP2 in the normal physiological state, there is intense 
interest in MeCP2 because of its role in the neurodevelopmental disease, Rett 
Syndrome (RTT). Specifically, many different missense and nonsense mutations located 
throughout the length of the MeCP2 polypeptide chain are associated with the onset of 
RTT (23,82-84).  
 
MeCP2 is 486 residues in length and has a mass of 53 kDa. It is monomeric when 
free in solution (85).  MeCP2 is digested into a number of limiting peptides by trypsin 
(85).  Subsequent N-terminal sequencing of these peptides yielded the linear domain 
organization of the protein. The N-terminal domain (NTD) encompasses residues 1-78, 
the methyl DNA binding domain (MBD) residues 79-167, the intervening domain (ID) 
residues 168-205, the transcription repression domain (TRD) residues 206-299, and the 
C-terminal domain (CTD) residues 300-486 (85). Importantly, the MBD (8), ID (86), and 
TRD (3) have previously been mapped to essentially the same locations using various 
functional assays (e.g. DNA binding, transcriptional repression), and nonsense 
mutations that delete the C-terminal ~200 residues are common in RTT (87). Thus, one 
obtains the same linear MeCP2 domain organization whether derived from structural or 
functional sources. 
 
Native MeCP2 is ~60-70% unstructured as shown by circular dichroism (CD) (85,88) 
and has a frictional coefficient indicative of a random coil as demonstrated by analytical 
ultracentrifugation (85). Hydrogen/deuterium exchange (H/DX) experiments have 
revealed that the entire MeCP2 polypeptide chain exhibits very rapid H/DX except for the 
MBD, and even the MBD shows faster H/DX than a typical globular protein (13). 
Moreover, while DNA binding locally stabilized the MBD fold, the remainder of the 
protein remained largely unstructured (13). The biophysical studies indicate that MeCP2 
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is an intrinsically disordered protein when free in solution and when bound to 
unmethylated and methylated DNA. Intrinsically disordered proteins lack secondary 
structure elements throughout much or all of their polypeptide chain, yet are functional 
(89-95). Consistent with the biophysical data, both the FoldIndex and PONDR algorithms 
predict that MeCP2 has long stretches of disordered sequence interspersed with short 
regions of secondary structure (85,96). MeCP2 is also predicted to have nine α-
molecular recognition features (α-MoRFs), which are segments of an intrinsically 
disordered protein that become α-helical upon binding to other macromolecules (97,98). 
The predicted α-MoRFs are distributed in each MeCP2 domain except the ID (63).  
 
In the present studies our working hypothesis was that full-length MeCP2 and those 
isolated domains that contain α-MoRFs would gain α-helix content in the presence 2-2-
2-trifluoroethanol (TFE), which stabilizes intramolecular hydrogen bonds in proteins (99-
102). TFE has been shown to induce α-helical structure in intrinsically disordered 
proteins such as the linker histones (103,104), measles virus nucleoprotein (105) and 
the carboxyl-terminal domain of heat-shock factor 1 (106). To test our hypothesis, we 
have used CD to determine the fraction of MeCP2 and its domains that are α-helical, β-
strand/turn, and unstructured as a function of TFE concentration. Our results indicate 
that full-length MeCP2 and all isolated domains except the ID become significantly more 
α-helical in TFE. Thus, there was a direct correlation between the presence of predicted 
α-MoRFs and TFE-induced acquisition of α-helical structure. The TRD became almost 
completely α-helical in 70% TFE, while the NTD, MBD, ID, and CTD remained partially 
unstructured under these conditions. Based on these results we discuss ways in which 





2.2 EXPERIMENTAL PROCEDURES 
2.2.1 Protein expression and purification.  Histone variant H5 was purified from 
native chromatin derived from mature chicken erythrocytes as described previously 
(107). Full-length MeCP2, NTD, MBD, ID, and TRD domains were expressed and 
purified using the Intein Mediated Purification with an Affinity Chitin-binding Tag 
(IMPACT) system (New England Biolabs). The CTD was expressed using a modified 
pET28a vector plasmid (Novagen). The MBD and TRD constructs contained an added 
sequence, EFLEGSSC, on their C-terminal ends as a result of previously described 
cloning methods (85,96).  The ID was cloned without this vestigial sequence and 
corresponded to the DNA sequence that codes for amino acids 168-205 from wild-type 
MeCP2 using the following primers (ID5’) 5’-GGA GCC CCC ATA TGC GAG AGC AGA 
AAC CAC CTA AGA AGC C-3’; and (ID3’) 5’-CAT AGG CTC TTC GGC ACT CTG ACG 
TGG CCG CCT TGG GTC TC-3’. Primers were designed to amplify DNA fragments 
cleavable by restriction enzymes Nde1 on the 5’ side and Sap1 on the 3’ side. The NTD 
construct was amplified to express wild type MeCP2 amino acids 1-78 using the 
following primers; (NTD5’)  5’-GAC ATA TGG TAG CTG GGA TGT TAG GGC TCA 
GGG AAG-3’; and (NTD3’) 5’- CAG AAT TCA GAA GCT TCC GGC ACA GCC GGG 
GC-3’.  The NTD insert was amplified from the wild type MeCP2 template such that it 
was cleaved by NdeI and EcoR1, gel-purified, and ligated into correspondingly digested 
and purified pTYB1 vector plasmid. The NTD also expresses with an additional non-
native eight amino acids, EFLEGSSC as a result of the NdeI and EcoR1 cloning strategy.   
  
E. coli BL21RP+ was used as host bacteria for expression by pTYB1 plasmid. A 
transformed bacterial colony was selected and grown in lysogeny broth to an optical 
density of 0.5 absorbance units (590 nm) at 37ºC. Translation was induced with 0.4 mM 
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isopropyl-β-D-thiogalactopyranoside (IPTG) at 18°C for 3 hours b efore harvest. Bacteria 
were centrifuged in an Avanti J-26 XPI preparative centrifuge (Beckman Coulter) in a 
JLA 8.100 rotor at 5,000 g for 10 minutes. Pellets were resuspended in wash buffer (25 
mM Tris, pH 7.5/100 mM NaCl) and centrifuged again under the previous conditions.  
Bacterial pellets were resuspended in column buffer (25 mM Tris–HCl pH 8.0, 500 mM 
NaCl)  with 0.1% Triton X-100, 0.2 mM PMSF, and  Protease Inhibitor Cocktail Set II 
(Calbiochem) added. Re-suspended bacteria were subjected to two rounds of sonication, 
90s each with a Branson Sonifier 450.  A large tip set to 50% duty cycle with a power 
output of 7 was employed. Sonicated lysate was poured into Oakridge tubes and 
centrifuged at 21,000 g for 25 min in a JA-17 rotor (Beckman). Clear supernatant was 
mixed with chitin beads (New England Biolabs) previously equilibrated in column buffer 
and the mixture was incubated at 4ºC overnight.  Errant contaminating bacterial DNA-
MeCP2complexes were washed from the samples from the chitin beads with five column 
volumes column buffer, followed by an equal volume column buffer at 900 mM NaCl final 
concentration.  Chitin beads were re-equilibrated with an additional 5 column volumes of 
500 mM NaCl column buffer. Column buffer with 50 mM DTT was passed over the 
column such that 1 cm buffer remained between the meniscus and top of the column 
bed in a 10 cm Kontes FlexColumn (Fischer). The column was left for 48-72 hours which 
allowed intein mediated cleavage.  Column buffer was used to elute protein from the 
chitin column. The eluant was diluted with column buffer with no salt from 500 mM to 
100 mM NaCl and loaded onto a HiTrap Heparin HP column (GE healthcare).  Proteins 
were eluted via step gradient from 100 mM NaCl to 1M NaCl buffer from the heparin 
column. A gradient using 100mM NaCl steps in 25 mm Tris, pH 7.5, 10% glycerol 
background buffer was employed. Peak fractions were loaded on a 12% SDS 
polyacrylamide gel to analyze for purity and/or degradation, then pooled and dialyzed 
into 10 mM Tris pH 7.5.(108) 
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The CTD was expressed using a modified pET28a vector plasmid (Novagen) with an 
N-terminal 6-histidine tag cleavable by PreScission protease (GE Healthcare). Modified 
vector was kindly supplied by Dr. Wayne Lilyestrom.  The CTD fragment corresponds to 
residues 310-486.  The CTD construct was amplified with an Nde1 site on the 5’ end and 
a BamH1 site on the 3’ end with a stop codon included directly 3’ to the BamH1 site. The 
forward primers used to amplify these constructs were (CTD5’) 5’-GAC ATC CAT ATG 
GAG ACG GTC AGC ATC GAG G-3’; and (TRD-CTD5’) 5’-GAC ATC CAT ATG GAG 
GGT GTG CAG GTG AAA AGG G-3’. The reverse primer sequence is (MeCP2 486 3’) 
5’-CTG GGA TCC CTA GCT AAC TCT CTC GGT CAC G-3’. Constructs were 
expressed and purified using Ni-NTA agarose beads (Qiagen) as previously described 
(109).    
 
2.2.2 Circular dichroism .  
Stock solutions of the respective proteins were prepared at ~500 µg/ml 
concentration and stored in glass test tubes. Concentrations were determined by 
bicinchoninic acid assay (Pierce BCA™ protein assay kit, Thermo Scientific) conducted 
on a 96-well microplate and measured in a Bio-rad Model 680 microplate reader at 560 
nm. Peptide concentration accuracy was verified by total amino acid analysis 
(Biophysics Core, Department of Biomolecular Structure, University of Colorado Denver 
Anschutz Medical Campus). Dilutions were prepared in glass test tubes to a final volume 
of 220 µL such that the final protein concentration of 0.12 mg/ml in 1 mM Na phosphate, 
0.2 mM Na3EDTA with either 0, 20, 50, or 70% volumetric concentrations of 99.8%  
trifluoroethanol (Acros organics, Fisher).   The final pH was adjusted to 7.4 when 
necessary. All buffers were purified though a 0.2 µM filter (Metricel® Pall Corporation) 
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and proteins were dialyzed extensively into their respective buffers using 3,500 MWCO 
dialysis tubing (Spectrum labs).  
 
CD spectra were recorded from 260-190 nm on a Jasco-720 spectropolarimeter.  
Samples were transferred to a cuvette with a 1 mm path length and cooled to 20ºC. 
Spectra were collected at a bandwidth of 1 nm with a scanning rate of 10 nm/s in 
continuous scanning mode and a response time of 16 s. From raw data, collected 
spectra were buffer-subtracted and converted from millidegrees to molar ellipticity using 




Where [θ] is the mean residue ellipticity (degrees cm2 dmol-1 residue-1), θobs is the 
ellipticity measured in millidegrees, M is the protein mean residue molecular weight, l is 
the optical path length of the cuvette in cm, and C is the concentration of the protein in 
mg/ml. Ellipticity data were analyzed using Spectra Manager software version 1.53.01 
(Jasco Corporation) and saved as text files. Data files were then deconvoluted against 
the SDP48 basis set using CDpro software including CONTINLL, SELCON3 and 
CDSTRR methods (110).  Estimates of percent secondary structure were averaged 








2.3.1 Histone H5 and full-length MeCP2 gain α-helical content in TFE . 
 As a control we first examined the effect of TFE on histone H5, which has been 
previously studied by CD (103).  Representative CD curves for H5 are shown in Figure 
2.1A. Visual inspection of the curves showed a trend toward α-helix formation with 
increasing TFE, as indicated by the disappearance of the trough at ~200-205 nm and an 
increase in the peaks at ~195 and 220 nm. To quantitate these results, the CD curves 
were analyzed with CDPro (Experimental Procedures; (110)) and the % calculated 
secondary structure plotted against TFE concentration (Fig. 2.1B). Results indicate that 
there was a dose-dependent interconversion of unstructured content to α-helical content 
with increasing TFE concentration, while the amount of β-strand/turn stayed essentially 
constant. Specifically, in 0% TFE, H5 was 68% unstructured, 9% α-helix, and 23% β-
strand/turn, while in 70% TFE H5 was 31% unstructured, 38% α-helix, and 31% β-
strand/turn. The data obtained with H5 reproduce the results of earlier studies (103), 
validating the experimental results obtained below with MeCP2 and its domains. 
 
The CD curves for full-length MeCP2 in TFE are shown in Figure 2.2A and a plot 
of % secondary structure against TFE concentration is shown in Figure 2.2B. As with H5, 
MeCP2 showed a dose-dependent increase in α-helix with increasing TFE concentration. 
In 0% TFE MeCP2 was 68% unstructured and 7% α-helix. This changed to 24% 
unstructured and 55% α-helix in 70% TFE. The β-stand/turn component was ~25% in all 
TFE concentrations. Thus, for full-length MeCP2, ~40% of the unstructured residues 





2.3.2 Induction of α-helix in isolated MeCP2 domains.  
To determine how the gain in secondary structure is distributed along the length 
of the MeCP2 sequence, we next characterized the effects of TFE on isolated MeCP2 
domains. A schematic illustration of the MeCP2 domain organization is shown in 
Chapter 1 Figure 1.2 and 1.3. A plot of % secondary structure against TFE concentration 
for the NTD is shown in Figure 2.3. The α-helix content was 5% in 0% TFE and 34% in 
70% TFE. Under these same conditions the unstructured content decreased from ~65% 
to ~34%. The β-strand/turn content stayed constant at ~30%. Thus, for the NTD, ~25% 
of the initial unstructured residues were converted to α-helix in 70% TFE 
 
Our analysis of the MBD is shown in Figure 2.4. In 0% TFE, the MBD was ~32% 
unstructured, ~10% α-helix, and ~54% β-strand/turn. By 70% TFE, the values were 
~29% unstructured content, ~35% α-helix, and ~37% β-strand/turn. The data in Figure 
2.5 indicate that for the MBD some of the β-strand/turn was converted to α-helix, while 
the % unstructured residues stayed constant.  
 
Results obtained for the ID are shown in Figure 2.5. The data indicate that there was 
no significant change in secondary structure content in TFE for this domain; the % 
unstructured, α-helical and β-strand/turn content remained constant at ~32%, ~12%, and 
~55%, respectively. The lack of α-helix formation is notable given that the ID is the only 
domain that is not predicted to contain an α-MoRF (see Discussion).  
 
Characterization of the TRD is shown in Figure 2.6. This domain showed 
fundamentally different behavior compared to the others. In 0% TFE the unstructured 
content was 81%, α-helix was 7%, and β-strand/turn was 12%. This changed to 5% 
unstructured content, 89% α-helix and 7% β-strand/turn in 70% TFE. Thus, despite the 
33 
initial high degree of disorder, the TRD was induced to almost completely form α-helix in 
70% TFE. 
  
Lastly, we analyzed the CTD. Plots of % secondary structure against TFE 
concentration for the intact CTD peptide are presented in Figure 2.7. In 0% TFE, the 
unstructured content was 70%, α-helix ~5% and β-strand/turn 25%. This changed to 
36% unstructured content, 32% α-helix and 34% β-strand/turn in 70% TFE. Thus, for the 

















Figure 2.1.  Histone H5 ( Gallus gallus) gains α-helical content in a dose-dependent 
manner with increased TFE concentration according t o circular dichroism.  (a) 
Circular dichroism spectra of histone H5 measured in 0% (□), 20% (●), 50% (◊), and 
70% (▲) TFE revealed conversion to alpha helical secondary structure by 
disappearance of the trough between 200-205 nm and heightened peaks at 195 and 220 
nm. (b) Percent secondary structure is plotted against % TFE after deconvolution of CD 
data from panel (a) using CDpro software (see experimental procedures). The % 
disordered (▲) decreased from 68% to 31% in 0% and 70% TFE respectively. The % α-
helix (♦) increased from 9% to 38% in 0% and 70 TFE respectively, while % β strand/turn 





Figure 2.2.  Full-length wild-type MeCP2 isoform e2 (Homo sapiens) gains α-helical 
content in a dose-dependent manner with increased TFE concentration according to 
circular dichroism. (a) Circular dichroism spectra of MeCP2 measured in 0% (□), 20% 
(●), 50% (◊), and 70% (▲) TFE reveal conversion to alpha helical secondary structure 
by disappearance of the trough between 200-205 nm and heightened peaks at 195 and 
220 nm. (b) Percent secondary structure is plotted against % TFE after deconvolution of 
CD data from panel (a) using CDpro software (see experimental procedures). Similarly 
to H5, wild type MeCP2 has decreased % disordered (▲) from 68% to 24% in 0% and 
70% TFE respectively. The % α-helix (♦) increased from 7% to 55% in 0% and 70 TFE 






Figure 2.3.  The N-terminal domain (NTD) of MeCP2 gains alpha-he lical structure 
while losing disorder in increasing TFE concentrati on.   Percent secondary structure 
is plotted against % TFE after deconvolution of CD data from using CDpro software (see 
experimental procedures). The % disordered (▲) decreased from 65% to 34% in 0% 
and 70% TFE respectively, while % α-helix (♦) increased from 5% to 34% , and % β 







Figure 2.4.  The Methyl CpG Binding Domain (MBD) of MeCP2 gains alpha-helical 
structure at the expense of beta strand/turn content in increasing TFE concentration 
while the amount of disorder remains constant according to circular dichroism.  Percent 
secondary structure is plotted against % TFE after deconvolution of CD data using 
CDpro software (see experimental procedures). The % disordered (▲) remained 
constant at ~30% over the course of TFE titration. The % α-helix (♦) increased from 5% 







Figure 2.5. The Intervening Domain (ID) of MeCP2 does not undergo detectable change 
in secondary structure content during TFE titration according to circular dichroism. 
Percent secondary structure is plotted against % TFE after deconvolution of CD data 
using CDpro software (see experimental procedures). The % disordered (▲), % α-helix 









Figure 2.6.  The Transcription Repression Domain (TRD) of MeCP2  almost entirely 
converts to α-helix in 70% TFE.  Percent secondary structure is plotted against % TFE 
after deconvolution of CD data from using CDpro software (see experimental 
procedures). The % disordered (▲) decreased from 81% to 5% in 0% and 70% TFE 
respectively. Most of the diminished disorder transformed to alpha helix as % α-helix (♦) 
increased from 7% to 89% , and % β strand/turn (■) decreased slightly from 12% to 7% 










Figure 2.7.  The C-terminal Domain (CTD) of MeCP2 went from a mostly disordered 
state to a structure with equal parts disorder, α-helix, and β-strand/turn with increased 
TFE concentration.  Percent secondary structure is plotted against % TFE after 
deconvolution of CD data from using CDpro software (see experimental procedures). 
The % disordered (▲) decreased from 70% to 36% in 0% and 70% TFE respectively. 
The % α-helix (♦) increased from 5% to 32%, and % β strand/turn (■) increased slightly 












In the present study we have examined how the hydrogen-bond stabilizing solvent, 
TFE (99,100,111-113), influences the α-helical content of MeCP2 and its isolated 
domains. CD experiments in the presence of TFE have proven useful in studying coil-to-
helix transitions in other intrinsically disordered proteins (103-106). Our working 
hypothesis was that TFE would mimic the effects of molecular recognition and induce α-
helix formation in those regions of MeCP2 that contain α-MoRFs (63). α-MoRFs are 
short (i.e., ~10-70 residue) stretches of an intrinsically disordered polypeptide chain that 
have the ability to gain α-helical structure concomitant with macromolecular interactions 
(97,98,114,115). MeCP2 is predicted to have one or more α-MoRFs in the NTD, MBD, 
TRD and CTD but none in the ID (63). Our results indicate that full-length MeCP2 and all 
of its domains except the ID acquire α-helical structure in a dose-dependent manner in 
TFE. Thus, there was a direct correlation between α-helix induction by TFE and the 
presence of predicted α-MoRF(s) in the domain. This suggests that many different 
regions of the MeCP2 polypeptide chain form α-helices and act as binding interfaces 
under the right conditions. Toward this end, the NTD interacts with HP1 (78), the MBD 
with unmethylated and methylated DNA (36,61,85,96,116) and the ATRX protein (74), 
the TRD with many different co-repressors (16,22,70,75,76,79) and unmethylated DNA 
(85,96), and the CTD with unmethylated DNA (96), chromatin (96), and RNA-splicing 
machinery (34,66). Moreover, some proteins interact with multiple MeCP2 domains, e.g., 
PU.1 binds to the NTD and TRD (80), CDKL5 binds to the TRD and CTD (70), and 
DNMT1 binds to the MBD, ID and TRD (79). 
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 Based on the CD (present studies) and H/DX (13) results, we envision the following 
paradigm for the structural basis of MeCP2 multifunctionality. When free in solution 
MeCP2 has regions of quasi-stable secondary structure located throughout the length of 
its polypeptide chain. Consequently, the protein sequence rapidly samples multiple 
secondary structures and the full-length protein is highly conformationally malleable. 
This intrinsic flexibility, together with strategically located coil-to-helix transitions allows 
the formation of many different macromolecular complexes. Finally, many nuclear 
regulatory proteins are components of large macromolecular assemblies that 
themselves are very malleable (117). Thus, its marked conformational flexibility may be 





























Non-specific unmethylated DNA binding activity in t he 
intervening and carboxy-terminal domains of MeCP2 h as been 















MeCP2 has historically been known and, in fact, named for its ability to bind 
methylated DNA, but recent in vivo experiments reveal it to be bound to both actively 
transcribed and repressed regions of the genome (see Chapter 1).  The significance of 
MeCP2 binding non-methylated DNA is further emphasized by the observation that it 
binds ubiquitously throughout the entire genome with a stoichiometry of one MeCP2 
molecule per every two nucleosomes in neuronal tissue (54).   These observations have 
focused experimental efforts in this chapter on examining which regions of the MeCP2 
molecule are responsible for binding non-methylated DNA and chromatin in vitro.  My 
interest in MeCP2 lies in its ability to bind DNA and to condense nucleosomal arrays into 
locally folded secondary chromatin structures and oligomeric suprastructures (24).   
MeCP2 consists of six protease-resistant domains organized into an intrinsically 
disordered, random-coil-like tertiary structure (85). These domains in linear order are the 
N-terminal domain (NTD), methyl DNA binding domain (MBD), intervening domain (ID), 
transcriptional repression domain (TRD), C-terminal domain-alpha (CTD-alpha) and C-
terminal domain-beta (CTD-beta), depicted in Chapter 1, Figure 1.2. The full length 
protein is 486 amino acid residues in length, has an unusually high overall average pI 
(~11.6), and exists as a monomer in physiological conditions.  
  The observation that MeCP2 does not self associate, the overall low incidence 
of large hydrophobic amino acid residues, and enrichment of lysine residues leading to a 
higher than average isoelecric point provide further evidence that MeCP2 is a model 
intrinsically disordered protein (IDP). These descriptors align with those outlined by Dr. 




“Disordered proteins should also be protected from aggregation because, unlike 
globular proteins, they contain few hydrophobic amino acids, which tend to stick 
together — and are instead rich in 'polar' amino acids that are happy swimming 
in water.” 
 
Like other model IDPs such as p53 and Sic1, MeCP2 also has numerous binding 
partners.  Reviewing the literature reveals in excess of 20 direct binding partners. 
Though disruption of binding to these partners undoubtedly plays a role in pathological 
phenotypes of Rett syndrome, the observation that four out of the six protease-resistant 
domains bind unmethylated DNA focused our investigation into the role of MeCP2 in 
chromatin architecture (8,36,61,96,116,118-120).     
The most clearly understood DNA-binding motif of MeCP2 is the MBD 
(11,12,121). When expressed as an isolated peptide (amino acids 77-167) MBD, 
compared to all other MeCP2 peptides, is least susceptible to degradation after 
purification (personal experience). The crystal structure of the MBD bound to a 
methylated 20mer double-stranded DNA molecule from the BDNF promoter reveals a 
three-stranded beta sheet along with a single 11 amino acid α-helix forming a wedge 
tertiary structure that fits non-specifically in the major groove of DNA.  This wedge 
makes contact by proxy to the methyl-group on a methylated CpG via a coordinated 
water molecule.   The portion of the MBD consisting of recognizable secondary structure 
is 34 amino acids in length accounting for 7% of the entire MeCP2 molecule.  Little 
structural information is known of the remaining 93% of the protein. Clinical reports of 
RTT-causing MeCP2 mutations show two widespread types of Rett mutations: missense 
mutations in the MBD, and nonsense mutations which result in truncation of the 
carboxyl-terminal portion of the protein. These are however not the only mutations 
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causing Rett syndrome.  Mutations along the entire length of MeCP2 have been reported 
(see frequency of amino acid mutation at the Rett syndrome database - 
http://bit.ly/fep0kk). 
Experimental observations presented in Chapter 2 revealed that MeCP2 has 
TFE-inducible alpha-helix distributed along the entire length of the protein excluding the 
ID.  The coincidence of DNA-binding activity and regions of inducible alpha helix by TFE 
titration in previous studies of the C-termini of histones H1 and H5 (103) led me to ask 
similar questions of MeCP2 domains.  Does the presence of inducible α-helices in 
MeCP2 domains coincide with unmethylated DNA-binding activity? I went on to use the 
same domains used in Chapter 2 and several additional fragments to search for 
unreported DNA-binding domains and narrow the regions of MeCP2 that bind 
unmethylated DNA. Though MeCP2 exists as 60% disordered in the absence of a 
binding partner or secondary structure-inducing solvents, it retains the ability to bind an 
array of partners, primarily unmethylated DNA.   
To better understand the molecular basis for MeCP2 interaction with 
unmethylated DNA, I characterized the DNA- and chromatin-binding properties of eleven 
MeCP2 domains or domain pairs when expressed and purified as individual 
polypeptides. Electrophoretic mobility shift assays (EMSAs) were used to assay DNA 
and chromatin binding and chromatin compaction.  Results indicate that that the MBD, 
ID, TRD, and CTD-alpha all bind to unmethylated DNA. Mutants in the full length protein 
confirmed binding sites identified in the ID and CTD-alpha ((96) and unpublished data 
from Dr. Mary Porter-Goff respectively). Quantification of the binding affinity yielded 
nanomolar dissociation constants for all unmethylated-DNA-binding regions (96).  In 
regions of MeCP2 where new DNA-binding domains were observed, point mutations 
were made to further narrow the DNA binding region.  The major contribution to this 
work came by in-depth investigation of the intervening domain (ID) and the strong 
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methylation-independent DNA-binding activity of this domain.  Point mutations in this 
domain indicate that the DNA binding is facilitated by residues that are N-terminal to 
residue 188 (aa numbered in context of full-length MeCP2).  
   Interestingly, parallel results agree that the ability of MeCP2 to compact 
nucleosomal arrays into secondary chromatin structures can be reproduced by the TRD-
CTD fragment of the protein.  There is consensus in the published results (see Chapter 
4) that the MBD acts as an autonomous domain that can recruit MeCP2 to methylated 
DNA (96). However, extensive engagement of a large internal region of the protein with 
unmethylated DNA, followed by binding to either other nonspecific DNA or histones by 
the CTD is necessary for full-length MeCP2 to condense nucleosomal arrays into novel 
locally folded secondary chromatin structures.   
 
3.2 Materials and methods: 
3.2.1 MeCP2 Domain cloning and expression: 
 Domains were expressed and purified using either the Intein-Mediated 
Purification with an Affinity Chitin-binding Tag (IMPACT) system or the Histidine-tagging 
modified pET28a vector system. Both methods are described in detail in Chapter 2 of 
this dissertation.  Constructs used in the present study are listed in table 3.1 with vector 









Table 3.1  MeCP2 constructs used in electrophoretic mobility s hift assays are 
listed . Corresponding amino acid numbers in relation to the full length MeCP2 protein 
are listed in middle column.  The vector plasmid housing each construct is listed in the 
right column. 1-Unable to express this construct. 
 
Domain – as defined by 
the Hansen Lab (85). 
MeCP2 
residues 
Vector Plasmid  
MeCP2 full length wt 1-486 ptyb1– (chitin binding protein) 
NTD 1-78 ptyb1 – (chitin binding protein) 
MBD 78-168 ptyb1 – (chitin binding protein) 
ID (intervening domain) 168-206 ptyb1 – (chitin binding protein) 
TRD 198-305 ptyb1 – (chitin binding protein) 
CTD (α+β) 300-486 ptyb1 – (chitin binding protein) 
R188E full length MeCP2 1-486 ptyb1 – (chitin binding protein) 
R188E - ID 168-206 ptyb1 – (chitin binding protein) 
GRP189-191AAA - ID 168-206 ptyb1 – (chitin binding protein) 
CTDβ (Adams) 354-486 petP – His-tag 
1CTDα 310-354 petP – His-tag  
Acidic domain 400-450 petP – His-tag 
TRD-CTD 198-486 petP – His-tag 











An alternate expression system was implemented for four MeCP2 constructs. 
This modified pet 28a plasmid system includes a PreScission protease site added 
between the histidine tag and the coding region. The vector, known as petP plasmid, 
was modified and provided to us by Dr. Wayne Lilyestrom. The modified pET28a vector 
is about 3,000 base pairs shorter than the pTYB1 vector and is less cumbersome for 
making point mutations.   
Fragments spanning residues 310-354, 355-486, 400-450 were synthesized, 
codon-optimized, and sub-cloned by geneart (www.geneart.com). Fragments spanning 
residues 300-486 and 206-486 were sub-cloned by traditional cloning methods 
described in Chapter 2 of this dissertation.  
Point mutants were prepared in the context of the full-length MeCP2 protein and the ID.  
Site-directed mutagenesis was done as described before (122). Single-stranded DNA 
primers were ordered from Integrated DNA technology (IDT).  For full-length and ID 
R188E point mutations the following primers were employed, forward 5’ – GGC AGA 
GGC GAG GGA CGC CCC AAA G – 3’, and reverse 5’ – CCC TTT GGG GCG TCC 
CTC GCC TCT GC – 3’. To generate the GRP189-191AAA triple alanine replacement 
mutant in the context of ID the following primers were used, forward 5’ – GGC AGA 
GGC CGG GCA GCC GCC AAA G – 3’, reverse 5’ – TGC CGC TCC CTT TGG CGG 
CTG CCC GG – 3’.  For the reactions described in the Carrigan protocol, Pfu Turbo® 
was used instead of PfuUltra® high-fidelity polymerase. Both enzymes are available 







3.2.2 Reconstitution of 208-12 Nucleosomal arrays : 
 Chromatin templates were reconstituted by combining histone octamers purified 
from Gallus gallus erythrocytes and a DNA  template consisting of  twelve tandem 
repeats of a  208-base pair sequence derived from the sea urchin Lytechinus variegatus 
5 S rRNA. Arrays were reconstituted according to the salt dialysis method of Hansen 
and Lohr (123). Experiments were repeated using recombinant wild-type Xenopus laevis 
octamers instead of the native Gallus gallus octamers. Xenopus histones were obtained 
from Teri McLain of the W. M. Keck Protein expression and purification facility for 
histones. 
 
3.2.3 Electrophoretic Mobility Shift Assay (EMSA): 
 Nucleoprotein complexes were analyzed by EMSA in native 0.8% agarose gel 
run in Tris, acetic acid, EDTA (TAE) buffer at 5 V/cm for 4-5 hours. Complexes were 
formed by mixing nucleosome arrays with indicated molar ratios of various purified 
MeCP2 constructs and allowed to incubate at room temperature for 30 minutes before 
loading on the gel. A molar ratio of 1 corresponded to one protein molecule per one 
repeat of 208 base pairs of DNA or per nucleosome repeat for arrays.  This translates to 
12 molecules of the respective protein per array or naked 208-12 DNA molecule. In all 
cases 200 ng of DNA was used if the substrate was naked DNA, while 400 ng of arrays 
were used.  Twice the amount of array was used because nucleosomes hinder the 
binding of ethidium bromide and impair visualization. Thus, more material is needed to 
see the nucleoprotein complexes as bands when an array is used as the substrate. 
Glycerol at 10% by volume concentration was used as a loading buffer to keep the 




3.3 Results and Discussion: 
3.3.1 DNA binding in the C-terminus of MeCP2 lies b etween residues 300-354: 
Specific focus has been placed on the C-terminus of MeCP2 as there is a high 
frequency of clinically observed C-terminal deletion mutations in the MeCP2 gene in Rett 
patients (87).   After our collaborators initially observed amino acids 335-486 (which they 
termed the CTDβ) bound to nucleosomal arrays but not to methylated DNA, I wanted to 
test the CTDα+β domain fusion (simply termed CTD) for this unique chromatin binding 
ability. I also wanted to compare this binding with the binding of the TRD-CTD domain 
fusion.  The TRD is known to have DNA binding ability as our collaborators had shown 
this domain fusion to have ability to compact chromatin templates nearly as efficiently as 
wt MeCP2 (85).  I also hypothesized that the short acidic portion of the C-terminal of 
MeCP2 spanning residues 400-450 may be responsible for histone binding based on its 
anomalously low isoelectric point (4.86) relative to the overall basic isolelectric point of 
full-length MeCP2 (9.5).  
The 0.8% agarose gel imaged in the Figure 3.1 contains three different DNA-
based templates; 208-12 DNA alone in the top left section of the image, subsaturated 
208-12 arrays loaded with ~11 recombinant tailless Xenopus octamers in the bottom left 
section, and subsaturated 208-12 arrays loaded with ~11 recombinant Xenopus 
octamers (with intact tails) in the top and bottom sections on the right third of the image 
(separated by the DNA ladders).  Each of the three DNA-based templates listed in the 
last sentence were incubated with either 2,4, or 6 molecules of wt MeCP2, CTD, TRD-
CTD, and 400-450 and run on the same agarose gel.  Experiments were conducted on 
one large agarose gel rather than split up on smaller gels so that direct comparisons 
could be made between electrophoretic mobility. This technique ensured that run-time, 
buffer concentration, and agarose percentage were uniform. Each band in this results 
section is a trans-UV illuminated DNA-based template stained with ethidium bromide 
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after binding the listed fragments of MeCP2 for 30 minutes at room temperature in a final 
volume of either 20 or 40 µl for DNA alone and chromatin templates respectively. The 
concentration of DNA template in all experiments was held constant at 8 nM. Mixtures 
were incubated in a sealed Eppendorf tube to maintain equal molar concentration of 















Figure 3.1  CTD shifts DNA alone, nucleosomal arrays, and taill ess arrays while the 
acidic region spanning residues 400-450 does not. The paneled pictures above were 
captured from the same 0.8% agarose gel. They show the relative electrophoretic 
mobility of 208-12, DNA alone, nucleosomal arrays with and without N-terminal tails. 
Each MeCP2 construct was incubated with 200 ng of array or DNA alone at 2,4, and 6 






3.3.2 There is no observable histone-tail dependenc e for wt MeCP2, CTD, TRD-
CTD or 400-450 MeCP2 peptides by electrophoretic mo bility shift assay. 
  According to the results in Figure 3.1 the absence of the histone N-
terminal tails does not change the shifting capacity of wt MeCP2, CTD, TRD-CTD, or the 
400-450 peptide. The relative mobility of each nucleoprotein complex matched in tailed 
vs. tailless arrays. This is a preliminary result indicating the role of histone tails in 
compaction is non-essential for nucleosomal array compaction, though it does not rule 
out a direct interaction between MeCP2 and the histone amino-terminal tails.   
 
3.3.3 The TRD-CTD domain fusion can bind and compac t both DNA and 
nucleosomal arrays similarly to wt MeCP2 while the CTD cannot.   
The EMSA in Figure 3.1 demonstrates DNA, nucleosomal arrays, and tailless 
nucleosomal arrays were compacted by both wild-type MeCP2 and the TRD-CTD 
domain fusion and unable to enter the agarose gel by a molar ratio of 6.  This is not the 
case for the CTD alone. At the highest molar ratio assayed, CTD was able to shift all 
templates but not to the same degree as wild-type or the TRD-CTD fusion.  The 
observation of the TRD-CTD having similar ability to compact nucleosomal arrays as 
wild-type MeCP2 is in agreement with the findings of our collaborators in Figures 4.3 and 
4.4 of Chapter 4. It is important to note that the domain nomenclature used in that paper 
differs significantly from the nomenclature used in the rest of this dissertation.  The 
differences are in the precise amino acid residue numbers that constitute the CTDα. 
Based on previously published trypsin digestion resistance mapping conducted by Dr. 
Valerie Adams, I define the CTDα as residues 310-354, whereas our collaborators 
define the CTDα as residues 261-330. Examining “Table 4.1. Domains of Human 
MeCP2 Used in this Study” in Chapter 4 reveals confusing nomenclature surrounding 
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the CTDα.  The CTDα is listed in the table but no corresponding residue numbers are 
listed and the “CTD” is there defined as residues 261-330. 
I was unable to express what the Hansen lab has defined as the CTDα (310-354) 
but I was able to express and purify residues 300-486 which is named CTD in this 
dissertation.  The observation that this CTD fragment (300-486) shifts DNA, nucleosomal 
arrays, and tailless arrays is being reported here for the first time.  Making a direct 
comparison between the shifting capacity of TRD-CTD fusion, wild-type MeCP2 and the 
CTD is also a novel observation.   
 
In the next set of gel shift experiments I further narrowed the region in the C-
terminal portion of MeCP2 that can shift DNA and chromatin templates.  Figure 3.2 
refines the initial observation in Figure 3.1 by examining smaller and further C-terminal 
pieces of MeCP2.  As Figure 3.1 shows, there is no significant difference between 
MeCP2 fragment-binding to tailed vs. tailless arrays.  Therefore tailless arrays were not 
used in the experiment depicted in Figure 3.2. I tested the ability of fragments 354-486 
and 335-486 in MeCP2  to bind and shift either 208-12 DNA alone (depicted in the top 
ppanel of Figure 3.2) or 208-12 nucleosomal arrays (depicted in the lower panel of figure 






Figure 3.2 MeCP2 fragment 335-486 shifts 208-12 DNA  and nucleosomal arrays 
while fragment 354-486 does not. Each MeCP2 construct was incubated with 200 ng 
of array or DNA alone at 2,4, and 6, 8 and 12 molecules MeCP2 fragment per 208 bp 








3.3.4 MeCP2 residues 400-450 cannot bind either DNA  or nucleosomal arrays.  
MeCP2 residues 400-450 were cloned and expressed as an isolated fragment because 
of the anomalously low isoelectric point of that fragment compared to the high average 
isoelectric point of the protein overall (4.86 compared to 9.95 respectively). It was 
hypothesized that this acidic bit of MeCP2 may be the piece responsible for histone 
binding. However, this was not the case in vitro as 400-450 expressed alone could not 
bind DNA or chromatin templates. This is clearly demonstrated in both Figures 3.1 and 
3.2 in which the 400-450 fragment has no effect on the electrophoretic mobility of DNA, 
nucleosomal arrays, or tailless arrays at any of the assayed molar ratios.  There were no 
observable shifts by the 400-450 fragment. 
 
3.3.5 Carboxy-terminal domain mutants 300-486 and 3 35-486 of MeCP2 bind 
unmethylated DNA and nucleosomal arrays, while resi dues 354-486 do not.   A 
pTYB1 plasmid containing a construct coding for MeCP2 amino acid residues 335-486 
was obtained from the lab of Chris Woodcock. This fragment, which they named the 
CTDβ, has 20 more amino acids on the N-terminal side than does the CTDβ 
(corresponding to residues 354-486) as named by our lab in 2007. In the study 
mentioned earlier (see Appendix I), the CTDβ as defined by Woodcock and Ghosh was 
used to establish a unique motif in the carboxy terminal of MeCP2 capable of shifting 
nucleosomal arrays but not DNA alone.  The data I collected and presented in Figure 3.2 
does not agree with these published results. I used the CTDβ (according to Ghosh; 335-
486) and the CTDβ (according to Adams; 354-486) and compared their ability to bind 
either 208-12 DNA alone or nucleosomal arrays.  I found the fragment 354-486 
incapable of shifting DNA alone or nucleosomal arrays, while fragment 335-486 was 
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able to shift both nucleosomal arrays and DNA alone.  This observation indicates the 
unmethylated-DNA-binding ability in the carboxy terminal of MeCP2 lies between 
residues 335 and 354.  When considered in conjunction with the observed ability of 
fragment 300-486 to bind both DNA and arrays in Figure 3.1 there is the possibility of 
additional DNA binding activity between residues 300-335. Current investigation by Dr. 
Mary Porter-Goff is testing this hypothesis by deleting this region of MeCP2 from the full-
length protein.   
It is worth noting that the EMSAs I presented in Figure 3.1 and 3.2 were 
conducted using the 208-12 tandem-repeat 5S DNA alone, arrays reconstituted with this 
DNA and recombinant wild type Xenopus laevis octamers, and arrays reconstituted with 
tailless Xenopus octamers.  These reagents differed from those used by our 
collaborators (Dr. Chris Woodcock) as they used the 601 DNA sequence alone and 
reconstituted into arrays.  There is a difference in primary sequence of the reagents 
used which may account for the discrepancy between Figure 3.2 of this dissertation and 
panels a. and d. in Figure 4.3 of Chapter 4. However, this is unlikely as Dr. Uma 
Muthurajan tested the same C-terminal constructs as I on 601 and 207 mono-
nucleosomes and obtained EMSA results that agreed with mine (personal 
communication).  Also, fragment 354-486 did bind to DNA and arrays at extremely high 
molar ratios but needed to be mixed at an order of magnitude higher concentration 
(ratios between 40-60 were required) than wild-type to have the same effect. This 
observation shows the extreme carboxy-terminus of MeCP2 has weak unmethylated-
DNA-binding ability.   
Parallel studies conducted in the lab of our collaborator Dr. Christopher 
Woodcock show that CTD-beta (beginning at residue 335 extending to residue 486) can 
bind to nucleosomal arrays but does not bind to naked DNA. It was concluded from this 
study that there is a chromatin-specific binding site in this domain. However, when I 
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attempted to repeat this result I was unable to reproduce this and instead showed the 
MeCP2 fragment extending from amino acid 335-486 to bind and shift both 208-12 DNA 
alone and reconstituted chromatin arrays.  The results are published, though this 
discrepancy in the data is not resolved. 
 
 
3.3.6 DNA binding in the intervening domain (ID) of  MeCP2 resides in residues 
168-188: 
Prior to the observation that the TRD-CTD domain fusion within MeCP2 was the 
minimum required region to facilitate nucleosomal array compaction (96) our lab had 
hypothesized that a motif within the intervening domain (ID) of MeCP2 (aa 168-206) 
might facilitate array compaction. This hypothesis prompted me to perform a scanning 
BLAST search in the human proteome using a frame of 10 amino acids within the ID of 
MeCP2. I was looking for motif homologues of this region of MeCP2 that might also have 
chromatin architectural functionality. Here I found a seven-amino acid stretch of identical 
homology between MeCP2 and the HMGA family of architectural transcription factors. 
That sequence is RGRPKGS and corresponds to a.a. 188-194 in the human MeCP2 
gene product (see Figure 3.3). Consequently, these seven amino acids exactly match 
the middle of the three AT-hook motifs in the HMGA1 proteins and only roughly match 


























I conducted a series of gel-shift assays to determine if this homologous AT-hook 
motif was a genuine DNA-binding domain in MeCP2.  I began by generating point 
mutant - R188E, a residue at the N-terminal end of the AT-hook homology, in the context 
of full-length MeCP2.  This point mutation significantly reduced the ability of the full-
length protein to bind and shift non-methylated DNA alone. Figure 3.4 shows an image 
of a 0.8% agarose gel run at 5V/cm for four hours with 200 ng 208-12 DNA in lanes 2-9 
with labeled λ BSTE II marker in lane 1 and 10. DNA was mixed and incubated with the 
indicated molar ratios of wild-type MeCP2 or R188E point mutant respectively, indicated 

















Figure 3.4  MeCP2 R188E has reduced ability to shift nucleosoma l arrays in EMSA. 
In this 0.8% agarose gel Lambda BSTE II marker is shown in lanes 1 and 10, 200 ng 
208-12 5S DNA alone in lanes 2 and 9, and the same amount of DNA incubated with 
human MeCP2 full length wild-type at a molar ratio (moles protein: moles 208bp repeat) 
of 1, 5 , and 10 in lanes 3-5, and the R188E mutant full length MeCP2 at the same 











The result depicted in Figure 3.4 led me to clone the intervening domain peptide 
alone (residues 168-206) (as described in the materials and methods section of Chapter 
2 of this dissertation) and assay its ability to bind DNA. The 38-a.a. peptide was able to 
shift 208-12 DNA alone as shown in Figure 3.5. I also observed this to be reversible by 
competing the peptide off the 208-12 DNA by incubating it with 208-1 DNA. ID peptide 























Figure 3.5. ID alone binds and shifts 208-12 DNA. Pictured is a 0.8% agarose gel. 
Lane 1 is a λ BstEII DNA marker. Lane 2 contains 208-12 DNA alone. Lanes 3-7 show 
decreased 208-12 DNA mobility when a higher ratio of ID molecules per 208 b.p. repeat 














3.3.7 The Intervening Domain (ID) of MeCP2 has a ro bust non-specific DNA 
binding motif between residues 168-188.   
There are two regions inside the primary sequence of MeCP2 that have 
homology to an AT-hook. These correspond to MeCP2 residues 188-194 (within the ID)  
and residues 267-274 (within the TRD) (Figure 3.3).  An AT-hook is a novel peptide motif 
that binds non-specifically to the minor groove of DNA.  There are three such domains in 
each of the high mobility group A (HMGA) family of non-histone nuclear proteins (124). 
These novel AT hook motifs all share a consensus core of amino acids with a glycine, 
arginine and proline (GRP) making up the three amino acids that are most evolutionarily 
conserved.   Of the two ‘AT hook’-like motifs in MeCP2 the one from residues 188-194 
has the GRP core while the other has a lysine inserted between the R and the P of the 
motif.  I had hypothesized that this homologous domain was responsible for the DNA-
binding activity observed in the isolated ID peptide apparent in the gel shift in Figure 3.5.  
I disproved this hypothesis and instead showed that the DNA-binding activity present in 
the ID is most likely located between residues 168-188.  When I made a triple point 
mutation substituting three alanines in place of the GRP consensus core in the context 
of the isolated ID peptide, I observed an increased DNA binding affinity in gel shift 
assays (Figure 3.5). A single point mutation at residue 188, R188E decreased DNA 
shifting activity of the peptide.  During the course of these experiments I hosted Dr. 
Raymond Reeves of Washington State University to present a seminar on AT-hook 
motifs. During the course of his visit the seemingly counter-intuitive results made sense.  
He explained that nanomolar affinity of the AT hook motifs in the HMGA proteins require 
that the GRP consensus core be flanked on the amino side by a proline in order to give 
the motif the steric pucker necessary for the motif to wedge into the minor groove of 
DNA.  The ‘AT-hook’ –like region of the ID, though it has seven identical amino acids to 
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the central AT-hook of the HMGA proteins it is missing a proline on the amino side of the 
GRP core, indicating this is not the region of the ID responsible for the DNA-binding 
activity of the isolated ID peptide.  The observed homology suggests the HMGA family of 
non-histone nuclear proteins as ancestors to MeCP2.  Further studies are needed to 
narrow the DNA binding activity of the ID between residues 168 and 188.  This observed 
binding activity of the ID was observed in agreement with our collaborators’ results and 
was published jointly. The primary data of our collaborators was used in Figure 4.3 of 
Chapter 4. Results of point mutations generated and tested in Figures 3.4 and 3.5 are 


























Unique physical properties and interactions of the domains of 
























Chapter 4 is reprinted from a paper I jointly authored that first appeared in 
Biochemistry online April 20th, 2010 (96). The entire paper can be accessed freely at the 
following shortened URL - http://bit.ly/gc3Qup.  My contributions to this collaborative 
effort included corroborating results using each of the six MeCP2 fragments listed in 
electrophoretic mobility shift assays to determine DNA and chromatin binding activity in 
MeCP2 domains.  In depth discussion about agreement and discrepancies among these 



















 MeCP2 belongs to a family of conserved vertebrate proteins that bind to 
symmetrically methylated CpG dinucleotides and, at least in some cases, transmit 
epigenetic signals encoded in DNA methylation (reviewed in (125,126)). The finding that 
mutations in human MeCP2 result in Rett syndrome (RTT), a debilitating 
neurodevelopmental disorder (23), and that its mis-regulation is common in other 
patients with Autism Spectrum Disorders (127,128), stimulated a focused effort to 
determine its function(s) and mechanism(s) of action. It is now clear from work with both 
humans and mouse models which recapitulate many of the human symptoms, that 
MeCP2 is required for the development and maintenance of neurons in some regions of 
the brain (128). However, it has been difficult to determine the molecular event(s) that 
are affected by MeCP2 deficiency or by RTT-causing mutations which lead to functional 
deficit(s). A complicating issue is that the function of MeCP2 appears to be largely 
context dependent, varying with species, tissue and cell type, and presence of binding 
partners. Xenopus MeCP2, for example, is important in neuronal fate decisions in early 
embryogenesis, a function not seen in mice (129). In humans, MeCP2 deficits have 
been linked to conditions other than RTT, including cancer (118,130,131) 
Protease-resistance and modeling studies have revealed that MeCP2 is a 
striking example of an intrinsically unstructured protein containing protease resistant 
domains having varying degrees of disorder (85). Early work identified a short (~90 
residue) ordered region of MeCP2 (between residues 75-164) with the ability to bind 
methylated DNA (8). This region, named the methylated DNA binding domain (MBD), is 
highly conserved (only four amino acid differences between Xenopus and humans). Its 
structure has been determined by both NMR and x-ray diffraction (11,12,132). DNA 
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methylation is typically associated with transcriptional repression, and indeed MeCP2 
has been shown to repress methylated genes in artificial systems in vitro (3). This 
transcriptional down-regulation activity was mapped to amino acids 207-310 and the 
region was accordingly termed the transcriptional repression domain (TRD) (3). The 
MBD and TRD together comprise ~40% of the 486 residue hMeCP2 sequence (Fig. 4.1a, 
upper diagram).  
 One early proposed mechanism of methylation-dependent repression 
involves an initial binding of MeCP2 to methylated DNA via the MBD, followed by TRD-
mediated recruitment of the Sin3A co-repressor and histone deacetylase complexes 
(HDACs). The subsequent deacetylation of histones in nucleosomes would render the 
local chromatin region more refractory to transcription (133). However, it is now clear 
that the mechanism of repression is often more complex, involving multiple MeCP2 
binding partners. For example, in non-neuronal Rat-1 cells, repression of the neuron-
specific NaCh type II gene by MeCP2 appears to involve at least three direct MeCP2 
binding partners (methylated DNA, CoREST, and the histone H3 lysine methyl 
transferase SUV39H1) as well as indirect contributions from REST/NRSF and HP1 (134). 
In addition, the TRD of MeCP2 has been shown to be an important recruitment platform 
for several transcriptional modulators and epigenetic regulators in addition to mSin3A 
and HDACs. These include Ski, N-COR (22), DNMT1 (79), histone H3K9 
methyltransferase (75), PU1 (80), splicing factors (34), BRM (77), RNA (65), and the 
RNA splicing machinery (64). The identification of numerous complexes that interact with 
MeCP2 suggests that additional modes of MeCP2 function remain to be discovered and 
call further attention to its identity as an intrinsically unstructured protein (85), which 
characteristically has large number of binding partners and multiple functions (135).  
Further insight into the complexity of MeCP2 biology has come from recent 
genome-level studies. These revealed that MeCP2 binding is not confined to chromatin 
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containing methylated DNA (5), and that MeCP2 binding can lead to both repression and 
up-regulation depending on the gene context (4). Evidence has also been presented that 
MeCP2 is involved in the maintenance of large-scale chromatin loops, perhaps by 
physically anchoring loop bases (136). This suggestion is consistent with the ability of 
MeCP2 to promote nucleosome-nucleosome interactions in vitro, a property that is 
enhanced by, but not dependent on DNA methylation (24,36,137). These findings 
establish that MeCP2 is a multifunctional protein, and suggest that the different functions 
are highly context dependent. 
With the exception of the MBD, very little is known about the structural properties 
of MeCP2 and how they contribute to the functional complexity of the intact protein. 
Studies of RTT-causing MeCP2 mutations show that the most prominent are a few 
missense mutations in the MBD that disrupt its structure and affect folding (11,88). There 
are, however, RTT-causing mutations throughout the entire molecule (see Rett 
syndrome database at http://mecp2.chw.edu.au/mecp2/), indicating that regions of 
MeCP2 other than the MBD and TRD contribute to its multiple functions. Indeed, several 
reports have associated specific functions with individual regions. For example, the N-
terminal domain of MeCP2 has been shown to mediate interactions with HP1 needed for 
transcriptional silencing during myogenic differentiation (78). The short (~45 residue) 
domain connecting the MBD and TRD has been recently shown to be instrumental in 
stable MeCP2 binding to chromatin in vivo (86), and a study of RTT patients showed that 
mutations tend to be located in this region (87). Finally, the C- terminal portion of MeCP2 
required for chromatin interactions in vitro (36) also harbors the Group II WW domain 
binding motif required for binding to splicing factors (34), and the SPxK DNA-binding 
motif found in histone H1. The importance of the C-terminal region for MeCP2 function is 
underscored by the frequent occurrence of C-terminal deletions in RTT patients (87).  
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In order to better understand the interactions and functions of the different 
domains of human MeCP2, we have undertaken a systematic study of their properties, 
focusing on their structure, their interactions, and their DNA and chromatin binding 
abilities. Our work shows that the different domains are highly diverse in many respects, 
revealing novel properties and providing new mechanistic insights regarding the overall 
structure of the protein. The MBD and TRD, with their ability to bind methylated DNA and 
unmethylated DNA, respectively, are clearly key functional elements. Here we show that 
the N-terminal domain flanking the MBD modulates the affinity of MBD-DNA binding. 
Further, the intervening domain (ID) between the MBD and TRD possesses a strong, 
autonomous methylation-independent DNA-binding activity and also facilitates MBD 
dependent binding. We also report that some domains show a dramatic acquisition of 
secondary structure upon DNA binding and, while there are 4 autonomous DNA binding 
domains in MeCP2, considerable synergism exists in their mode of binding. Further, 
when bound to DNA, some domains increase the stability of MeCP2. Specific inter- 
domain interactions are seen both in cis, and in trans, suggesting that these physical 
couplings play an important role in MeCP2 structural organization and function. We have 
also expanded our understanding of MeCP2 as an intrinsically unstructured protein, and 
show that it has an unusually large number of interspersed Molecular Recognition 
Features (MoRFs) (97,138), short regions predicted to acquire structure when 
complexed with binding partners. The occurrence of several RTT-causing mutations 
within MoRFs further underscores their importance in MeCP2 function. Taken together, 
these studies significantly advance our understanding of the molecular basis of the 





4.3 Materials and methods 
4.3.1 Cloning MeCp2 domains and linear combinations  of domains 
To construct the NTD (residues 1-90), an amplicon extending 100-bp 5’ of the 
NdeI site into the pTYB1 vector sequence and carrying a 3' EcoRI linker 
(GACCGTGAATTC) was generated by PCR from full-length pTYB1-MeCP2 cDNA 
carrying MeCP2 cDNA between NdeI and EcoRI sites, using the following primer pairs:  
NTD Forward 5’ CCGGTTTAAACCGGGGATCTCGATCC 3’, NTD Reverse  
5’ GTTAGAGAATTCGTCACGGATGATGGAGCGCCGCTG 3’. The forward primer used 
in this amplification reaction was complementary to a site 100 bp upstream of the 
MeCP2 start codon in the pTYB1 vector. 
To construct the MBD (residues 75-164), ID (residues165-210), TRD (residues 207-310), 
CTD-α (residues 261-330) and CTD-β (residues 335-486), amplicons with 5’ NdeI and 3’ 
EcoRI linkers and additional hexanucleotide overhangs at each end were engineered 
using the following primer pairs.  
MBD Forward primer 5’CAATGACATATGGAAGCTTCTGCCTCCCCCAAACAGC 3’, 
Reverse primer 5’ GTTAGAGAATTCGCTCCCTCTCCCAGTTACCGTGAAG 3’ 
ID Forward primer 5’ CAATGACATATGCCCTCCCGGCGAGAGCAGAAACC 3’, 
Reverse primer 5’ GTTAGAGAATTCCACCTGCACACCCTCTGACGTGGC 3’ 
TRD Forward primer 5’ CAATGACATATGGTGCAGGTGAAAAGGGTCCTGGAG 3’, 
Reverse primer 5’ GTTAGAGAATTCCTCCCGGGTCTTGCGCTTCTTGATG 3’  
CTD-α Forward primer 5’CAATGACATATGCCTCAGGCCATTCCCAAGAAACGGG3’, 
Reverse primer   5’ GTTAGAGAATTCCTCACCGAGGGTGGACACCAGCAG 3’  
CTD-β Forward primer 5’CAATGACATATGGGACTGAAGACCTGTAAGAGCCCTGG 3’, 
Reverse primer 5’ GTTAGAGAATTCGCTAACTCTCTCGGTCACGGGCGTC 3’ 
The domain combinations NTD-MBD (residues 1-164), MBD-ID (residues75-210) 
and TRD-CTD (residues 207-486) were engineered using the following primer pairs 
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(NTD-MBD: NTD forward primer, MBD reverse primer; MBD-ID: MBD forward primer, ID 
reverse primer; TRD-CTDα-CTDβ: TRD forward primer, CTD-β reverse primer). The 
triple domain NTD-MBD-ID was synthesized using the primers 5' - 
CCCGGTTTAAACCGGGGATCTCGATCCCGC - 3' forward and 5' - TTTCAG 
AATTCCTGCACACCC TCTGACGTGGCCGC - 3' as reverse. 
Following PCR amplification the amplicons were double digested with EcoRI and 
NdeI and cloned into double digested pTYB1 vector following standard ligation 
procedure. 
Full-length wildtype MeCP2 and R294X were prepared as described. (31) 
 To synthesize MBD-tetraCys, a modified pTYB1 expression vector was 
constructed where the cDNA corresponding to the tetraCys sequence. 
AEAAHRWCCPGCCKTF (GTTAGAGAATTC 
GCTGCTCATCGTTGGTGTTGTCCTGGTTGTTGTAAAACTTTT CTCGAG GATTGA, 
(underlined bases constitute the hexanucleotide extension to facilitate restriction 
digestion, italicized bases represent the EcoR I and Xho I site) was inserted in frame 
between the Eco RI and XhoI sites in the polylinker preceding the intein tag (the Sce 
VMA intein/chitin binding domain) such that insertion of the MBD amplicon between the 
NdeI and EcoRI sites generated MBD domain-tetraCys-intein-CBD tag fusion. The 
tetraCys peptide with flanking HRW and KTF tripeptides was chosen because 
HRWCCPGCCKTF was shown earlier to have a better quantum yield than the core 
CCPGCC peptide on binding to FlAsH reagent (139). 
 
4.3.2 Protein purification 
 Isoform 1 of human MeCP2 (WT and R294X) as well as the individual domains 
and linked domain constructs were purified using the IMPACT system (New England 
Biolabs) as described (36,88). For NTD and CTDβ, proteins were applied to heparin HP 
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columns in 100 mM NaCl and eluted using salt steps from 0.1 to 1.0 M NaCl with 
increments of 0.1 M. Salt fractions containing the pure proteins were pooled and, if 
required, concentrated using Centricon concentrators (Amicon Inc). 
 
4.3.3 DNA and NA preparation 
Methylated and unmethylated 45-bp segment of promoter IV of the mouse brain-
derived neurotrophic factor (BDNF) gene were prepared as described (88). 601-12 DNA 
was purified, methylated and reconstituted into saturated/ undersaturated nucleosomal 
arrays as described (36). 
 
4.3.4 Electrophoretic mobility shift assay (EMSA) 
To analyze DNA/nucleosomal array (NA) binding efficiency and methylation 
specificity of the MBD, ID, MBD-ID, NTD-MBD, NTD-MBD-ID and TRD-CTDα-CTDβ 
constructs, unmethylated or methylated target DNA/NA (200ng), was mixed and 
incubated with various amounts of polypeptide in binding buffer (100 mM NaCl,10 mM 
Tris, 0.025% NP-40, 0.25 mM EDTA [pH 7.4]) at room temperature for 30 min. Two fold 
unmethylated competitor DNA or mononucleosome (400 ng) was included in 
experiments using DNA and NA as substrates respectively. Electrophoresis was 
performed on prechilled 1% agarose type IV gels, which were run at 85 V for 4 h at 4°C 
in TAE (40 mM Tris, 24 mM acetic acid, 0.5 mM EDTA [pH 8.3]) buffer.  
To compare the DNA/NA binding efficiency of the rest of the MeCP2 fragments, 
methylated 601-12 DNA/NA was incubated with various amounts of protein (NTD, MBD, 
ID, TRD, CTD-α, CTD-β, TRD-CTDα-CTDβ) in the same binding buffer in absence of 
competitor and electrophoresed as mentioned above. Gels were stained by ethidium 
bromide, photographed with the Kodak Gel 200 system, and analyzed using ImageJ. For 
each EMSA experiment two to three trials were performed. 
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4.3.5 Electron Microscopy (EM)  
Sample fixation, grid preparation, and darkfield EM imaging were as described 
(88). 
 
4.3.6 Circular Dichroism (CD) 
For each CD related experiment two to four trials were performed. CD spectra of 
domains and their DNA complexes were acquired and analyzed as described (140). 
Estimates of secondary structure were calculated using CONTINLL and reference set 7 
on Dichroweb (141,142), which, in addition to a set of structured proteins (140,143), also 
contains five denatured proteins, aimed at moderating any possible structural bias of 
CONTINLL. Estimates of secondary structure derived using CDSSTR closely resembled 
those from CONTINLL. We showed earlier (88) that estimates of secondary structure in 
MBD and full-length MeCP2 derived using CONTILL and LIN-COMB is almost identical 
(144). To further probe the consistency and reproducibility of structural estimates derived 
using CONTINLL, two to four independent data acquisitions for each individual fragment 
were deconvolved. 
To determine the nature of the spatial packing between different domains of 
MeCP2 we used a fragment complementation approach. For each pairwise comparison 
(NTD+MBD, MBD+ID, MBD+TRD, MBD+CTDα, NTD+ID, ID+TRD, ID+CTDα, 
NTD+TRD) CD data were acquired separately for the two domains and also for their 
mixture, keeping the concentrations constant (145). Each mixture was incubated for 15 
minutes at room temperature prior to acquisition of data. The CD spectrum for each pair 
mix (A+B) was then subtracted from the spectrum obtained by addition of the individual 
spectra ((A)+(B)) of the constituent domains, and the difference at each wavelength was 
expressed as a percent of the sum of the individual spectra [((A)+(B))-(A+B)]/((A)+(B))]. 
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4.3.7 Fluorescence Spectroscopy 
For thermal unfolding studies, fluorescence emission spectra of MBD and 
polypeptides containing the MBD together with contiguous domains were collected and 
analyzed, and Tm values derived as described (88). Experiments with domains alone 
included a re-cooling step to verify reversibility. DNA-containing samples used a 1:2 ratio 
of protein : DNA. Thermal melting reversibility cannot be assessed for DNA protein 
complexes, and the Tm values are therefore denoted as ‘apparent’. Data shown in Table 
4.4 are averages of three independent sets of data.  
 
4.3.8 Solvent accessibility of Trp104 using acrylam ide quenching 
Two or three independent fluorescence quenching measurements for each 
polypeptide were performed on a PTI QM1 spectrofluorometer over a 95 nm window 
from 305 to 400 nm using 2 nm emission and excitation slits with an integration time of 
0.3 s and 0.5nm steps. 4M acrylamide stock solution was prepared in buffer containing 
10 mM Tris, pH 7.4, 100 mM NaCl, and 0.25 mM Na2EDTA. Fluorescence excitation 
was carried out at 295nm. At this wavelength there is no inner filter effect due to 
acrylamide (146). In agreement with this, at 295nm and at 324 nm the maximum 
concentration of acrylamide used in the assay (310µM) had negligible absorbance. For 
each acrylamide concentration, solvent-only spectra were subtracted from the solvent + 
protein data. Examination of the solvent-only spectra showed that emission intensity was 
not affected by acrylamide concentration. Fluorescence quenching was assessed by the 
addition of varying amounts of 4.0M acrylamide stock solution to 2.5µM protein in a final 
volume of 600µl. For each acrylamide concentration a separate reaction mixture was 
prepared and incubated ~30 minutes prior to data acquisition to ensure attainment of 
equilibrium. There was no spontaneous quenching of Trp104 during the ~3 min data 
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acquisition period. Overlays of spectra of the same reaction mixture after 30 minutes 
showed no visible change. Fluorescence quenching data were analyzed by using the 
Stern-Volmer equation: 
 F0/F=1+ Ksv*Q (Eq 1) 
, where F0 and F are the initial (in absence of quencher) and final (in presence of 
quencher) fluorescence intensities, Q is the quencher concentration and Ksv is the 
effective quenching constant. Fit of this equation to the raw data (F0/F) yielded the Ksv 
and a y intercept of 1. 
 
4.3.9 Fluorescence labeling of tetraCys-MBD and ani sotropy 
MBD-tetraCys stock solution was incubated with 10mM DTT for 6hr at 4°C 
following which it was dialyzed extensively against 50 mM Tris-HCl (pH 7.8), 100 mM 
NaCl, 2.5 mM TCEP, 0.1 mM EDT and 1 mM EDTA. ~50µM MBD-tetraCys was then 
incubated overnight at room temperature with 2 molar equivalents of FlAsH EDT2 
(LumioGreenTM labeling reagent, Invitrogen) and dialyzed extensively against the same 
buffer in the dark at 4°C. A two-fold molar excess of F lAsH label for purified tetraCys 
fusions has been shown to be sufficient for efficient labeling (147,148). FlAsH-EDT alone 
has negligible fluorescence whereas the tetraCys peptide-bound FlAsH undergoes a 
boost in quantum yield in excess of 104 fold (149), indicating that the observed 
fluorescence originated from the bound reagent. Fluorescence anisotropy 
measurements were performed on a PTI QM1 spectrofluorometer equipped with an 
excitation and emission polarizer, using 8 nm emission and excitation slits with an 
integration time of 1sec. The excitation wavelength (λex) was 500nm and the emission 
scan used a window of 10nm (525-535nm). A constant amount of labeled MBD (100nM) 
was mixed with various amounts of other domains covering a range of 10nM to 10µM, 
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and incubated for 5 minutes prior to data acquisition. Fluorescence anisotropy was 
calculated using:  
r = (Ivv-GIvh)/ (Ivv+2GIvh) (Eq 2)  
, where r is the fluorescence anisotropy of FlAsH labeled MBD-tetraCys, Ivv and Ivh are 
the fluorescence intensities collected with a vertically oriented excitation polarizer and 
vertically (Ivv) and horizontally (Ivh) oriented emission polarizer (146). G is the correction 
factor for the difference in sensitivity of the detection system for vertically and 
horizontally polarized light and expressed as: 
G= Ihv/Ihh, where Ihv and Ihh are the fluorescence intensities collected with a horizontally 
oriented excitation polarizer and vertically (Ihv) and horizontally (Ihh) oriented emission 
polarizer. G factor correction was done for each data acquisition cycle keeping the 
machine settings identical. The basal anisotropy of FlAsH-labeled tetraCys MBD varied 
from ~0.1-0.12 between experiments. The anisotropies of complexes were normalized 
by dividing the anisotropies at each input concentration by the anisotropy of the 
tetraCys-MBD fusion in the respective experiment. Plots of normalized anisotropy versus 
increasing complementary unlabeled protein fragment (TRD, ID) concentration were fit 
to a four parameter logistic binding model using Psi plot (150). The goodness of fit for 
TRD and ID were rTRD=0.998 and rID=0.992 respectively. The dissociation constant y=D+ 
((A-D)/(1+(X/C)B)), where Y is the normalized anisotropy, d is the anisotropy at infinite 
concentration of the complementary MeCP2 domain, A is the anisotropy at zero 
concentration of the complementary MeCP2 domain, x is the concentration of the 
different MeCp2 domains, and C is the inflection point on the fitting curve which is 





4.3.10 DNA binding affinities of MeCP2 fragments  
The blunt ended fluorescein labeled 22bp duplex with a single symmetrically 
methylated CpG was synthesized by annealing complementary single strands of an 
HPLC-purified 22-bp DNA segment of mouse BDNF promoter IV 
strand 1 5' - /56-FAM/CCCTATAA/Me-dC/GGAATTCATAATG - 3' 
strand 2 5' - CATTATGAATTC/Me-dC/GTTATAGGG. 
Fluorescence anisotropy measurements were performed on a PTI QM1 
spectrofluorometer equipped with an excitation and emission polarizer, using 20 nm 
emission and 26nm excitation slits with an integration time of 8 sec. The λex used was 
480 nm and the emission was collected over a window of 4nm (518-521nm). A constant 
amount of labeled DNA (100pM) was mixed with various amounts of MBD, MBD-ID, 
NTD-MBD, and TRD-CTDα-CTDβ covering a range of 100pM to 60nM and NTD, ID, 
TRD, CTD-α and CTD-β covering a range of 1nM to 600nM and incubated for 10 min 
prior to data acquisition. Anisotropy was calculated at 520nm using Eq 2. Anisotropy 
values were normalized using the equation rnorm= (rn-r0) / (rmax-r0) where r0 is the raw 
anisotropy at 0 protein input, rmax is the raw anisotropy at maximum  protein input, rn is 
the raw anisotropy at each protein concentration and rnorm is the corresponding 
normalized anisotropy. The global dissociation constant of domain DNA interaction was 
obtained from least square fits of plots of normalized fluorescence anisotropy versus 
protein concentration. For comparing the binding affinity of NTD and CTD-β to the other 
domains (e.g. ID) anisotropy values were normalized using the equation rnorm= rn/r0. 
 
4.3.11 Sedimentation velocity 
Sedimentation velocity experiments were performed with Beckman Optima XL-I 
analytical ultracentrifuge using absorbance optics. 208-12 nucleosomal arrays 
reconstituted on methylated DNA were mixed with the appropriate MeCP2 construct in 
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50mM NaCl, 10mM Hepes, 0.25mM EDTA and sedimented at a velocity of 18000 rpm 
and temperature of 20±0.1 C. The sample absorbance was 0.7 A260 and the molar ratio 
of protein to nucleosomal array ranged from 1 to 4. The data were analyzed (151) using 
the Ultrascan data analysis program. Plots of the boundary fractions against their 
corresponding S20,w values yielded the integral distribution of sedimentation coefficients. 
Each experiment was repeated two to three times. 
 
4.3.12 Compositional profiling 
To gain insight into the relationships between sequence and disorder, amino acid 
composition of MeCP2 was analyzed using an approach recently developed for 
intrinsically disordered proteins (152). To this end, the fractional difference in 
composition between MeCP2 (or a set of disordered proteins from the DisProt database, 
(153) and a set of ordered proteins was calculated for each amino acid residue. The 
fractional difference was calculated as (CX-Corder)/Corder, where CX is the content of a 
given amino acid in a given protein (or protein set), and Corder is the corresponding 
content in a set of ordered proteins and plotted for each amino acid. In corresponding 
plots, the amino acids were arranged from the most order-promoting to the most 
disorder-promoting according to the amino acid distribution in DisProt database (153). 
 
4.3.13 Disorder, α-MoRF prediction, and modeling  
Disorder predictions for MeCP2 were made using PONDR® VLXT (152). 
Potential interaction sites, molecular recognition features (MoRFs) that gain functionality 
upon a disorder-to-order transition induced by binding to a partner, were identified by the 
α-MoRF predictor which detects short (≤20 residue) stretches within long regions of 
disorder with the potential for helical structure acquisition upon binding (97,114). The 
algorithm utilizes a stacked architecture, where PONDR® VLXT is used to identify short 
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predictions of order within long predictions of disorder, and then a second level predictor 
determines whether the order prediction is likely to be a binding site based on attributes 
of both the predicted ordered region and the predicted disordered region surrounding it.  
 The UCSF Chimera software (www.cgl.ucsf.edu) was used to visualize 




4.4.1 MeCP2 domain nomenclature 
In this study, we establish the structural and functional properties of 6 domains of 
hMeCP2 isoform 1 both individually, and as contiguous fusions. With the exception of 
the MBD, these regions do not constitute independently evolving structural units. 
However, in addition to their protease resistance, there is strong evidence, discussed 
below, that they have unique structural and functional properties and in that context, are 
considered domains. Table 4.1 lists the salient features of the MeCP2 polypeptides we 
prepared, and Figure 4.1a (upper panel) shows their locations within the parent protein. 
Flanking the MBD are the N-terminal and Intervening domains, termed NTD and ID 
respectively. The long C-terminal domain (CTD) includes a highly protease-sensitive 










Table 4.1. Domains of human MeCP2 used in this stud y 
Nomenclature used here Alternate 
name 
Polypeptides prepared 
for this study  
Number of 
residues 
N-terminal domain (NTD) HMGD1(11) 1-90 90 
Methylated DNA binding 
domain (MBD) (34) 
 75-164 90 
Intermediate domain (ID) 
(36) 
 HMGD2 (11) 165-210 46 
Transcriptional repression 
domain (TRD) (16) 
 207-310 104 
C-terminal domain (CTD  261-330 70 
CTD-α    
CTD-β  335-486 156 
NTD-MBD  1-164 164 
MBD-ID  75-210 136 
NTD-MBD-ID  1-208 208 
TRD-CTD  207-486 280 










4.4.2 Most MeCP2 domains are extensively disordered  
The predicted distribution of structured and unstructured domains in MeCP2 is  
well illustrated by the output of PONDR (Predictor of Naturally Disordered Regions) 
(152,154)(Fig. 4.1a, lower panel). A portion of the MBD contains a region predicted to 
adopt a stable secondary structure, and is the only region for which structure is known at 
the atomic level (11,12). Other short segments of predicted order occur throughout the 
protein and are found in all the domains except the short ID (Fig. 4.1a). This alternating 
pattern of disorder and order is also predicted by the FoldIndex algorithm (85). 
Unstructured proteins tend to have an amino acid composition that favors structure-
disrupting residues (153,155,156) and MeCP2 represents an extreme case of this 
skewing, exceeding that of the unstructured proteins in the DISPROT (153) data base 
(Fig. 4.1b).  
To assess the inherent secondary structure content of individual domains and 
determine whether the distribution of secondary structure agrees with the predicted 
disorder/order map of MeCP2, two to four independent circular dichroism (CD) spectra 
were recorded for each domain (Fig. 4.2a). Of the six domains, the MBD was the only 
one showing a characteristic positive band in its CD spectrum at ~197 nm, indicative of 
significant ordered secondary structure (Fig. 4.2a). The others had a negative band in 
this region, indicating extensive disorder, with the NTD and TRD being the most strongly 
disordered. Estimates of the different types of secondary structure were obtained using 
CONTINLL (88,141,142) deconvolution (see Materials and Methods for details). 
Deconvolution produced highly reproducible estimates of secondary structure for each 
domain (Table 4.2).  
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In agreement with previous findings (11,85,88), the MBD is ~60% structured, with 
~45% β-sheet/turn, and ~15% α-helix. The proportion of predicted unstructured 
sequence for the NTD, ID, and CTD ranged from ~62% to ~78% (Table 4.2), consistent 
with the net 60% unstructured sequence in intact MeCP2 (85,88). The amount of 
disorder in each of the domains determined by CD (Table 4.2) is close to that predicted 



























Table 4.2. Secondary structure content of MeCP2 dom ains based on CONTINLL 
deconvolution of CD data 




α-helix β-strand β-turn total 
NTD 9 (0.3) 4 (0.3) 9 (0) 22 78 (0.6) 
MBD(34) 15 (0.3) 27 (0.3) 18 (0.3) 60 40 (0.3) 
ID 9 (0.9) 16 (0.33) 13 (0.6) 38 62 (0.6) 
TRD 8 (0.3) 3 (0.8) 11 (0.4) 22 78 (0.5) 
CTD-α 7 (0.5) 12 (1.0) 12 (0) 31 69 (0.5) 












Figure 4.1. Organization of MeCP2 and relation to di sorder predictions 
(a) Upper panel – map of MeCP2 showing the six major domains identified by partial 
proteolysis (11). The graph shows the order-disorder score of MeCP2 predicted by 
PONDR VLXT, a neural network predictor of native disorder (39). Grey bars denote 
predicted molecular recognition features (MoRFs) – see discussion. 
(b) The amino acid composition of MeCP2 is characteristic of a highly unstructured 
protein.  Bar chart (filled bars) show differences in amino acid composition between 
MeCP2 and the average composition of a set of ordered proteins for each amino acid. 
Positive values and negative values correspond to greater and lesser abundance of an 
amino acid in MeCP2 compared to ordered proteins. Clear bars show the differences in 
average composition for each amino acid between disordered proteins from the DisProt 
database (54)  and the same set of ordered proteins. The amino acid residues are 
arranged in an increasing order of disorder promoting potential (54). For explanation 
regarding calculation of fractional difference in composition see materials and methods. 
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4.4.3 MeCP2 domains differ in their ability to bind  DNA and chromatin  
 Native electrophoretic mobility shift assays (EMSAs) provide a qualitative 
estimate of the DNA and chromatin interaction properties of MeCP2 (36,157), allowing 
the exploration of a wide range of DNA: protein ratios. The distribution of shifted species 
provides some indication of the nature of the interactions involved. We previously 
reported strikingly large mobility shifts when full-length MeCP2 interacts with DNA and 
nucleosomal arrays (NAs) (36). Here, we dissect the extent of these mobility shifts 
domain-by- domain. Substrates consisted of tandem (n=12) arrays of a 207 bp sequence 
containing the ‘601’ nucleosome positioning sequence (158), either as naked DNA, or 
after reconstitution with core histones to yield 12-mer nucleosomal arrays (NAs). Input 
ratios are expressed as moles of protein per nucleosome or 207 bp DNA. Since each 
207 bp fragment contains 18 methylatable CpGs, the highest molar ratio of peptides 
used here in the absence of competitor is approximately equivalent to one polypeptide 
per two methyl CpGs. The higher input ratios of peptides in EMSA and EM experiments 
were used to simulate a situation of local enrichment of peptides as may occur in cases 
such as the MeCP2-regulated BDNF (Brain Derived Neurotropic Factor) promoter III 
which contains a region of closely spaced CpGs (119). Also, we have found that closely 











Figure 4. 2. Circular dichroism spectra of MeCP2 do mains reveal marked 
differences in secondary structure content. 
CD spectra are representative of two - four separate acquisitions. (a) Compared to the 
195nm peak indicative of β-sheet structure within the MBD (black squares), all the other 
domains show a negative band in the 195nm-198nm region indicative of disorder. NTD 
(black circles), TRD (white circles) and CTDα (black rhombi) have lower structure 
content than ID (stars) and CTDβ (half filled circles) (see Table 4.1 for quantitation).(b) 
Addition of DNA (methylated as well as unmethylated) to the ID induces changes typical 
of the formation of α-structure, namely a marked increase in positive ellipticity at 195nm 
and negative in the 220-225nm range. (c) Addition of DNA (methylated as well as 
unmethylated) to the TRD results in an increase in order irrespective of the methylation 
status of the DNA. 
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 Full length MeCP2 induces pronounced shift with both DNA and NAs 
even at low molar inputs of the protein. These shifts are enhanced in case of methylated 
substrates (Fig. 4.2b far right). Among the individual domains, the NTD and CTD-β stand 
out as inducing only very minor mobility shifts in DNA, whereas the ID, TRD, and CTD-α 
fragment all induce marked shifts (Fig. 4.3a). The shifts induced by these three domains 
are methylation-independent (Figure 4.3c), accounting for the substantial methylation-
independent binding observed with intact MeCP2 (Fig. 4.3b) (24,85,137).  Further 
support for DNA binding by the ID comes from the finding that a R188E MeCP2 mutant 
has a significantly lowered gel mobility compared to wild type (data not shown). A slightly 
different fragment containing the TRD (residues 198-305) also has been shown to bind 
DNA (85). In general, the shifts with DNA and NAs are qualitatively similar. However, the 
CTD-β is a clear exception, inducing a moderate but reproducible shift with NAs but not 
with naked DNA (Fig. 4.3a, c). This result is consistent with earlier findings that deletion 
of 192 residues of the C-terminal portion of MeCP2 results in deficient NA compaction 





Figure 4.3. MeCP2 domains induce electrophoretic mo bility shifts upon addition to 
DNA or chromatin.   
Gel images for each experiment are representative of two to three separate trials. 
(a) Interaction between individual MeCP2 domains and DNA. Domains (NTD, MBD, ID, 
TRD, CTDα, CTDβ, TRD-CTDα-CTDβ) were incubated with methylated 601-12 DNA at 
molar input ratios of 0 to 8, and the products are displayed on 1% agarose gels. The ID, 
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TRD and CTDα induce substantial retardation of the DNA. In contrast, the MBD shows 
only minor shifts and the NTD appears to have virtually no interaction with DNA. 
(b) To examine methylation specificity, MBD and constructs that include its flanking 
domains were incubated with unmethylated (–) or methylated (+) DNA in the presence of 
two-fold excess of 208-1 DNA competitor at molar input ratios of 0 to 10. A distinct 
methylation-dependent enhancement of the gel shifts is seen in all constructs containing 
the MBD. Of particular interest is the large shift shown by the NTD-MBD construct, which 
suggests a synergism between these two domains. Full length MeCP2 produces 
pronounced gel shift at much lower input than the MBD containing contiguous domain 
fusions. (c) The ID and TRD-CTD polypeptides produce strong shifts, but there is no 
methylation-dependent enhancement. (d, e) as (a, b) but with 601-12 nucleosomal 
arrays (NAs) as substrate and 208-1 mononucleosomes as competitor. With the 
exception of CTD-β which induces a moderate but consistent mobility shift with 
chromatin but not with naked DNA, the patterns of electrophoretic shift with DNA and 




















4.4.4 The DNA and NA binding properties of the MBD and CTD are modulated by 
their flanking domains 
To determine if there were inter-domain effects, we compared the DNA and 
chromatin interactions of several constructs comprising multiple contiguous MeCP2 
domains. (Note that throughout, we use hyphens to denote constructs encompassing 
adjacent MeCP2 domains yielding information on DNA and chromatin interactions in cis, 
and the ‘+’ symbol to denote different MeCP2 domains combined in solution and 
providing information on trans interactions). The TRD-CTD fusion comprising the C-
terminal 280 residues of MeCP2 promotes pronounced shifts with both DNA (Fig. 4.3a, 
far right) and NAs (Fig. 4.3d, far right). This is consistent with DNA binding by TRD and 
CTD-α, and chromatin binding by the CTD-β (Fig. 4.3a, d). The gel shifts seen with the 
TRD-CTD construct reflect the additive binding effect of the constituent domains, and is 
consistent with the concerted binding by these domains that would be required for 
chromatin condensation and/or oligomerization (also see Figs. 4 and 5).  
For the MBD-containing constructs, it was important to compare gel shifts 
obtained with methylated and unmethylated DNA or chromatin substrates. For these 
experiments we used a two-fold excess of unmethylated 207 base pair DNA or 
mononucleosome competitor to enhance methylation-dependent effects (36,88). With 
this level of competitor, higher protein: DNA ratios are needed to observe significant 
mobility shifts. As a control, the MBD alone shows a reproducible methylation-dependent 
enhancement in mobility shift with methylated DNA (Fig. 4.3b) and chromatin (Fig. 4.3d 
far left). The NTD-MBD construct showed methylation independent and dependent 
binding both to DNA and chromatin, but, surprisingly, the observed mobility shifts were 
much larger than expected from a mere sum of the moderate shift induced by MBD and 
zero shift induced by NTD (Fig. 4.3a, b and  d, e). This synergistic shift enhancement 
suggests a strong structural and/or functional coupling between NTD and MBD eliciting a 
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binding mode uncharacteristic of either of the individual domains. This phenomenon 
cannot be explained by a simple increase in electrostatic shielding since the net charge 
of the MBD (5 at pH 7.4) is higher than that of NTD-MBD (4 at pH 7.4) in the reaction 
buffer. Thus, while the MBD may be the minimal domain necessary to recognize 
methylated DNA, MBD function is clearly impacted by the adjacent non-DNA binding 
NTD in a way that is likely to enhance its DNA-binding affinity (see later). The EMSA 
patterns obtained with MBD-ID were also different than MBD, with significant smearing 
(Fig. 4.3b). This likely reflects formation of non-specific higher order complexes via 
cross-linking by the MBD-ID fragment, with its two independent DNA-binding regions. 
The NTD-MBD-ID construct interacted with DNA and chromatin much like NTD -MBD, 
although the gel shifts were slightly more pronounced with the longer construct (Fig. 4.3 
b, e). It should be stressed that methylation-enhanced shifts occur only with MBD-
containing polypeptides. Examples of this are shown in Fig. 4.3c where, for ID and the 
TRD-CTD fusion (TRD-CTDα-CTDβ), the methylation state of the DNA has no effect on 
the induced shift.  
 
4.4.5 Contiguous fusions of certain MeCP2 domains i nduce condensation of NAs 
 Full length MeCP2 is a potent chromatin architectural protein, inducing 
extensive compaction and self-association of nucleosomal arrays (24,36). To determine 
which domains of MeCP2 were important for this phenomenon, we first investigated 
changes in sedimentation velocity of defined nucleosomal arrays (NAs), which provide a 
sensitive and quantitative assessment of their state of compaction (159). We prepared 
methylated 601-12 NAs and measured the influence of individual domains and multi-
domain constructs on their sedimentation properties. MeCP2 domains and constructs 
comprising multiple domains, shown by EMSA to interact with chromatin, were mixed 
with methylated 601-12 NAs, and diffusion-corrected sedimentation coefficient 
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distributions were obtained by analysis of sedimentation boundaries using van Holde-
Weischet method which is particularly well suited for polydisperse systems such as 
population of nucleosomal arrays with multiple compaction states (151). Results from 
two to three independent experiments show that at the ionic strength used in these 
experiments (50 mM NaCl), NAs alone give a sedimentation profile typical of a slightly 
folded conformation, with a nearly homogenous population between boundary fractions 
of ~20% to ~70%, and an average s20,w value of ~32 (±2) S (Fig. 4.4). Full-length 
MeCP2 at a 1:1 input ratio induced a dramatic increase to ~63S (Fig. 4.4), similar to our 
earlier observation in the 5S 208-12 NA system (24). Higher input ratios of full-length 
protein result in the formation of rapidly sedimenting complexes due to MeCP2-mediated 
self-association of NAs (data not shown).  
For the MBD and constructs that included its flanking domains, the sedimentation 
coefficient distributions obtained at an input ratio of two polypeptides per nucleosome 
are presented in Fig. 4.4. The MBD alone increased the sedimentation coefficient by 
only ~2(±1) S, indicating binding but little or no array compaction (binding of two MBD 
molecules to each nucleosomal unit in an array results in a ~10% increase in mass for 
the complex and would be expected to increase the array sedimentation coefficient by a 
few S units). The NTD –MBD construct, which produced a prominent electrophoretic 
mobility shift (Fig. 4.3d), caused an increase in sedimentation coefficient of ~4.5 (±0.5) S, 
whereas MBD-ID resulted in a sedimentation coefficient increase of ~6 (±1) S. These 
results show that each of these fragments binds to nucleosomal arrays but induces only 
small increases in array compaction. A more substantial increase in compaction of ~11 
(±1) S was seen with the NTD-MBD-ID construct (Fig. 4.4), and the most striking result 
was obtained with TRD-CTD. Binding of the latter caused an increase of ~26 (±3) S in 
the homogeneous segment of the population indicating a level of NA compaction similar 
to that caused by full-length MeCP2 albeit at double the protein input. Binding of the 
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TRD-CTD fragment also produced a significant fraction of heterogeneous self-
associated arrays (Fig. 4.4, boundary fraction >60%), as did full-length MeCP2. These 
results suggest that the TRD-CTD fragment may be able to recapitulate the chromatin 
condensing functions of the full-length protein. At a four-fold molar input of domains and 
domain fusions, the relative differences in levels of compaction of NAs remained largely 









Figure 4.4. Sedimentation velocity reveals differen ces in the ability of MeCP2 
domains to compact nucleosomal arrays 
Methylated 601-12 nucleosomal arrays were incubated with a two-fold molar 
input of MeCP2 constructs in 50mM NaCl, 10mM Hepes, 0.25 mM EDTA and analyzed 
by sedimentation velocity. NAs alone (circles) MBD (squares), NTD-MBD (triangles), 
MBD-ID (diamonds), NTD -MBD-ID (circles with cross), TRD-CTD (stars) and full-length 
MeCP2 (hexagons). For characterization of the full-length MeCP2 an equimolar input of 
protein was used since a two-fold input causes extensive self-association and 
oligomerization.  






Figure 4.5. Direct EM observation reveals differenc es in conformational changes 
induced in undersaturated nucleosomal arrays by MeC P2 domains  
Subsaturated NAs were mixed with different MeCP2 fragments at input ratios of 
8 molecules of protein per 208 bp DNA, fixed, and imaged using darkfield EM. (a-i) 
Representative images of NAs showing the range of conformational changes from none 
for the MBD and NTD, to extensive compaction and self-association for the TRD-CTD 






4.4.6 Different domains of MeCP2 induce distinctive  changes in NA morphology  
Observation by electron microscopy (EM) of the compaction state of individual 
NAs provides a direct measure of the impact of protein binding on array morphology and 
complements the EMSA and sedimentation studies. From the images it is possible to 
compare compaction effects quantitatively, and examine the initial changes at the 
nucleosome and linker DNA level that lead to overall increases in condensation. For 
these purposes, it is useful to employ “subsaturated” NAs where linker remains visible 
during the initial stages of compaction (36). Hence, in this study, we reconstituted 
methylated 601 DNA templates with 6-8 (rather than 12) nucleosomes, exposed them to 
the defined fragments of MeCP2 at various input ratios, and imaged the resulting 
complexes using darkfield EM.  
In the absence of protein, the NAs were fully extended (Fig. 4.5a). Little change 
in conformation was seen with either MBD or NTD alone (Fig. 4.5b, c), consistent with 
the EMSA data on saturated NAs (Fig. 4.3). All the other individual domains induced 
partial clustering of nucleosomes within arrays (Fig. 4.5d-g), leading to significant 
(p<0.001) reductions in array diameter (diameter of the smallest circle that fully encloses 
the array; Fig. 4.5k). The three contiguous constructs examined (MBD-ID, NTD -MBD, 
and TRD-CTD) also showed nucleosome clustering and array compaction (Fig. 4.5h-j), 
with decreased array diameters (Fig. 4.5k) that parallel the increased sedimentation 
coefficients seen in Fig. 4.4. Consistent with its potency in inducing gel shifts and 
increasing sedimentation velocity, the TRD-CTD was the most effective at compaction, 
with a mean diameter significantly (p<0.0001) smaller than all of the other MeCP2 
fragments. In addition to compacted individual arrays, the TRD-CTD construct induced 
self-association of arrays (Fig. 4.5j, far right panel), consistent with our observation of a 
large fraction of heterogeneous rapidly sedimenting material (Fig. 4.4). The full-length 
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protein induces extensive array oligomerization under these conditions, (32) precluding 




















Figure 4.6. Interactions between the MBD and flanki ng domains revealed by 
tryptophan accessibility 
Fluorescence quenching by acrylamide analyzed using Stern Volmer plots shows 
that the fluorescence of Trp 104 in the MBD is differentially accessible depending on the 
flanking domains present. MBD only (circles). NTD-MBD (stars), MBD-ID (diamonds), 
MeCP2 1-294 (circles with cross), full-length MeCP2 (squares). Plots are linear up to 











4.4.7 The MBD is structurally coupled to other MeCP 2 domains 
In a previous study focusing on the properties of the MBD, we used fluorescence 
spectroscopy to monitor the solvent exposure (146) of the single tryptophan at position 
104, and reported that domains flanking the MBD provided solvent protection to W104 
(88). Here, we examine this effect in more detail, using the collisional quenching agent 
acrylamide to avoid complications due to the differing fragment sizes, and hence 
tumbling rates. The extent of quenching of the W104 by acrylamide provides a direct 
measurement of its solvent accessibility, and allows the identification of flanking domains 
that provide protection from quenching in cis. The results of two to three independent 
measurements for each fragment (Fig. 4.6) show that acrylamide most effectively 
quenches the fluorescence signal of tryptophan in the MBD alone (quenching constant 
Ksv 8.4 M
-1), and least effectively in full-length MeCP2 (Ksv 3.9 M
-1). Intermediate levels of 
quenching (Ksv 7.3 M
-1 and 6.8 M-1) were obtained for NTD -MBD and MBD-ID, 
respectively. Tryptophan fluorescence from the truncation RTT mutant R294X, which is 
approximately equivalent to NTD-MBD-ID-TRD showed greater protection from 
quenching than other constructs (Ksv 4.9 M
-1) but was less effective than the full-length 
protein. These results indicate that within the full-length protein, the structure of the MBD 
is influenced by associations with other domains that lead to the shielding of W104 from 
solvent exposure. All the MeCP2 domains contribute to this shielding (particularly NTD, 
ID, and TRD), suggesting that inter- domain coupling occurs within the overall structure 
of the full-length protein. In this respect, it is interesting to note that an NMR study of a 
region of the chicken homolog of MeCP2 approximately equivalent to the human MBD-
ID construct, suggested that it may act as a platform for interaction with other regions of 




4.4.8 Inter-domain coupling occurs in trans and aff ects secondary structure 
Inter- domain interactions that are crucial to the stability of the native state of the 
protein are often strong enough to be sustained in trans in mixtures of protein fragments 
(161). Fragment complementation approaches to define tertiary organization of domains 
are particularly helpful for proteins refractory to crystallization as is the case with MeCP2. 
To test for such associations between MeCP2 domains, we prepared a construct in 
which a tetra-cysteine motif was fused to the MBD and labeled with the FlAsH reagent 
(149,162) at a level that produced a robust emission (Fig. 4.7A insert). The labeled MBD 
was titrated with a second domain and evaluated using fluorescence anisotropy for inter-
domain interactions that cause it to tumble more slowly. The results indicated that the ID 
and TRD were able to bind the MBD in solution, with dissociation constants of ~4 µM 
and ~2.5 µM respectively (Fig. 4.7a). In contrast, no interactions were observed between 
MBD and NTD. A weak effect was seen with the CTD-β, but only at high molar inputs.  
We also investigated inter- domain associations in trans using CD, which can 
detect changes in secondary structure of one or both components in a mixture of the two 
(163). For each pairwise comparison, data were acquired separately for the individual 
domains and also for their mixture. With the NTD+MBD, MBD+ID, and MBD+TRD 
mixtures, we observed a clear difference between the summed individual CD spectra 
and the spectrum of an equimolar mixture (Fig. 4.7b, c), indicating that an interaction 
between domains led to change(s) in secondary structure. The failure to observe an 
interaction between the MBD and NTD with anisotropy may be due to the location of the 
tetra-Cys moiety at the largely unstructured C-terminus of the MBD. Also, binding by 
NTD distal to the C-terminus may not result in changes in rotational freedom of the label 
and thus not affect anisotropy. 
The CD approach also allows domain interactions not involving the MBD to be 
investigated. None of the domain combinations that lacked the MBD gave any evidence 
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of interaction. Examples are shown for the NTD + ID and ID + CTD-β pairs (Fig. 4.7c). 
Thus, it appears that the role of the MBD is not solely as a methylation-dependent DNA 
binding domain, but it also acts as a structural ‘core’ of the protein, participating in 























Figure 4.7. In trans interactions between MeCP2 dom ains revealed by 
fluorescence anisotropy and CD 
(a) Fluorescence anisotropy of fluorescently-labeled MBD upon mixing with other 
MeCP2 domain constructs. In the presence of ID (open circles) and TRD (filled circles), 
the MBD shows marked increase in anisotropy whereas addition of NTD (open squares) 
caused no change in anisotropy. CTDβ (filled squares) gave a small increase at higher 
input ratios. Error bars denote standard errors of mean. Insert shows the robust 
emission spectrum of the MBD-tetraCys bound FlAsH complex. (b, c) Fragment 
complementation was also detected by using CD to monitor interactions between 
domain pairs caused by changes in secondary structure. For each pairwise comparison 
(A:B), data were acquired separately for the two different domains (A) and (B) and also 
for their mixture (A+B). Plots show the difference spectra at each wavelength expressed 
as a percent of the spectrum obtained by addition of the individual spectra [((A)+(B))-
(A+B)]/((A)+(B)). (b) MBD+ID (squares) and MBD+TRD (circles) spectra show strong 
differences from the composite spectrum of the individual domains while the 
MBD+CTDβ pair shows only a minor change. (c) The NTD+MBD pair (circles) show a 




4.4.9 Impact of DNA binding on secondary structure  
Intrinsically disordered proteins often undergo binding-induced increases in 
secondary structure content. Given the multiple DNA-binding domains and large degree 
of intrinsic disorder spread throughout MeCP2, we were interested to determine whether 
DNA binding leads to structural alterations. For DNA-binding experiments, we selected a 
45 bp segment of the brain-derived neurotropic factor (BDNF) III promoter that has a 
single CpG unit and is known to be a target for in vivo MeCP2 binding (72,119). A similar 
stretch of BDNF DNA was used in the MeCP2 complex for which the x-ray structure has 
been determined (12). The ID and TRD, when mixed with an equimolar amount of the 45 
bp DNA substrate, resulted in striking changes in far-UV CD profiles, independent of the 
DNA methylation state (Fig. 4.2 b, c). These changes result from significant increases in 
secondary structure content (from ~38% to ~59% for ID; from ~22% to ~30% for the 
TRD (Table 4.3)). For ID, the acquired structure is approximately equally divided 
between α-helix and β-strand, while for the TRD; the increase is in the β-strand 
component. As previously reported, in the presence of DNA, the MBD shows no change 
in secondary structure with unmethylated DNA, but acquires a methylation-dependent 











Table 4.3. Changes in secondary structure of MeCP2 domains upon DNA binding.  
 
Domain % ordered secondary structure 
Without DNA With DNA 
Full-length MeCP2 351 421 
NTD 22 23 
MBD  601 661 
ID 38 59 
TRD  22 30 
CTD-α  31 30 
















Table 4.4 Thermal stability of MeCP2  














MBD75-164 44.9 (±0.1) 46.6 (±0.6) 1.7 54.3 (±0.3) 9.4 
NTD-MBD1-164 40.4 (±0.6) 46.3 (±0.1) 5.9 54.5 (±0.3) 14 
MBD-ID75-210 46.7 (±0.2) 55.7(±0.3) 9 63.8 (±0.2) 17.1 
NTD-MBD-ID1-208 43.1 (±0.1) 58.6(±0.4) 15.5 67.1(±0.2) 24 
MeCP21-294 45.3 (±0.1) 56.3 (±0.3) 11 64.6 (±0.2) 19.3 
Full-length MeCP21-486 44.5 (±0.2) 55.7 (±0.5) 11.2 63.1 (±0.4) 18.6 
Tm – increase in melting temperature upon DNA binding 















4.4.10 Domains of MeCP2 differ in their affinity fo r DNA, and contribution to 
thermal stabilization upon DNA binding 
To measure affinity between DNA and different MeCP2 domains, we used a 22 
bp segment of the BDNF promoter containing a single centrally located methylated CpG 
dinucleotide and a fluorescein label at one end. DNA binding by a given protein fragment 
reduces the DNA tumbling rate in solution and can be measured by following changes in 
steady-state anisotropy of the fluorescein label. Fig. 4.8 a-c shows the changes in 
anisotropy as a function of concentration of MeCP2 domains, and constructs with linked 
domains. Amongst MBD and MBD containing contiguous domain fusions, NTD-MBD 
showed the highest DNA binding affinity (Kd 0.8 nM), 10-fold higher than the MBD alone 
which showed the weakest binding (Kd 8.5 nM) (Fig. 4.8a, c). MBD-ID (Kd 1.4 nM) bound 
to DNA with 6 fold higher affinity than MBD and ~50-fold higher affinity than ID alone (Kd 
75nM) (Fig. 4.8a, b). This clearly shows that while the ID contains an autonomous DNA 
binding domain, it also facilitates MBD-mediated binding. Unlike ID, NTD does not bind 
to DNA as an isolated domain (Fig. 4.8c), but when coupled to MBD markedly enhances 
its binding affinity, consistent with our EMSA data.  
The constituent domains of TRD-CTD fusions showed considerable variability in 
their DNA binding affinity. Unlike TRD and CTD-α, which bound with affinities of 20 nM 
and 96nM respectively (Fig 8b), CTD-β induced small increases in fluorescence 
anisotropy and only at very high protein concentrations (~600nM) (Fig. 4.8c). 
Interestingly the TRD-CTD fusion construct bound DNA more strongly (Kd 3.6 nM) than 
its constituent domains suggesting that, in addition to their autonomous binding 
capacities, coupling between the constituent domains results in emergent binding 
properties. In summary, in increasing order of DNA binding affinity, the domains of 
MeCP2 can be arranged as NTD, CTD-β, CTD-α, ID, TRD, and MBD. 
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 Since DNA binding to MeCP2 also confers thermal stability to the protein 
(88), it was of interest to determine the contributions of the different domains to the 
overall stability. To assess stability, we monitored the fluorescence emission of the 
single tryptophan in MeCP2 (W104 in the MBD) over the temperature range from 10°C 
to 85°C. We first compared the melting profiles of t he MBD alone with those of the 
longer constructs containing the MBD. As previously reported, the MBD has an apparent 
Tm (50% melt temperature) of ~45 °C ( 34), and similar values were obtained with MBD-
ID and MeCP21-294 which includes most of the TRD. Unexpectedly, the Tm of NTD-MBD 
domain fusion was lower than MBD (Table 4.4), suggesting that the NTD holds the MBD 
in a relatively destabilized state (thus lowering the Tm).  
Each protein fragment was then mixed with methylated or unmethylated DNA 
consisting of the 45 bp segment of the BDNF promoter with a single centrally located 
methylatable site, and thermal melting profiles obtained and analyzed (Table 4.4). Two 
important patterns emerge. First, unmethylated DNA acts as a stabilizing agent, 
consistently inducing increases in Tm. Here, the MBD alone stands out in inducing only a 
small stabilization of only ~2 °C, whereas additional domains generate a much greater  
enhancement in thermal stability. Second, when the DNA is methylated, there is a 
consistent increase of ~8 °C in the T m of all constructs. Interestingly, the stabilizing effect 
of methylated DNA on the NTD-MBD-ID fragment exceeds that of the full-length protein. 
The very similar apparent thermal stabilities of MeCP21-294 and full-length MeCP21-486 
indicate that the C-terminal domain of the molecule does not contribute to the overall 







Figure 4.8. Quantitation of DNA binding affinity of  MeCP2 fragments  
(a) Normalized fluorescence anisotropy, rnorm= (rn-r0) / (rmax-r0) , of a 5’-fluorescein labeled 
22bp fragment of BDNF promoter DNA with a single methylated CpG was measured in 
the presence of increasing concentrations of MeCP2 fragments: MBD (black squares), 
NTD-MBD (white circles), MBD-ID (black circles) and TRD-CTD (white squares). Error 
bars denote standard errors of mean. X axis (protein concentration) and Y axis 
(normalized fluorescence anisotropy) are linear normal. (b) as in (a) but with different 
MeCP2 domains: ID (black triangle), TRD (black circle), CTD-α (black squares). Error 
bars denote standard errors of mean. X axis (protein concentration) is log decimal and Y 
axis (normalized fluorescence anisotropy) is linear normal. (c) Normalized fluorescence 
anisotropy, rnorm= (rn/r0), of the same DNA substrate as in (a) and (b) in the presence of 
increasing concentrations of NTD (black circle), ID (black triangle), CTD-β (black square).  
ID is included both in 8b and 8c to provide a reference scale for the two different types of 
normalizations used in 8b and 8c. Error bars denote standard errors of mean. r0 = raw 
anisotropy at 0 protein input, rmax = raw anisotropy at maximum protein input, rn = raw 











Figure 4.9. Structure of MBD bound to DNA suggests that MoRFs flank interaction 
surfaces.  
Model of the MBD (tan, light blue and green) of hMeCP2 bound to 20bp of BDNF 
promoter DNA (gray), PDB file 3c2i (6). The MBD α-MoRFs are located in residues 87-
104 (light blue) and 133-150 (green). The two MoRFs form a contiguous surface that is 
predominantly hydrophilic, winding across the MBD opposite the DNA interaction surface. 
Arrows point to the solvent accessible surface area of Trp104 (black), and the surface 
exposed regions (blue) of Arg106, Arg 133, and Phe155 where Rett syndrome-causing 
point mutations result in significant changes in the local surface properties (13). These 
all contribute to a MoRF surface, suggesting a role in inter- and intra-protein interactions 











 Due to its high degree of disorder, the overall structure of full-length 
MeCP2 is not readily amenable to structure determination by x-ray crystallography or 
NMR. However, our domain-by-domain dissection of MeCP2 has provided important 
insights into the physical and functional properties of this unique unstructured protein. An 
overarching aspect of MeCP2 biology is the role that disorder plays in supporting its 
multiple functions. Importantly, the structure content of the full length protein is largely 
similar to the sum of the weighted average structure of its domains and the small 
difference can be attributed to changes in secondary structure resulting from interdomain 
associations largely involving the MBD in the context of the full length protein. As further 
discussed below, the MBD appears to be the central hub for MeCP2 tertiary structure, 
forming contacts with the NTD, ID, and the TRD.  
 
4.5.1 The large number of MoRFs may account for the  functional and structural 
versatility of MeCP2. 
 The functions of intrinsically disordered proteins are often coupled to the 
acquisition of structure upon binding to a partner (164-167). In this respect, it is 
significant that MeCP2 gains secondary structure and undergoes striking thermal 
stabilization upon binding to DNA (Table 4.4). α-MoRF predictors (97,114) (see materials 
and methods) predict nine α-MoRFs in MeCP2. This is an unusually large number for a 
protein of this size (165), but is consistent with its predicted distribution of order and 
disorder. There is at least one predicted MoRF in each MeCP2 domain except the ID. 
Some of these sites may be involved in long-range intra-protein contacts within MeCP2, 
promoting the cis and trans domain interactions documented above.  
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Two MeCP2 point mutations, R133C and A140V located in the MBD resident α-
MoRF 133-150, have been shown to impair MeCP2’s interactions with the ATRX protein 
leading to improper nuclear localization of ATRX, a phenomenon implicated in ATRX (α-
thalassemia/mental retardation X-linked) syndrome (74). In the x-ray structure of the 
MBD-DNA complex (12) the two discontinuous MoRFs, 87-104 and 133-150 (Fig 1), 
form a continuous surface (Fig 4.9). Both α-MoRFs are thus maximally accessible and 
constitute potential interaction surfaces for MeCP2 domains or protein partners. 
Strikingly, several RTT-causing mutations in the MBD are proximal to these candidate 
interaction surfaces, explaining the deleterious effects of these mutations on MeCP2 
function (Fig. 4.9). 
 
4.5.2 MeCP2 harbors multiple autonomous binding sit es that affect the overall 
interactions of the protein with DNA and chromatin.  
Although MeCP2 was originally identified as a protein that binds specifically to 
methylated DNA, it has been shown since that MeCP2 can also bind to unmethylated 
DNA, albeit less efficiently (5,24,36,162). In this study we have shown that of the 4 
autonomous DNA binding domains, ID and TRD acquire significant secondary structure 
upon binding to DNA, a phenomenon that has also been reported for key proteins such 
as Jun, Fos, GCN4 and histone H1 (104,168,169). MBD is solely responsible for 
methylation specific binding (Fig. 4.3b). The autonomous non-specific DNA binding 
capabilities of the ID, TRD and CTD-α-β suggest that full-length MeCP2 is poised to 
make unusually extensive contacts with DNA which coupled with their highly disordered 
nature and ability to undergo binding-induced structural changes, suggests that the 
simultaneous or selective engagement of these domains will promote considerable 
functional variability. 
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The slight but consistent enhancement of shift seen with nucleosomal arrays 
when incubated with CTD-β, over DNA with which there was virtually no shift (Fig. 4.3d), 
can be attributed to a putative histone-binding region(s) in the C terminal half of MeCP2. 
This is in agreement with earlier work suggesting a role of the C-terminal domain in 
specific binding to chromatin, most likely to histone H3 (24,61,170). 
 
4.5.3 Properties of multi-  domain fragments of MeCP2 reveal structural and 
functional synergism between domains 
Upon incubation with NTD-MBD both DNA and NA undergoes striking 
enhancement of electrophoretic shift compared to the minor shift with MBD and zero 
shift with NTD. Furthermore a 10-fold higher binding affinity of NTD-MBD to methylated 
DNA compared to MBD alone (Fig. 4.3b, e and 4.8a, b), suggest that conformational 
coupling between these domains possibly through their MoRFs results in a synergistic 
increase in DNA binding efficiency, and/or methylation specificity. Furthermore, thermal 
unfolding suggests that the NTD holds the MBD in a relatively destabilized state which 
may be more potent in DNA binding as evident from the higher affinity of NTD-MBD for 
methylated DNA than of MBD. This is also evident from the fact that upon binding to 
DNA, NTD-MBD undergoes a more pronounced thermal stabilization than the MBD. 
Two distinct mechanisms for coupled binding and folding of unstructured proteins 
have recently been proposed: folding upon binding, and conformational selection (171). 
For MeCP2, both mechanisms may be operating: while the acquisition of structure by 
the ID and TRD domains upon binding to DNA is definitely a case of binding-induced 
folding, inter- domain interactions within MeCP2 could select for conformations 
favorable for DNA binding, as in the NTD-induced enhancement of the DNA binding 
affinity of MBD. In addition, the unstructured regions of MeCP2 will populate an 
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ensemble of conformations from which those that favor binding by specific partner 
proteins may be selected.  
Another case of synergistic binding is seen with TRD-CTD, which binds to DNA 
with 6-fold higher affinity than TRD and 30-fold higher affinity than CTD-α. It is also the 
most potent in terms of inducing mobility shifts of DNA and NAs (Fig. 4.3a, c, d). 
Furthermore, the remarkable compaction and self-association of NAs induced by the 
TRD-CTD fusion suggests contributions from both the DNA and histone binding sites in 
this fragment.  
The apparent synergism between certain domains in DNA and chromatin binding 
is consistent with the conformational coupling between MBD and other domains of 
MeCP2 detected in cis and trans and is likely to contribute to the folding behavior and 
tertiary structure of MeCP2. Long-range interactions between interspersed structured 
segments may result in a loose folded structure with intrinsically disordered domains 
extending from one or two structural ‘hubs’. Such as structure is likely promote 
simultaneous interaction with multiple partners conferring considerable functional 
flexibility to MeCP2. 
 
4.5.4 The two halves of MeCP2 involved in DNA and c hromatin binding 
 The DNA binding properties of the MBD are strongly modulated by the 
flanking domains, suggesting that the NTD-MBD-ID region constitutes a functional entity 
with both methylation-dependent and independent DNA binding abilities. The TRD-CTD 
also functions as an independent unit with chromatin compacting and oligomerizing 
properties. This suggests that MeCP2 is effectively organized into an N-terminal 
functional unit composed of the NTD, MBD and ID and a C-terminal unit composed of 
the TRD, CTD-α and CTD-β.  
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 While both the TRD (207-310) and CTD-α (261-330) fragments bind DNA 
efficiently, DNA-induced structure acquisition is limited to the TRD polypeptide. This 
suggests that residues 207-260 within the TRD house DNA binding activity while 
residues 310-335 harbor the DNA binding activity seen in CTD-α. In support of the 
former, deletion mutagenesis of the isolated TRD suggests its DNA binding region lies 
between residues 245-270 (data not shown). The exclusive binding of CTD-α to NAs 
(Fig. 4.3c), strongly suggest that this domain specifically interacts with nucleosomal 
histones. While the extent of NA compaction induced by TRD-CTD approaches that 
seen with the wild type protein, a higher ratio of the TRD-CTD polypeptide is needed to 
see an equivalent effect. This would be expected if the NTD-MBD-ID mediated DNA 
binding acts in concert with TRD-CTD mediated DNA binding and also contributes to 
inter- and intra-nucleosomal associations of NAs.  
 
4.5.5 In vitro functions of MeCP2 domains strongly correlate with their function in 
vivo 
 Our results indicating the importance of MeCP2 domains other than the 
MBD and TRD are supported by in vivo data. For example, the heterochromatin-
associated HP1 protein has been shown to interact with the NTD (78), perhaps 
contributing to the co-localization of MeCP2 and HP1 in pericentromeric heterochromatin. 
However, while the NTD appears to be necessary for the pericentromeric localization of 
MeCP2, it is evidently not sufficient, but also requires the MBD (172). This is in 
agreement with our data that NTD largely plays a role in regulating MBD mediated 
binding. Important roles for the ID have also been established. The ID has been shown 
to be a universal component of the MeCP2 fragments required for interaction with the 
co-repressors mSin3A (16), N-CoR and Ski (81), H3 methyl transferase (173), p20, a 
putative Xenopus protease (71), as well as the DNA methyltransferase Dnmt1 (22). A 
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fluorescence recovery after photobleaching study (86) has recently demonstrated that 
deletion of either the ID or the TRD markedly increases MeCP2 intranuclear mobility. 
This suggests that the DNA induced disorder-to-order transition of the ID and the TRD 
reported here significantly stabilizes MeCP2-chromatin complexes, perhaps providing a 
larger window for downstream repressor recruitment or secondary interactions required 
for the structural modulation of chromatin.  
 Our finding that full-length MeCP2 and TRD-CTD induce clustering of 
nucleosomes with looping out of non-nucleosomal DNA (Fig. 4.5) (36) is consistent with 
the growing in vivo evidence for a role of MeCP2 in stabilizing large chromatin loops 
(174-176). The presence of independent DNA and chromatin-binding domains in 
multiple regions of MeCP2, allowing a single MeCP2 molecule to bind two or more 
regions of chromatin, would contribute to the stabilization of a loop base. Interestingly, in 
this regard, the MBD-ID fragment has been reported to contain a MAR binding site (34). 
A role in loop maintenance would not be possible with the MBD alone with its very 
limited compaction ability, but may require the additional DNA-binding properties of the 
ID and the chromatin binding properties of the CTD. The pathological effects of C-
terminal truncations of MeCP2 both in RTT patients and a mouse model (133) may be 
understood in this context.  
 On the basis of the work presented here, a new picture of MeCP2 biology 
is emerging in which its intrinsically disordered nature is a key property. The novel 
properties of MeCP2 elucidated here support a global structure for MeCP2 that can 
engage in a wide range of potential binding events and conformational changes, 
promoting functional outcomes which will vary according to the specific context of the 
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5.1 Preface  
Chapter 5 is reprinted from a paper I coauthored that first appeared in the 
Journal of Biological Chemistry online April 4th, 2011. The entire paper can be 
accessed freely at the following shortened URL - http://bit.ly/ig4A7s.  My 
contributions to this collaborative effort were to express and purify all protein, and 
protein fragments analyzed. Additionally, where nucleoprotein complexes of 
MeCP2 and 198-1 DNA (methylated and unmethylated) were used, I methylated 
the DNA and reconstituted the complexes at a stoichiometry I had worked out 
through trial and error that provided complexes with ample DNA:MeCP2 ratio to 
ensure free protein was not present to distort the Hydrogen Deuterium exchange 
and subsequent mass-spectroscopic analyses. Please see experimental 
procedures; Protein expression and purification, and Formation of MeCP2--DNA 













Methyl CpG binding protein 2 (MeCP2) is named for its ability to selectively bind to 
methylated CpG dinucleotides (2), acting through its methyl DNA binding domain 
(MBD)(8). MeCP2 is a 53 kDa nuclear protein that is present in high amounts in 
neuronal tissues, where its stoichiometry approaches one MeCP2 per nucleosome 
throughout the genome (54). In addition to binding unmethylated and methylated DNA 
(36,63,116,120) chromatin (24,36,61,63) and RNA (65), MeCP2 interacts with many 
different nuclear proteins, including Sin3a (16), SUV39H1 (75), HP1 (78), DNMT1(79), 
Ski and N-COR (22), PU.1 (80), BRM (77), and ATRX (74). While originally 
hypothesized to be a specific repressor of methylated genes (16), MeCP2 is now 
recognized to be multifunctional, with roles in transcriptional activation and repression 
(4), RNA processing (64), and  chromatin organization (5,24,54,177). Consistent with 
these results, MeCP2 is localized to both promoter and intergenic regions in the nuclei of 
neuronal cells (5). Of note, mutations located throughout the entire length of the MeCP2 
amino acid sequence are associated with Rett Syndrome (RTT), a severe X-linked 
neurodevelopmental disorder that afflicts about one in 10,000 girls (23,82). MeCP2 
dysfunction is also involved in autism spectrum disorders (127,128) and certain cancers 
(130,131). Hence, it is important to understand the structure/function relationships that 
apply to MeCP2 in both the health and disease states. 
 
Intrinsically disordered proteins lack well-folded traditional tertiary structure over 
some or all of their polypeptide sequence (39,89,91,92,135). Several biophysical 
techniques that measure averaged solution behavior have recently documented that 
MeCP2 is an intrinsically disordered protein. Steady-state circular dichroism (CD) 
measurements revealed that MeCP2 in solution is ~60% unstructured, 35% β-strand/turn, 
and 5% α-helix (85,88). Sedimentation equilibrium studies showed that free MeCP2 is a 
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monomer over a wide concentration range and sedimentation velocity analysis yielded a 
sedimentation coefficient of 2.2S (85). Taken together, the analytical ultracentrifugation 
results demonstrated that MeCP2 has a frictional coefficient that would be expected for a 
random coil-like molecule. Thus, one can infer from these averaged data that 
considerable portions of the MeCP2 polypeptide chain lack secondary structure. 
However, while the atomic structure of the isolated MBD fragment has been solved 
alone (11) and in complex with methylated DNA (12), because of its highly disordered 
nature there is no fine resolution structural information available for full length MeCP2, 
either when free in solution or when bound to DNA.   
 
Mass-spectrometry-based hydrogen/deuterium exchange (H/DX) has emerged as a 
powerful technique for studying the structure of monomeric intrinsically disordered 
proteins and their higher-order complexes at high resolution. For instance, the dramatic 
reduction of H/DX rates along the polypeptide backbone of amyloid forming proteins has 
been characterized at amino acid resolution following their assembly into amyloid (178). 
For full length MeCP2, H/DX has the promise to substantially extend the averaged 
biophysical measurements by providing fine resolution mapping data that locates 
regions of secondary structure throughout the protein sequence..  
 
In the present studies, we apply H/DX to the analysis of full length MeCP2 when free 
in solution and when bound to unmethylated and methylated DNA. Results demonstrate 
that the MBD is the only domain within free MeCP2 that shows even modest protection 
from H/DX, and even the H/DX of the MBD is fast compared to a typical globular protein. 
This indicates that full length MeCP2 rapidly samples many different conformational 
states and tertiary structures when free in solution. We further show that binding of 
MeCP2 to unmethylated DNA substantially decreases the global conformational 
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flexibility of the MBD, while the rapid H/DX exchange elsewhere in the protein was 
unaffected. Thus, even with the increased H/DX protection in the MBD, full length 
MeCP2 remains a very intrinsically disordered protein when bound to DNA. Relative to 
binding to unmethylated DNA, binding to methylated DNA only slightly increases the 
conformational rigidity in a local region within the N-terminal portion of the MBD. Finally, 
we to examine the effects of several common RTT mutants on the properties of the 
isolated MBD, and  find widely varied effects. Taken together, the H/DX experiments 
have yielded high resolution structural dynamics data characterizing the extreme intrinsic 
conformational flexibility of full length MeCP2, and also provided accompanying 
information about how the structure and stability of the MeCP2 MBD is affected by DNA 
binding and certain specific RTT mutations.  For the latter case, the implications for 
treatment of RTT are discussed.  
 
5.3 EXPERIMENTAL PROCEDURES 
 
5.3.1 Protein expression and purification  : 
 Full length human MeCP2 isoform e2 and the isolated R106W, F155S, and 
T158M mutant MBD polypeptides were purified using a modification of the protocol 
described previously (85). Recombinant proteins were expressed using the IMPACT 
system (New England Biolabs). Constructs were subcloned into the ptyb1 plasmid vector. 
MBD mutant constructs were kindly supplied by Dr. C.L. Woodcock.  All purified proteins 
contained a vestigial sequence, EFLEGSSC, on their C-terminal ends as a result of 
cloning methods previously described (85). Escherichia coli BL21RP+ was used as host 
expression bacteria grown in lysogeny broth at 37°C to an optical density of 0.5 
absorbance units, induced with 0.4 mM IPTG and cooled to 18°C for 2-3 hours prior to 
harvest. Expression hosts were pelleted in an Avanti J-26 XPI preparative centrifuge 
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(Beckman Coulter) in a JLA 8.100 rotor at 5,000 g for 15 minutes. Pellets were 
resuspended in wash buffer (25 mM TRIS pH 7.5/100 mM NaCl) and repelleted under 
the same conditions. Clean pellets were resuspended in column buffer (25 mM Tris–HCl 
pH 8.0, 500 mM NaCl) supplemented with 0.1% Triton X-100, 0.2 mM PMSF, and  
Protease Inhibitor Cocktail Set II (Calbiochem), followed by two rounds of sonication, 
90s each, using a Branson Sonifier 450 with a large tip at 50% duty cycle and a power 
output of 7. Lysate was transferred to Oakridge tubes and spun at 21,000 g for 25 min in 
the preparative centrifuge in a JA-17 rotor (Beckman). The supernatant was bound 
overnight to chitin beads (New England Biolabs) previously equilibrated in column buffer. 
Chitin beads were washed with five column volumes column buffer, decanted and 
washed with an equal volume column buffer supplemented with NaCl to 900 mM NaCl 
final concentration to wash off errant bacterial DNA left from sonication.  Chitin beads 
were washed with an additional 5 column volumes 500 mM NaCl Column buffer. Chitin 
binding protein-MeCP2 chimeras were cleaved on the column 
(40)(179)(179)(179)[180][180][179](179)(179)(177)(125)(125). Column buffer 
supplemented with 50 mM DTT was passed through the column such that 1 cm buffer 
remained between the top of the column bed and the meniscus in a 10 cm Kontes 
FlexColumn (Fischer) and left for 48-72 hours for complete cleavage. Protein was eluted 
from the chitin column with column buffer, diluted from 500 mM to 300 mM NaCl and 
loaded onto a HiTrap Heparin HP column (GE healthcare).  Proteins were eluted from 
the heparin column via step gradient from 300 mM NaCl to 1 M NaCl buffer using 100 
mM NaCl steps in 25 mM Tris, pH 7.5, 10% glycerol background buffer. Peak fractions 





5.3.2 Formation of MeCP2-DNA complexes : 
Unmethylated and methylated 198 bp DNA fragments derived from the sea 
urchin 5S rRNA gene were prepared as described (85). This DNA has 12 methylatable 
CpGs. Purified MeCP2 (155 µl; 0.80 mg/ml) was added to either an unmethylated or 
methylated 198 bp DNA fragment (430 µl; 0.2 mg/ml) in a total of 585 µl of 10 mM Tris 
(pH 7.5), 10 mM NaCl buffer.  MeCP2 minimally binds 11 bp of DNA (61).  Under these 
conditions, unmethylated and methylated DNA binding sites were present in molar 
excess over MeCP2, and DNA concentrations always were above the Kd (120) such that 
H/DX was being measured under saturated binding conditions and dual population (i.e. 
bound and unbound to DNA) affects were avoided. 
 
5.3.3 H/DX reactions 
A total of 10 µl of each sample (4-10 µg full length MeCP2 [alone or in a complex 
with the indicated DNA fragment] or 0.4-3 µg MBD fragments [the wild type version or 
indicated RTT-associated mutation]) was mixed with 30 µl of D2O containing 10 mM Tris 
(pD 7.2), 10 mM NaCl and incubated at the indicated temperature. At each indicated 
timepoint, the H/DX samples were added to vials containing 60 µl of a quench solution 
(0.8 M guanidinium-HCl, 0.8% formic acid, 10% glycerol) at 0oC and immediately frozen 
in liquid N2. The samples were stored at -80
oC until analysis by MS. 
 
5.3.4 Protein fragmentation and MS: 
H/DX samples were individually melted at 0oC, then injected (100 µl) and pumped 
through tandem immobilized protease (pepsin and fungal protease XIII; both from Sigma) 
columns (50 µl/min, 1 X 20 mm [16 µl] columns of each protease coupled to Poros 20 AL 
support [Applied Biosystems]). Protease generated fragments were collected onto a C18 
HPLC trap column (2.5 X 0.5 mm). Peptides were eluted into and through an analytical 
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C18 HPLC column (0.3 X 75 mm) by an acetonitrile gradient (12-55% B; 6 µl/min; 
solvent A, 0.1 % formic acid; solvent B, 0.1% formic acid, 99.8% acetonitrile) and the 
effluent was directed to the mass spectrometer (LTQ Orbitrap XL, ThermoFisher 
Scientific). The SEQUEST software program (ThermoFisher Scientific) was used to 
identify the likely sequence of the parent peptides using nondeuterated samples via 
tandem MS.  
 
 
5.3.5 H/DX analysis 
DXMS software (Sierra Analytics) was used for searching the MS1 data from H/DX 
samples and calculating the centroid of the isotopic envelope of each peptide using a 
general scheme that is described elsewhere (180,181). Peptides that score highly in the 
DXMS program were checked for matching of calculated versus known mass, charge 
state, and the retention time of the peptide on the C18 column, and peptides that 
satisfied these criteria were selected for further analysis. The level of H/DX occurring at 
each timepoint is expressed as either the number of deuterons or the percentage of 
exchange within each peptide. In each case, corrections for loss of deuterium label by 
individual peptides during H/DX-MS analysis were made through measurement of loss of 
deuterium from reference samples that had been deuterated under denaturing 
conditions as described elsewhere (182,183). For generating deuterium exchange 
profiles (181,184), maps of rate-classes along the polypeptide sequence was assembled 
using the H/DX data, employing a strategy in which the (generally smaller) peptides 
containing one or two rate classes were first placed in primary sequence register, 
followed by placement of peptides with two, and then three rate classes, in a manner 
that required that placement of the rate classes of the amides in each peptide conform to 





We first used H/DX to analyze the polypeptide backbone dynamics of full length 
MeCP2 when free in solution (Fig. 5.1). Because MeCP2 binds strongly to unmethylated 
and methylated DNA (63), we also determined the dynamics of H/DX when MeCP2 was 
bound to an unmethylated 198 bp DNA fragment derived from the sea urchin 5S rRNA 
gene (85)(Figs. 1-3 and supplemental Figs. 5.1-3), and to the methylated version of the 
same DNA fragment (Figs. 5 and 6 and supplemental Figs. 5.4-6). In Figures 5.2-6 the 
H/DX experiments characterize full length MeCP2, focusing on the MBD region of the 
protein.  
 
5.4.1 H/DX demonstrates the extreme conformational plasticity of full length 
MeCP2 when free and bound to DNA: 
The H/DX approach consisted of incubation of the samples in heavy water (D2O) at 
4°C to exchange deuterium with the amide protons alon g the polypeptide backbone of 
MeCP2. At time points spanning 101 s to 104 s, the exchange reactions were quenched, 
MeCP2 fragmented by proteolysis, and deuterium incorporation measured by mass 
spectrometry. Protection from H/DX in native proteins or protein/DNA complexes is 
expected in those regions that are folded into stable secondary structures. This is due to 
the fact that measurable amide protons are hydrogen bonded and must transiently lose 
secondary structure, locally or globally, in order for exchange to occur (185).  
 
In our experiments, peptides covering 87% (free MeCP2) or 73% (MeCP2 bound to 
unmethylated DNA) of the entire length of the MeCP2 sequence were initially identified 
by MS/MS and then successfully monitored over the entire time course of exchange. 
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Areas where coverage was not achieved tend to be unstructured (for example, compare 
residues ~160-200 and ~250-280 in the -/+ DNA maps in Fig. 5.1). In the absence of 
DNA, H/DX along nearly the entire length of MeCP2 was rapid, with 64% of all peptides 
measuring >90% of complete exchange by the first time point (10 s). The sole region 
that exhibited measurable protection from H/DX was found in the peptides spanning 
amino acids ~90-160, closely overlapping the MBD of MeCP2 (which encompasses 
residues 78-162). These results indicate that when free in solution full-length MeCP2 
has only one region of even marginally stable secondary structure, corresponding to the 
MBD. Moreover, the H/DX of even the MBD was faster than would be expected for a 
typical globular protein in which most of the amide backbone was engaged in hydrogen 
bonding. Thus, the entire polypeptide chain of free full length MeCP2 is intrinsically 
disordered. 
 
When bound to unmethylated DNA under saturating conditions, the MBD-derived 
peptides were much slower to exchange, while there was no change observed in the 
very rapid H/DX at any other location in the MeCP2 protein sequence (Fig. 5.1 and 
supplemental Fig. 5.1). Thus, although the stability of the MBD was greatly increased 
when MeCP2 was bound to unmethylated DNA, the remainder of the polypeptide chain 
stayed extremely disordered. The MBD only accounts for 17% of the 486 residue full 
length protein. Thus, the data in Figure 5.1 demonstrate that MeCP2 remains very 
intrinsically disordered even when bound to DNA. Given that the MBD was the sole 
region to show evidence of secondary structure formation, we focused our next 
experiments on high resolution H/DX characterization of the dynamics of the MBD in full 









FIGURE 5.1. Protection from H/DX before and after DNA binding i s detectable only 
within the MBD of MeCP2 . Each horizontal bar represents an individual peptide derived 
from MeCP2 when free in solution (MeCP2), or bound to unmethylated DNA (MeCP2 + 
DNA). They are color coded for the percent deuteration at 4°C at each timepoint (10 1, 
102, 103, and 104 s), as represented by an individual stripe within each bar. The MBD is 
enlarged on the lower left, with an individual peptide enlarged further and labeled to 







5.4.2 Rapid sampling of partially unfolded states o ccurs within the MBD when 
MeCP2 is free in solution: 
Since the MBD region was particularly well represented with many partially 
overlapping peptides, we could employ a strategy with three rate classes (0-10 s, 10-100 
s, >100 s) to finely map H/DX exchange. Similar exchange profile strategies that utilize 
partially overlapping peptide information have been especially informative when 
combined with crystal structures (184,186). In the absence of DNA, only small regions 
(i.e. stretches of 1-4 amino acids.; blue positions in Fig. 5.2A and B) exchange amide 
protons for deuterons slower than 100 s. Thus, the stability at many locations within the 
MBD is the same or only marginally greater than the remainder of the MeCP2 
polypeptide chain when the protein is free in solution. Further, when the H/DX profile of 
the MBD of free MeCP2 is mapped (Fig. 5.2C) onto the crystal structure of the MBD (12) 
it is clear that even in the most rigid portion of each β-strand and the α-helix in this 
region must rapidly sample partially unfolded and partially folded conformations in order 
to allow for the relatively rapid H/DX (i.e. nearly complete exchange by 1000 s at every 
location) that is observed in the MBD of the free full length protein (Fig. 5.1).  
 
5.4.3 Rapid sampling of partially unfolded states w ithin the MBD is restricted when 
MeCP2 binds to unmethylated DNA: 
MeCP2, when bound to unmethylated DNA under saturating conditions, has many 
more residues within the MBD that are substantially protected from H/DX (Fig. 5.2D). On 
the level of individual peptides, while exchange is complete by 104 s within the MBD  of  
the free protein, when MeCP2 is bound to DNA, several MBD residues remain protected 
from H/DX at the same 104 s time point (Fig. 5.3 and supplemental Figs. 5.2 and 5.3).  
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When we examined the H/DX protection imposed upon the MeCP2 MBD due to 
unmethylated DNA binding in closer detail (Fig. 5.2E), we noted that the H/DX profile 
closely matched the known secondary structural elements (11,12) of the isolated MBD 
(Fig. 5.2F, blue residues labeling the most protected regions of MeCP2 when bound to 
DNA). In the crystal structure of the MBD bound to methylated DNA (12), the majority of 
the surface of the isolated MBD is exposed to solvent, not buried with the surface of the 
bound DNA. The amide protons of R111, D121, and R133 (labeled red in Fig. 5.2, 
panels G and H) are the only positions predicted from the crystal structure (12) to 
become protected by DNA (or water) contacts, which cannot explain the extent of 
protection of H/DX we observed upon unmethylated DNA binding by MeCP2 (compare 
protection in Fig. 5.2, panels B and E). Our scheme for generating H/DX profiles of the 
MBD allowed for resolution down to a small number of amino acids (see 
EXPERIMENTAL PROCEDURES). As described above, there is a strong correlation 
between the H/DX of the MBD of MeCP2 when bound to unmethylated DNA and the 
secondary structure of the MeCP2-methylated DNA complex (Fig. 5.2E and 5.2F). Our 
H/DX profiles (Figs. 2B and 2E) were generated without bias toward any structural 
information, but if we include predicted protection (Figs. 2G and 2H) in positioning the 
measured H/DX on each peptide, the final profile (Fig. 5.2I) only differs from the 
unbiased profile (Fig. 5.2E) at seven positions. This indicates that the slowed backbone 
exchange upon unmethylated DNA binding corresponds to global stabilization of the 







FIGURE 5.2. Stabilization of the MBD upon unmethylated DNA bind ing results 
from restricted sampling of intrinsic unfolding rat es. A, Deuterium exchange profile 
maps for each peptide of the MBD of free MeCP2 in solution are color coded as 
described in EXPERIMENTAL PROCEDURES. B, The consensus exchange rate at 
each position (spanning residues 91 [the N-terminal residue of the MBD clear in the 
crystal structure (37) to residue 157 [the C-terminal residue where our high-density 
coverage of the MBD ends]) from panel A is shown in a single linear representation. C, 
The consensus map from panel B overlaid onto the crystal structure of the MBD (the 
DNA is not shown; PDB ID 3C2I). D, The exchanged deuterons for each MBD peptide 
bound to unmethylated DNA, mapped as in panel A. E, The consensus map of panel D. 
F, The consensus map from panel D overlaid onto the crystal structure of the MBD. G, 
The MBD sequence with the location of residues where the amide proton is engaged in 
a hydrogen bond in the crystal structure (black), as well as the position of the reported 
residues (37) with direct DNA contacts. H, Mapping of the residue labeling from panel G 
onto the MBD crystal structure. I, A structure-biased consensus map using the same 
number of slow (blue), medium (yellow), and fast (red) exchanging amino acid position 
as in panel E. Note how closely the slow (blue) residues in the final consensus map 
match amide proton protection predicted by the stable structure obtained by others by 
crystallography (37). This indicates that the increase in protection upon binding to 
unmethylated DNA result from stabilizing the overall fold of the MBD rather than 
increasing protection locally at its relatively small DNA binding surface.  
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To summarize, our data indicate that the H/DX protection of the MBD upon 
binding of MeCP2 to unmethylated DNA occurs mainly via domain-wide restriction of 
rapid sampling of its secondary structural elements, not by inaccessibility to solvent due 
to steric hindrance imposed by DNA. That is, the increase in H/DX protection upon 
binding unmethylated DNA is due to stabilization of the overall fold of the MBD rather 
than increased local protection at its relatively small DNA binding surface. In addition, 
there are fundamental changes in the flexibility of the MBD structure that occur upon 






















FIGURE 5.3. The MBD is protected from H/DX upon binding unmethy lated DNA.  A, 
The location on the crystal structure (PDB ID 3C2I) of a representative MBD peptide 
(amino acids 104-124). B, Comparison of H/DX for this peptide from free MeCP2 and 
MeCP2 bound to DNA. C, Side-by-side analysis of raw data for the peptide from panel B 
from free MeCP2 (left) or MeCP2 bound to unmethylated DNA (right). Dotted blue and 
red lines are guideposts to highlight the differences in m/z shifts reflecting the magnitude 




5.4.4 Binding to methylated DNA locally restricts c onformational flexibility within 
the MBD: 
Given that MeCP2 only has a modest preference for methylated DNA over 
unmethylated DNA (120), we were curious of the extent to which binding to methylated 
DNA would correspond to increased H/DX protection within the MBD (or elsewhere in 
the protein). Our initial experiments (Figs. 1-3) were performed at 4oC to slow the 
chemical exchange rate and maximize our ability to see any protection at all for free 
MeCP2. Since many residues were completely protected from exchange at 104 s when 
MeCP2 was bound to unmethylated DNA at 4oC (Figs. 1 and 3 and supplemental Figs. 2 
and 3), we predicted that increasing the temperature would be necessary to perform a 
reasonable time course that spanned the exchange rates of most of the protected 
portions of the MBD in the case of DNA (either unmethylated or methylated)-bound 
MeCP2. To determine if this was the case, we first analyzed MeCP2 at a single time 
point at three varied temperatures (4oC, 23oC, and 37oC) and measured H/DX on 
peptides within the MBD (Fig. 5.4). This experiment indicated that increased temperature 
(most likely corresponding to predictable higher chemical rates of H/DX (185)), 
increased the amount of H/DX within the MBD. Thus, we chose to perform an expanded 
time course (1 × 101, 1 × 102, 1 × 103, 1 × 104, 2.5 × 104, and 1 × 105 s time points) of 
H/DX at 37oC. With peptide coverage spanning much of the full length of MeCP2 in all 
three cases (MeCP2 alone, +unmethylated DNA, and +methylated DNA; supplemental 
Fig. 5.4), the only observed region with any measurable protection from H/DX once 
again was within the MBD (Fig. 5.5A). In the absence of DNA, all MBD peptides 
were >90% deuterated at 10 s, with substantial slowing (most greater than 103-fold) of 
exchange for all MBD peptides when MeCP2 was bound to either unmethylated or 




In the MeCP2-methylated DNA crystal complex (12), structured waters connect the 
methyl groups on the DNA with specific MBD residues (R111, D121, Y123, and R133) 
via hydrogen bonding. To test how the conformational flexibility of the MBD is affected 
by methylated DNA-specific contacts, we carefully examined representative peptides for 
which we had a comprehensive MS data set for all samples and time points. Peptides 
spanning the N-terminal ~half of the MBD, i.e., amino acids 90-106 (Fig. 5.5B and 
supplemental Fig. 5.5) and amino acids 104-123 (Fig. 5.5C and 5.6A-D), showed clear 
reduction in H/DX rates when MeCP2 was bound to methylated versus unmethylated 
DNA, while peptides spanning the C-terminal ~half of the MBD, i.e., amino acids. 124-
138 (Fig. 5.5D and supplemental Fig. 5.6) and amino acids 142-157 (Figs. 5E and 6A,E-
G), showed little or no alteration. The N-terminal peptides showed additional protection 
exceeding that which would be expected if the residues only were involved in hydrogen 
bonding with the structured waters. For instance, none of the residues in the amino acids 
90-106 peptide, and only three (R111, D121, and Y123) in the amino acids 104-123 
peptide, are directly bonded to the structured waters implicated in methylated DNA 
specificity, yet several additional amide protons exhibit slowed exchange that was 
dependent upon binding to methylated DNA (Fig. 5.6B and supplemental Fig. 5.5). On 
the other hand, the third residue (R133) that participates in a hydrogen bond with one of 
the structured waters appeared to have almost no influence on H/DX exchange within 
the MBD (see a representative peptide corresponding to amino acids 124-138; 
supplemental Fig. 5.6). These results indicate that: 1) relative to binding to unmethylated 
DNA, binding to methylated DNA affects H/DX locally (only the N-terminal ~half of the 
MBD) and not globally throughout the entire domain, 2) the additional protection of the 
N-terminal MBD peptides is consistent with additional local rigidity, not solely backbone 
protection resulting from the residues directly hydrogen bonded to the structured waters 
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that are coordinated with the methyl groups on the DNA, and 3) the local added 
protection from H/DX upon binding to methylated DNA versus unmethylated DNA is not 
due to differences in binding kinetics with the MBD since the C-terminal peptides 
(spanning amino acids ~124-157) exchange with indistinguishable slow kinetics when 
MeCP2 is bound to either DNA fragment compared to the rapid H/DX when MeCP2 is 

























FIGURE 5.4. Temperature dependency of H/DX within t he MeCP2 MBD. Peptides 
from a representative region within the MBD of free MeCP2 (i.e. unbound to DNA) are 
shown as single horizontal bars. Color-coding corresponds to the level of H/DX after 104 

























FIGURE 5.5. Binding to methylated DNA further incre ases protection from H/DX 
within the N-terminal but not C-terminal portion of  the MBD.  A, Peptides from the 
MBD are shown for free MeCP2 (top), MeCP2 bound to unmethylated DNA (middle), 
and MeCP2 bound to methylated DNA (bottom). Data are presented as in Fig. 5.1. B-D, 
Representative peptides that span the MBD with the indicated amino acid positions are 
enlarged and compared. The residues boxed in red indicate positions that directly 
contact DNA and/or form bonds with water molecules that are coordinated with the 




















FIGURE 5.6. Representative MBD peptides showing protection fro m H/DX when 
MeCP2 binds to unmethylated DNA and methylated DNA.  A, The location on the 
crystal structure of the MBD bound to methylated DNA (PDB ID 3C2I) of representative 
MBD peptides (amino acids 104-123 [pink] and 142-157 [yellow]). B and D, Comparison 
of H/DX for peptides amino acids 104-123 (panel B) and amino acids 142-157 (panel D) 
from free MeCP2 and MeCP2 bound to unmethylated DNA and methylated DNA. C and 
E, Side-by-side analysis of raw data for the indicated peptides from free MeCP2 (left), 
MeCP2 bound to unmethylated DNA (middle), or MeCP2 bound to methylated DNA 
(right). Labeling is as in Figure 5.3C.  
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5.4.5 RTT Mutations in the MBD Have Varied Effects on Local and Domain-wide 
Flexibility: 
Mutations within the MBD are common in RTT patients, with many of the most 
frequent missense mutations (such as R106W and T158M) predicted to disrupt 
stabilizing interactions within the domain (12).  For instance, the side-chain of R106 
forms hydrogen bonds with the polypeptide backbone at positions T158 and Val159 (12). 
The extent to which these hydrogen bonds affect dynamic protein behavior is not easily 
discernable from static structures, but we reasoned that H/DX would provide a fine 
resolution dynamic measurement to directly assess the local and domain-wide effects of 
RTT mutations in the MBD (Fig. 5.7). For this analysis, H/DX experiments were 



















FIGURE 5.7. Effects of Rett Syndrome-associated mis sense mutations on the 
conformational flexibility of the isolated MBD.  A, The level of H/DX at 2.5 × 101 s are 
color-coded as indicated on horizontal bars representing peptides derived from the wild 
type (WT) MBD, and the MBDs harboring the indicated point mutations. Data from all 
time points monitored (1 × 101, 2.5 × 101, 1 × 102, and 2.5 × 102 s) are shown in 
Supplemental Figs. 7-10. The black arrows indicate the representative peptide (amino 
acids 124-138, compared panels C and D, below). B, The location on the MBD crystal 
structure (PDB ID 3C2I) of the peptide (amino acids 124-138) highlighted in panels C 
and D. The positions of the amino acid side-chains in the RTT MBD mutants that were 
investigated are shown as colored spheres. C, Comparison of H/DX for a peptide (amino 
acids 124-138) from the MBD. D, Side-by-side analysis of raw data for the WT MBD and 





Our results indicate that the R106W MBD mutant had generally similar H/DX 
behavior as the wild type (WT) MBD (Fig. 5.7A, C, and D), with increased H/DX 
protection in the β1 peptide and only minor acceleration of exchange occurring in 
peptides spanning amino acids ~140-155 (Fig. 5.7A). By contrast, the F155S mutation, 
which removes hydrophobicity from within the MBD protein fold (see the position of F155 
in Fig. 5.7B) and has been shown previously to greatly destabilize the MBD by 
fluorescence anisotropy measurements and melting experiments (88), forces the entire 
MBD to sample unfolded conformations at rates that are several orders of magnitude 
higher than for the protected residues in the wild type MBD. Consequently, for the 
F155S mutant, even at the earliest time point (10 s) there is complete exchange 
throughout the domain (Fig. 5.7C and supplemental Fig. 5.9). The side-chain of T158 is 
predicted from the co-crystal structure to be important for the integrity of the so-called 
Asx-ST motif (located at the C-terminal end of the MBD), in part by making hydrogen 
bonds with the polypeptide backbone at positions G161 and R162 (12). T158M is the 
site of the most common point mutation in RTT, accounting for ~9% of all cases 
(Rettbase; http://mecp2.chw.edu.au/). Despite residing in the MBD C-terminus, the 
T158M mutation surprisingly only affects conformational dynamics spanning portions 
well into the N-terminal folded portion of the MBD, including amino acids ~125-155 (refer 
to Fig. 5.7D and the representative peptide [amino acids 124-138] that fits into the major 
grove of DNA [Fig. 5.7B]). The H/DX behavior of the RTT MBD mutants indicates the 
variable extent to which these common mutations affect the local and global 







5.5.1 Full length MeCP2 structure: 
The structure of full length, wild type MeCP2 is not consistent with a conventional 
protein comprised of stable, folded domains. Based on averaged biophysical 
measurements the conformation of full length MeCP2 is very disordered, e.g., 
deconvolution of CD data yields 60-65% unstructured content and the protein sediments 
as if it were a random coil (85). Prediction algorithms (PONDR-VXT, FoldIndex) also 
yield estimates of ~65% disorder, with short regions of predicted order interspersed 
throughout an otherwise intrinsically disordered polypeptide chain (85,96). MeCP2 is 
composed of six biochemically defined domains: the N-terminal domain (NTD), the MBD, 
the intervening domain (ID), the transcriptional repression domain (TRD), and the C-
terminal domain alpha and beta (CTDα and β) (Fig. 5.8;(85,96)). CD analysis of the 
isolated MeCP2 domains indicates that each has between 60-80% unstructured content 
with the exception of the MBD, and even the MBD is ~40% unstructured (47; Fig. 5.8). 
While the steady-state CD experiments have documented the extensively unstructured 
nature of full length MeCP2, they also have raised an important question: Is the 35-40% 
averaged secondary structure content calculated to be present in MeCP2 and its 
domains in the form of stable three-dimensional structures, or does it result from an 
ensemble of folded structures that each rapidly samples unfolded, random-coil state(s) 
during the course of the steady-state measurements? Our H/DX experiments indicate 
the latter possibility is correct. We obtained nearly total peptide coverage of the MeCP2 
polypeptide chain in our experiments, and all domains of MeCP2 except the MBD 
underwent essentially complete H/DX at the earliest measureable time point (Fig. 5.1). 
While H/DX was slower in the MBD, in the absence of DNA binding it still was faster than 
the H/DX of a typical globular protein.  Accordingly, we envision that the full length 
MeCP2 polypeptide chain rapidly samples many different secondary structures, and 
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equilibrates between multiple tertiary structures, even when bound to DNA. In this regard, 
various domain-domain interactions in cis and trans have been detected previously 
(88,96), consistent with the conformational malleability of full length MeCP2 observed by 
H/DX.  
 
What are the functional advantages of the extreme conformational flexibility and fast 
conformational sampling exhibited by MeCP2? This is a key question, as it is relevant to 
the subject of intrinsically disordered proteins in general. Given that intrinsically 
disordered proteins often acquire secondary structure in conjunction with 
macromolecular interactions (171), we propose that enhanced conformational flexibility 
and rapid structural sampling: 1) provide the biochemical basis of MeCP2 
multifunctionality by allowing a 53 kDa monomeric protein to bind to so many different 
macromolecular partners (16,22,74,75,77,78,80,173) facilitate the formation of higher 
order macromolecular complexes involved in MeCP2 function that themselves are 
conformationally malleable (see (117)). 
 
5.5.2 MeCP2-DNA interactions 
Very few proteins have been investigated where H/DX has been used to probe the 
conformational rigidity imposed by binding to DNA. One case is the Lac repressor, which 
is capable of binding to non-specific DNA sequences, but binds specifically to its 
operator sequence with >106-fold higher affinity (187). When bound to DNA 
nonspecifically, the conformational flexibility of the folded portion of the Lac repressor 
DNA binding domain is unaffected as measured by H/DX (188). Only upon forming the 
base specific hydrogen bonds with its operator sequence (189), is there imposed a 
substantial (105-fold) increase in conformational rigidity throughout the Lac repressor 
DNA binding domain (188). Another example is the rigidity imposed upon core histones 
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during nucleosome assembly.  Sub-nucleosomal histone complexes, upon assembly into 
nucleosomes, undergo >103-fold protection from H/DX, spanning the globular domains 
of each of the core histones (180). For both Lac repressor and histone H/DX protection 
upon DNA binding, the effects appear to be global throughout domains (i.e. not local at 
the points directly contacting DNA). Moreover, the H/DX data for these proteins cannot 
be explained generally by solvent inaccessibility in the bound state, but rather by 
inflexibility gained in secondary structural elements upon either specific (Lac repressor) 
or non-specific (histone) DNA binding.  
 
In the case of MeCP2, we found that global, domain-wide inflexibility is conferred to 
the MBD upon non-specific binding to a 198 bp unmethylated DNA fragment. Moreover, 
binding to the methylated version of the same DNA (containing 12 CpG sites) 
subsequently leads to additional local protection in the MBD. These results are 
consistent with previous steady state CD measurements showing increased secondary 
structure due to DNA binding (88). The global inflexibility gained upon unmethylated 
DNA binding is substantial—at least 1000-fold at many locations throughout the MBD 
(Figs 1 and 3 and supplemental Fig. 5.2). Importantly, a clear feature upon comparing 
the effects on MBD polypeptide backbone dynamics resulting from binding unmethylated 
or methylated DNA is not the differences in H/DX, but the striking similarities. That is, our 
H/DX experiments strongly suggest that the MBD folds and recognizes double-stranded 
DNA in a manner that is very similar when it is bound to either unmethylated or 
methylated DNA. There is somewhat more protection in the N-terminal half of the MBD 
when bound to methylated DNA, but no measurable differences in the C-terminal half 
(Figs. 5 and 6 and supplementary Figs. 5 and 6). Thus, we can conclude that in addition 
to the changes imparted by unmethylated DNA binding, the methyl groups coordinate 
waters with the MBD in a manner that increases the affinity of the DNA interaction 
147 
several-fold and increases backbone rigidity in the N-terminal half of the domain, which 
contains three of the four residues that interact with the structured waters.  The NMR 
solution structures (11) and the crystal structure (12) provide clear views of a favored 
folded state of the molecule, but in order to understand the dynamics of 
unfolding/refolding of the MBD, a measurement that is capable of characterizing 
dynamic protein behavior, such as the H/DX approach described here, needed to be 
employed. In this regard, CD analysis has showed that MeCP2 and many of its isolated 
domains gain secondary structure content when bound to unmethylated and methylated 
DNA (88,96). These averaged measurements are likely assaying the same global and 
local decreases in MBD flexibility observed by H/DX. 
 
Previous studies have demonstrated that the isolated ID, TRD, and CTDα domains of 
MeCP2 each are capable of binding unmethylated DNA in native gel mobility shift 
assays (96). However, as discussed above, the H/DX experiments find no evidence of 
protection outside the MBD when MeCP2 is bound to unmethylated DNA. Thus, the ID, 
TRD, and CTDα may continue to sample multiple conformational states even as they 
interact non-specifically with DNA. It is also possible that the incomplete regions of the 
H/DX profiles seen when MeCP2 is bound to unmethylated DNA (Fig. 5.1) result from 
peptides that remained bound to DNA even after denaturation and digestion. MeCP2 is 
an abundant chromatin associated protein in vivo (54,86). In terms of chromatin we 
speculate that the MBD binds to linker DNA (36,61,120), while other DNA binding site(s) 
are used to interact with nucleosomal DNA and help MeCP2 physically envelop the 
nucleosome (190). This in turn promotes compaction of MeCP2 bound chromatin fibers 
(24,61). In sum, our H/DX experiments allowed us to access site-specific backbone 
dynamic information that complements the earlier structural studies and significantly 
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extends our understanding of the physical and chemical mechanisms of DNA binding of 























FIGURE 5.8. Diagram of MeCP2 domain organization with the percen tage of each 
domain that is unstructured, as measured by CD , in dicated for each domain.
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5.5.3 MBD RTT mutations: 
The H/DX approach has yielded novel information about the flexibility of several 
common RTT MBD mutants that cannot be discerned from the static co-crystal structure 
or averaged solution measurements. All three mutations (R106W, F155S, and T158M) 
that we chose to study replace side-chains that do not directly contact DNA (or waters 
coordinated by the methyl groups on methylated DNA), but rather were predicted from 
static models (11,12) to be important for the structural integrity of the MBD. For example, 
on the basis of direct hydrogen bonding seen in the crystal structure, the T158 residue 
was proposed to stabilize the Asx-ST motif in the extreme C-terminal region of the MBD 
along with residue R106 in the N-terminal portion of the MBD, yet with the T158M 
mutant the H/DX clearly showed increased flexibility of peptides that span the secondary 
structural elements (β1 and β2 strands, and α2 helix) that lie between the MBD termini 
(Fig. 5.7). The R106W mutant is predicted to be disruptive of the Asx-ST motif (12) and 
potentially disruptive to the integrity of the entire MBD. However, for this mutant the 
H/DX was virtually identical to the wild type MBD, clearly not generating instability that 
leads to a higher frequency of sampling an unfolded state that is transmitted throughout 
the domain. Ultimately, the H/DX data suggest that interactions between the N-terminus 
and C-terminus of the MBD that are likely to be disrupted by either the T158M or R106W 
mutations may affect DNA binding, and indeed, this has recently been demonstrated 
(88). The F155S mutant does not affect any proposed hydrogen bonds with DNA or 
water-mediated DNA contacts, yet this mutation yields the most rapid conformational 
sampling of any of the three mutations tested probably by its disruption of hydrophobic 
contacts with the many neighboring side-chains lining the interior of the MBD fold. As 




         Our H/DX studies of three frequent RTT mutants indicate that MBD mutations that 
each cause RTT in a physiological context can do so in a manner that either disrupts or 
preserves the flexibility of the folded state of the MBD. Final structures are useful in 
predicting the local and global effects of mutation of amino acid sequence, and our H/DX 
studies of the MBD mutant proteins illustrates the further utility of site-resolved dynamic 
protein measurements to determine the extent to which point mutations affect backbone 
dynamics. Our studies of the F155S and T158M mutations also raise the tantalizing 
prospect that a subset of MBD-localized RTT mutations may benefit by so-called small 
molecule chaperones to return the MBD to the relative stability of the wild type protein, 
and we propose that RTT should be added to the growing list of diseases where such 
pharmacological stabilization of mutant disease causing gene products is pursued as a 



















Experimental observations of an intrinsically disor dered protein 
- MeCP2; critical discussion of observed DNA bindin g activity 


















The work outlined in this dissertation represents one part of a 
contemporaneous collaborative effort to experimentally observe the MeCP2 gene 
product behaving as an intrinsically disordered protein (IDP).  An IDP is a protein 
or protein region that does not continuously hold a well-defined secondary or 
tertiary structure.  Diverse methods were used, including hydrogen-deuterium 
exchange (H/DX) (appendix 1), high-speed atomic force microscopy (hsAFM) 
(collaborative manuscript in preparation) and circular dichroism (CD). Each 
method of investigation was performed in solution state rather than in crystal 
state. This allowed us to directly observe the flexibility of MeCP2 and to 
corroborate it accordingly to disorder prediction algorithms (89,90,191). 
FoldIndex© was the primary prediction algorithm used. The method I have used 
in this collaborative effort to measure extent and type of disorder in MeCP2 is CD.  
I will first discuss the definition of an intrinsically disordered protein, then I will 
hypothesize about the role of intrinsic disorder in MeCP2 function and finally, 
from CD analysis and non-methylated DNA-binding assays, I will make 
conclusions and propose models for how MeCP2 binds at least 20 different 
protein partners and how MeCP2 may use a folding tertiary structure to 
orchestrate chromatin architecture. 
 
6.1.1 How is intrinsic disorder defined? 
An intrinsically disordered protein (IDP) is defined as a whole protein or 
protein region that does not naturally form and maintain regular secondary or 
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tertiary structure when isolated in solution at physiological conditions, yet is 
functional.  IDPs can form classical α-helix, β-strand, polyproline II helix, or 
irregular secondary structure conformations while encountering binding partners. 
This is not always the case, as IDPs may also remain disordered while binding or 
not binding other proteins. It is predicted by multiple disorder prediction 
algorithms, including FoldIndex©, that nearly 40% of all human proteins harbor at 
least one intrinsically disordered region of 30 amino acids or more and that 25% 
of all human proteins are entirely disordered (94). These predictions contradict a 
long-standing central tenet of molecular biology which states that the function of 
a protein depends on it maintaining a thermodynamically stable three-
dimensional structure in which intermolecular non-covalent interactions confer a 
narrow range of conformers.   Studies using high-resolution nuclear magnetic 
resonance and small-angle x-ray scattering techniques have revealed that some 
functional regions were disordered during enzymatic activity (192,193). Inherent 
in the emerging paradigm is that protein segments can function when transiently 
or “durably disordered” (44).   A durably disordered protein or protein fragment is 
defined as a peptide that maintains disorder constitutively, even during activity, 
including engagement with a binding partner. 
MeCP2 shares distinct characteristics with predicted IDPs. Namely, 
MeCP2 has a low incidence of large hydrophobic amino acid residues (2.4%), 
and enrichment of lysine residues (13.4% lysine). Shared physical characteristics 
along with 60% predicted disorder according to Foldindex© reveal MeCP2 is an 




Disorder is observed in two major classes of chromatin architectural 
proteins (ChAPs): ATP-dependent complexes and AT- independent factors 
(ATFs). These are reviewed extensively on page 154 of a book on IDPs by Dr. 
Peter Tompa (92). MeCP2 represents an ATP-independent ChAP regulating 
accessibility of transcriptional machinery to the genome. The structural state of 
chromatin can be remodeled through bending and distortion by ATFs such as 
MeCP2.  Indeed higher order chromatin organization is enabled by the flexible 
regions which can simultaneously bind DNA and proteins, facilitating inter-loci 
bridging between strands of chromatin. This phenomenon was observed recently 
using a chromatin immunoprecipitation–combined loop assay in which MeCP2 
bridged chromatin loci 11 kb apart (136). Interestingly, the HMGA family of 
chromatin architectural proteins discussed in Chapter 3  not only have sequence 
homology to MeCP2 but also share a similar degree of overall disorder and 
functionality of DNA bending and chromatin-strand bridging. The results 
presented in the preceding chapters provide a more complete understanding of 
how specific sub-domains of MeCP2 bind non-methylated DNA and whether they 
have evolved to undergo complete transition from disorder to order or maintain a 
certain amount of durable disorder no matter how favorable the solvent 
conditions are for inducing secondary structure. 
The MeCP2 monomer previously has been observed to be 60 percent 
disordered by circular dichroism (CD) analysis and this observation is in 
agreement with the disorder percentage predicted by FoldIndex© (85). Although 
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the methyl-CpG-binding domain (MBD) and transcription repression domain 
(TRD) were also studied by CD as isolated domains in this previous report, the 
manner in which intrinsically disordered regions of MeCP2 either acquire 
secondary structure or remain disordered was not studied.  The work here tries 
to paint a more complete picture of either induced secondary structure or durably 
maintained disorder along with a more complete map of non-methylated non-
specific DNA-binding activity among sub-domains of MeCP2.   
  
6.1.2 Method used to observe intrinsic disorder in MeCP2 and constituent 
fragments. 
 The primary method used was circular dichroism (CD) 
spectroscopy to observe full-length MeCP2 and constituent fragments as they 
underwent disorder-order transition upon titration with trifluoroethanol (TFE), an 
organic solvent known to stabilize α-helices in protein and polypeptide solutes 
(194).  Using this method, I sought to observe MeCP2 and constituent fragments 
as individual objects of study in a highly controlled and purified in vitro setting.  
Attempts were made to use a 60mer double-stranded DNA molecule in order to 
observe structural changes upon binding; however, the DNA addition resulted in 
large contributions to the CD signal that could not be reliable subtracted as a 
blank.  I chose to perform titration of MeCP2 with TFE, as TFE has been called 
the “magic” solvent for its unique ability to overcome this signal to noise hurdle in 
the far UV range. Another option might have been to use a non-polar solvent, but 
this was not an option due to the insolubility of small peptides in polar solvents.  
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Peptides as short as 38 amino acid residues were used in the present work. TFE 
solvates peptides well and has the unique ability to stabilize intra-H-bonded 
secondary structures like α-helices or β-turns (195). I hypothesized the regions of 
MeCP2 with the most numerous binding partners would acquire the most 
secondary structure upon TFE titration.   
The other aspect of investigation in this dissertation has been observation 
of MeCP2 and constituent fragments as they bind to non-methylated DNA and 
chromatin templates in electrophoretic mobility shift assays.  
 
6.2 Overall discussion and conclusions 
 The data presented in Chapter 2 of this dissertation allow 
conclusions to be made about the disorder-to-order transition of full-length 
MeCP2, the six protease resistant domains and one domain fusion (the TRD-
CTD).  The historical reproducibility of the technique was established by 
comparing the acquisition of secondary structure by purified native Gallus gallus 
histone - H5 to recombinant human wild-type MeCP2 protein.  A shift in predicted 
alpha-helical percentage of full-length H5 was first reported in 1988 (103). In the 
absence of TFE histone, H5 had 17% predicted alpha helix, and in the presence 
of 50% TFE had 50% predicted alpha helix.  The results presented here match 
that initially reported result within experimental error and add titration points of 20 
and 70% TFE.   
Rather than repeating exactly the previously reported method (103), I 
chose to use an additional percentage of TFE in the titration. The use of four 
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titration points (0, 20, 50, and 70%TFE) provided a wider view of the disorder-to-
order transitions than the use of three percentages in the previous method (0, 50, 
and 65%). Using a broader concentration range also allowed observation of 
pieces of MeCP2 that reached a plateau in percent acquired secondary structure 
and those that acquired more structure at each increasing percentage TFE.  This 
allowed me to differentiate between those regions that durably maintain disorder 
and those that do not.  
  Interestingly, the transcriptional repression domain (TRD) alone 
had the most dramatic shift from disorder to alpha helix in the presence of TFE. 
TRD changed from less than 10% alpha-helical in the absence of TFE to nearly 
89% alpha helix in 70% TFE.  I initially hypothesized the observation of dramatic 
induction of alpha helix in the TRD indicated the TRD had more protein binding 
partners than the rest of the fragments. However, upon review of the literature 
this is not the case.  I have listed in Table 6.1 all proteins and nucleic acids 
reported to bind to MeCP2, and noted the amino acid residues within MeCP2 to 
which the interactions were narrowed, as well as the method or methods used in 
the respective studies.  Examination of this Table reveals that two out of twenty 
one MeCP2-protein interactions are exclusively assigned to the TRD domain of 
MeCP2. In the four other cases where TRD is mentioned as the region of 
interaction the result also includes other domains expressed as domain fusions 
with TRD.  Despite the observed difference in observed secondary structure 
induction in TRD being 45% higher than any other domain, this does not seem to 
correlate to the number of binding partners. In fact, according to the current set of 
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reported proteins that interact with MeCP2, the incidence of binding region 
seems to be equally distributed along the entire length of MeCP2.  This 
observation brings added understanding to Rett syndrome pathology, explaining 
why mutations along the entire length of MeCP2 lead to a diseased state. Indeed, 
if each domain has reported protein binding partners, mutations in each domain 
can affect the role of MeCP2 in maintaining dynamic chromatin architecture. 
 
6.2.1 Alternative hypothesis and future directions.  
  If the TRD does not have more binding partners than the other 
domains, does 45% more α-helix acquired by TRD in TFE titration compared to 
all other domains have physiological relevance? Further experiments need to be 
done to determine this. Considering the result and the reported number of 
binding partners I hypothesize that the role of the TRD is to act as a collapsible 
hinge upon DNA- and/or factor-binding bringing the two halves of MeCP2 in 
closer proximity. This speculative model entails MeCP2 folding in half at the 
center of the TRD. There is a known bipartite nuclear localization sequence 
(NLS) within the TRD between residues 255 to 271 (RKAEADPQAIPKKRGRK) 
(196). The two proline residues located in the middle of this NLS may give the 
TRD a pivot point for two long inducible alpha helices (55 amino acid residues N-
terminal and 45 C-terminal to the NLS) to emanate and fold similar to a pair of 
open to closed scissors upon trans-cis isomerization of the prolines at residues 
261 and 265. This folding event may be triggered by binding nuclear transport 
receptors. MeCP2 folding in half may allow it to pass through the nuclear pore 
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complex.  If this folding point exists it may play a key role in the chromatin 
condensation activity of MeCP2. The significance of this region is highlighted by 
the observation that two of the most common Rett mutations occur on either side 
of this hypothetical “folding” center, the R255X and the R270X which are the 3rd 
and 4th most common Rett mutations with an incidence of 265 and 245 cases 
reported respectively world-wide.   I recommend atomic force microscopy be 
conducted on full-length MeCP2 and TRD in the presence of increasing amounts 
of TFE, or  DNA to allow direct visualization of this proposed folding helix model. 
These experiments would verify or reject the proposed model of prolines 261 and 
265 acting as a point of symmetrical folding for MeCP2 nuclear transport and 


















Table 6.1 MeCP2 domain interactants. 
Interactant of MeCP2  MeCP2 region of interaction  Method used in observation  
RNA (64,65)  Not defined Native 5% PAGE and autoradiography (gel shifts) used. 
DNA (8,36,54,116,118-
120)       
                                          
MBD, ID, TRD, CTD 
 
Electrophoretic mobility Shift Assay (EMSA), Analytical 
Ultracentrifugation (AUC), Fluorescence anisotropy, 
Capillary electrophoresis mobility shift assay, 
Chromatin Immunoprecipitation (ChIP) 
formin-binding protein 
(FBP)  and HYPC 
11(34,66) 
CTD -  amino acid residues 325-
486 “WW binding region” 
Co-Immunoprecipitation and western blot 
YB-1 (64)   Co-IP and 
western blots used. 
 
Full length MeCP2 and a MeCP2-
308X truncation mutant used. 
308X altered but did not ablate 
binding to YB-1. 
Co-Immunoprecipitation and western blot 
Sin3a and HDACs (16)                    TRD, residues 207−310 
 
Glutathione-S-transferase (GST) pulldown experiments 
and western blot 
SUV39H1 (81)           
 
Not defined, other than MBD 
alone does not  bind 
Co-Immunoprecipitation and western blot 
HP1 (78)                                         NTD (aa 1-55) 
 
Co-Immunoprecipitation and western blot 
DNMT1 (79)              MBD, ID, and TRD    Glutathione-S-transferase (GST) pulldown experiments 
with rat MeCP2 and rat DMNT1 
Ski and N‐COR (22)   
 
ID-TRD loosely defined as 
residues 162-309  
Glutathione-S-transferase (GST) pulldown experiments 
with human MeCP2 and mouse Ski and N-COR 
PU.1 (80)                            NTD (1-92) or TRD (207−309)  Glutathione-S-transferase (GST) pulldown experiments 
with mouse MeCP2. 
Brahma (Brm),  catalytic 
component of SWI/SNF 
(197)   
Not defined Co-Immunoprecipitation and western blot 
ATRX (a SWI2/SNF2 
DNA helicase) (74) 
MBD, residues 78 -169  Glutathione-S-transferase (GST) pulldown experiments 
with mouse MeCP2 
Histone H3K9 
methyltransferase (75)      
MeCP2 carries a methyl 
transferase activity methylating H3 
lysine9 in the MBD and extreme c-
terminus of the TRD 279-486 also, 
methylates H3K9  
Glutathione-S-transferase (GST) pulldown experiments  
TFIIB (76)                                TRD, residues 204-310 Glutathione-S-transferase (GST) pulldown experiments 
HIPK2 - homeodomain-
interacting protein kinase 
2  (68)  
Binding region not defined but, 
MeCP2 is specifically 
phosphorylated at Ser 80 by 
HIPK2 
Glutathione-S-transferase (GST) pulldown experiments 
HMGB1 (73)                                                 CTD, residues 380–386    Glutathione-S-transferase (GST) pulldown experiments 
CDKL5 (70)                                         TRD-CTD, residues 202–486 Glutathione-S-transferase (GST) pulldown experiments 
HDAC1 (72)                                                   Not defined Glutathione-S-transferase (GST) pulldown experiments 
CBF1  (69)                                  Not defined Glutathione-S-transferase (GST) pulldown experiments 
lamin B LBR (67)                                                      ID, residues  162 to 202 Glutathione-S-transferase (GST) pulldown experiments 










6.2.2 Induced α-helix in MeCP2 sub domains correlates precisely wi th 
predicted molecular recognition features (MoRFs). 
A molecular recognition feature (MoRF) is a relatively short piece of a 
protein (an average length of 20 amino acid residues) that acquires secondary 
structure upon recognition of a binding partner. The binding partner could be 
another protein or a small molecule. These interacting partners form a well-
defined complex where either one or both partners acquire secondary structure 
from a previously disordered state (97). There are nine predicted MoRFs along 
the length of MeCP2: two in the NTD, two in the MBD, one in the TRD and four in 
the CTD (63). The ID is the only MeCP2 domain without a predicted α-MoRF.  
There is a direct correlation between observed acquisition of α-helix upon TFE 
titration of MeCP2 domains and incidence of predicted MoRFs.  Each domain, 
except the ID, acquires at least 30% α-helix in 70% TFE. The ID which has no 
predicted αMoRF maintains a constant percentage of all secondary structures 
throughout TFE titration. This suggests that the region of the ID has evolved to 
durably maintain disorder as it stays disordered even in a solvating environment 
extremely conducive to secondary structure formation.  This correlation may 
indicate that the presence of an αMoRF automatically predisposes a peptide to 
undergo a disorder-to-order transition. However this correlation cannot be 
labeled causative until further tests are done.  Observation of a significant 
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number of peptides with predicted αMoRFs that did not acquire α-helix in CD 
TFE titration, or the observation of a significant number of peptides without 
predicted αMoRFs but still able to acquire alpha helical character would nullify 
this hypothesis.  
 
6.2.3 Isolated Methyl CpG Binding Domain (MBD) lose s β-strand/turn while 
gaining α-helical secondary structure upon TFE titration. 
Unlike the other four MeCP2 domains investigated, MBD was unique in 
losing β-strand/turn character while acquiring α-helical character. Disorder 
remained constant at the level of 30% in the presence of 0 to 70% TFE.   The 
MBD is known to house the most rigidly structured motif in the entire MeCP2 
molecule, as evidenced by the NMR and crystal structures of this three-stranded 
β strand/turn, one α-helix wedge, and the hydrogen deuterium exchange data 
presented in appendix 1.  This motif is 34 amino acids long while the entire MBD 
fragment contains 90 amino acids. The flanking 50 amino acids are predicted to 
maintain some order though they do not show up in NMR or the crystal structure.  
According to the CD analysis, in 0% TFE the MBD is found to have over 50% β-
strand/turn. The conversion from β-strand/turn to α-helix may be achieved due to 
these flanking regions, separating and settling MBD into a more stable 
thermodynamic equilibrium.  The intra-helix hydrogen bonds of an α-helix are 
more stable than inter-strand hydrogen bonds inherent to β-sheet structure within 
a less polar solvent.  The maintenance of 30% disorder in the MBD throughout 
TFE titration indicates that a certain amount of the MBD has durable disorder. 
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The MBD is unique in that the α-helix and β-strand/turn are themselves transient 
and not derived from preexisting disorder but from each other.  
 
6.2.4The carboxy terminal domain (CTD) of MeCP2 con verts disorder to 
both α-helix and β-strand/turn. 
The CTD, unlike the other domains, represents a truly transiently 
disordered peptide.  In this case having a wider range of titration points is 
valuable, allowing subtleties in the disorder-to-order transition to be observed.  In 
the absence of TFE, the CTD is 70% disordered, with 25% β-strand, and 5% α-
helix.  The initial drop in disorder at 20%TFE was not converted into alpha helix, 
but shifted β-strand/turn percentage to 42% while bumping the α-helix up to 10%.  
As more TFE was added the β-strand/turn came down to 39% to match disorder, 
while there was a more dramatic conversion to α-helix at this step to 22%. In the 
presence of 70% TFE α-helix barely takes over with just over 33%, whereas β-
strand/turn and disorder are depleted equally, allowing α-helix to form.  Though 
there is only a 5% overall increase in β-strand/turn percentage from 0-70% TFE, 
seeing the middle titration points of 20 and 50% sheds light on the nature of the 
conversion and the lowest energy states of the peptides.  This observation in 
conjunction with the hypothesis that there are molecular recognition features that 
have β-strand/turn, complex, and irregular structure suggest that a given region 
of disorder may be able to interact with multiple binding partners and upon 






6.2.5 MeCP2 sub-domains have different combinations  of durable and 
transient disorder.   
Reflecting on the above observations, it is apparent that MeCP2 domains 
each have a unique mixture of durable and transient disorder.  The TRD seems 
to have no durable disorder as it is able to almost entirely convert to α-helix in 
70% TFE. The MBD has extremely durable disorder, as the propensity for high 
percentage TFE to stabilize alpha helix was forced to draw on existing β-
strand/turn to form more α-helix while the durably disordered portion of MBD held 
disorder at 30%.  Unlike the MBD, the ID seems to have dedicated order as well 
as durable disorder, because TFE titration has no effect on the percentage of 
order of this peptide.  ID holds its secondary structure and lack thereof robustly 
over the course of the TFE titration.  The CTD and NTD are mixtures of transient 
and durable disorder. Both fragments start at very high percent disorder (~70%) 
and converge on 33% disorder, 33% β-strand/turn, and 33% α-helix.   
The existence of various amounts of durable or transient disorder in each 
domain studied in this work did not correlate to the ability of the respective 
domains to bind DNA or nucleosomal arrays. This suggests each domain 
capable of binding DNA does so either by acquiring secondary structure upon 






6.2.6 MeCP2 and constituent fragments bind to unmet hylated  DNA and 
chromatin templates. 
In Chapter 3 of this dissertation it is reported that full-length MeCP2 , and 
its truncated versions containing residues 206-486, 300-486, and 335- 486  all 
decrease mobility of double-stranded DNA alone and nucleosomal arrays 
progressively when incubated together at increasing molar ratios by 
electrophoretic mobility-shift assay. Residues 354-486 and 400-450 were not 
observed to have any effect on electrophoretic mobility of any DNA-based 
template assayed. No difference in mobility retardation was observed between 
MeCP2 fragments incubated with nucleosomal arrays reconstituted with tailless 
or wild-type histones.  It is worth noting that wild-type MeCP2 and residues 206-
486 nucleo-protein complexes were so large and interconnected at a molar ratio 
of 6 moles MeCP2 fragment to 1 mole 208 base pair repeat that they did not 
enter the gel matrix. This observation could indicate compact complex formation 
and is observed when these constructs are incubated with DNA alone, wild-type 
nucleosomal arrays, or tailless arrays.  In my hands histone N-terminal tails were 
not required for array compaction by wild type MeCP2 or residues 206-486 
(TRD-CTD).     This fact does not rule out the possibility of a direct interaction of 
MeCP2 and histone N-terminal tails. The observation suggests this potential 
histone NTD - MeCP2 interaction is not necessary for array compaction.   
The minimum MeCP2 domain combination required for nucleosomal array 
compaction is the TRD-CTD.  The further C-terminal truncation fragment 300-486 
was unable to form complexes large enough not to enter the 0.8% agarose gel 
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matrix and therefore did not compact nucleosomal arrays to the same degree.  
This result is consistent with electrophoretic mobility-shift assay and analytical 
ultracentrifugation observations made by our collaborators (see Figure 4.3. 
panels a. and d. and Figure 4.4 in Chapter 4) (96).   
If MeCP2 folds in half by the collapsible hinge mechanism I hypothesized 
in section 6.2.1 and this mechanism is required for nucleosomal array 
compaction, then the existence of at least three independent DNA-binding 
domains between residues 206-486 should exist.  At least one DNA binding motif 
has been observed in the TRD while another was observed in the carboxy-
terminal domain.  Further deletion mutations need to be assayed to determine 
the precise location of independent DNA-binding domains in the TRD CTD 
fragment not previously reported. 
Though residues 300-486 were not able to compact nucleosomal arrays 
this fragment did exhibit robust ability to shift naked DNA, nucleosomal arrays 
and nucleosomal arrays lacking N-terminal tails.  This led to the question: where 
does DNA-binding activity stop in the C-terminal portion of MeCP2? Two further 
C-terminal truncation mutants, residues 335-486 and residues 354-486 were 
assayed (see Figure 3.2).  It was observed that 335-486 was able to shift DNA, 
and nucleosomal arrays, while residues 354-486 were unable to shift either DNA 
template. From these results at least one DNA-binding motif between residues 
300-354 can be inferred. This result leaves open the possibility of two 
independently acting DNA-binding motifs between residues 300-354.  
Observation of residues 335-486 binding both DNA and nucleosomal arrays 
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differed slightly from the result of our collaborators.  They observed residues 335-
486 as able to shift nucleosomal arrays but not DNA alone.   
The results I present here in Figure 3.2 clearly show MeCP2 fragment 
335-486 shifting both nucleosomal arrays and naked DNA.  Though preference 
of this fragment for arrays over DNA alone is published, I was unable to 
reproduce this. I conclude that MeCP2 does not require histone binding for 
chromatin compaction activity, but rather depends on at least four non-specific, 
unmethylated-DNA binding motifs in the MBD, ID, TRD and CTD in the majority 
of binding sites among neuronal cell nuclei.   
Though the intervening domain (ID) was previously shown to be essential 
for MeCP2 localization in chromatin via fluorescence recovery after 
photobleaching (FRAP) method in an in vivo study (86), direct observation of the 
ID binding DNA as an isolated domain was not reported until our collaborative 
publication (see Chapter 4). Though my results (see Figure 3.3-3.5) did not 
appear in this publication and the fragment I cloned and expressed was slightly 
smaller (matching  38 MeCP2 residues - 168-206) than that used by our 
collaborators (matching  46 MeCP2 residues -165-210), our results were in 
agreement. Indeed, we both concluded from EMSAs conducted with the ID 
incubated with DNA that the ID robustly shifted DNA. My work with this region of 
MeCP2 between the MBD and TRD continued to probe for a more precise 
location of DNA binding activity.  I found that the MeCP2 residues with exact 
homology to the central AT-hook motif of HMGA proteins are not the primary 
residues engaged in DNA binding. This conclusion is based on the observation 
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that mutating the AT-hook consensus core sequence with three alanines actually 
increased DNA shifting activity of the ID peptide (see center three lanes in Figure 
3.5). This observation is consistent with the observation that the R188E point 
mutation severely inhibited DNA binding both in full length MeCP2 Figure 3.3) 
and the ID peptide (Figure 3.5) suggests DNA binding activity of the ID is housed 
between residues 168-188. Further truncations of the ID would test this 
hypothesis.   
This result is interesting from an evolutionary perspective. It can be 
inferred from homology that MeCP2 and the HMGA family of non-ATP dependent 
ChAPs share a common ancestral gene. This gene product probably had an AT-
hook motif and at a certain point after the divergence of MeCP2 and HMGA 
proteins, the AT-hook retained DNA-binding ability in the HMGA proteins while 
the MeCP2 gene product maintained DNA-binding activity but shifted that activity 
just N-terminal to the original binding region.  Keeping this functional drift idea in 
mind while comparing the CD results of the ID, I hypothesize that the ID binds 
DNA while maintaining durable disorder but has evolved into this state of 
maintained disorder by a series of mutations from a protein ancestor that once 
had the requisite palindrome for a “true AT-hook” motif.  A “true” AT-hook has 
two prolines that bookend the GRP consensus core, giving the novel motif the 
steric pucker required to bind the minor groove of AT rich DNA regions (198).  I 
hypothesize further that over the course of evolution MeCP2 lost this AT-rich 
tracking ability, trading this functionality for more ubiquitous genomic distribution 




The systematic dissection of the MeCP2 gene product from amino 
terminal through carboxy terminal presented in this dissertation represents a 
significant expansion of our knowledge of the structural diversity of MeCP2.  As a 
direct result of these studies two DNA-binding domains previously unreported in 
the literature have been identified and corroborated by collaborators (96). One 
DNA-binding domain was discovered in the intervening domain between the 
MBD and the TRD and another between residues 300 and 354 in the C-terminal 
portion of the protein.  The unique physical properties of each protease-resistant 
domain spanning the entirety of MeCP2 reported allow speculations to be made 
on how MeCP2 uses transient and durable disorder to bind a variety of partners, 
including proteins, methylated and unmethylated double-stranded DNA, 
chromatin, and RNA.  Experimental observation of MeCP2 and constituent 
fragments by CD directly agrees with data obtained by hydrogen/deuterium 
exchange results presented in appendix 1. The primary conclusion from that 
work is that MeCP2 maintains robust disorder in the absence of a binding partner 
and has only a slight increase in observable rigidity when bound to methylated 
and unmethylated DNA (assigned to the MBD). Comparing results from the CD 
analysis presented in Chapter 2 of this dissertation and the results of Chapter 4 
clearly demonstrates MeCP2 as an archetypical intrinsically disordered protein 
with functional portions that probably maintain a disordered state while engaged 
with binding partners.  Further, data from the TFE titrations suggest the CTD of 
MeCP2 is capable of acquiring both α-helix and β-strand secondary structures in 
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different solvating contexts. Extrapolating this observation to the crowded jungle-
like state of the nucleus implies that it is possible that the same disordered region 
in the CTD of MeCP2 may be able to acquire different secondary structures 
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